Pyrrolopyrimidine ITK inhibitors
Covalently modifying ITK inhibitors and pharmaceutical compositions of cysteine, synergistically inhibiting ITK and JAK3, solving the problem of ITK-mediated T cell activation in diseases, achieving effective immunosuppression and reduced inflammatory response under low toxicity.
Patent Information
- Application Number
- CN202411055491.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-10
- Filing Date
- 2019-08-12
- Publication Date
- 2024-12-06
AI Technical Summary
Existing ITK inhibitors are not effective in targeting ITK-mediated autoimmune and inflammatory diseases, and traditional drugs have problems with high drug-specific toxicity and high dose requirements during the treatment process.
A compound was developed to inhibit the catalytic domains of ITK and JAK3 by covalently modifying cysteine to achieve synergistic inhibition of T cell activation, and ITK inhibitors and pharmaceutical compositions were prepared for the treatment of ITK-mediated diseases .
This method can effectively inhibit the activity of ITK and JAK3, reduce T cell activation, reduce inflammatory response, and achieve immunosuppression under low toxicity, with potential effects in treating ITK-mediated diseases.
Smart Images

Figure CN119080779A_ABST
Abstract
Description
[0001] This application is a divisional application of the PCT international application PCT / US2019 / 046182 filed on August 12, 2019, which entered the Chinese national phase on April 8, 2021, and whose Chinese patent application number is 201980066579.2 and whose invention name is "Pyrrolopyrimidine ITK inhibitors".
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 717,400, filed August 10, 2018, which is hereby incorporated by reference in its entirety for all purposes. Technical Field
[0004] The present application relates to the preparation and application of pyrrolopyrimidine ITK inhibitors. Background Art
[0005] The Tec (Tyrosine kinase expressed in hepatocellular carcinoma) family of tyrosine kinases (TFTKs) consists of five family members: Tec, BTK (Bruton's tyrosine kinase), BMX (myeloid kinase on chromosome X, also known as ETK), RLK (resting lymphocyte kinase, also known as TXK), and ITK (interleukin-2-inducible T-cell kinase, also known as EMT and TSK). These kinases are central to the regulation of hematopoietic cell biology and, more specifically, the development and activity of lymphocytes and myeloid cells. TFTKs share structural similarities with other non-receptor tyrosine kinases while displaying some family-specific motifs, resulting in a diverse domain architecture associated with complex localization, scaffolding, and activation mechanisms. Typically, TFTKs contain an amino-terminal plekstrin homology domain (PH domain) involved in lipid interactions and membrane targeting, followed by a proline-rich domain that is typically involved in Zn binding. 2+ The BTK homology domain (BH) of the phosphotyrosine binding SH2 domain and the carboxyl-terminal ATP binding kinase domain form the TFTK structure. With the exception of ETK and TEC, which are expressed in hepatocytes and endothelial cells, respectively, TFTK expression is generally limited to hematopoietic lineage cells. BMX is expressed in monocytes, granulocytes, and cardiac endothelial cells, while BTK is expressed in B cells and mast cells, but not in plasma cells and T cells. TEC, RLK, and ITK are all expressed in T cells. To date, the TFTK with the most obvious biological effect in T cells is ITK.
[0006] It has been shown that antigen / MHC-dependent activation of the T cell receptor (TCR) transduces its signal through ITK. TCR stimulation causes the activation of the kinase LCK and the subsequent phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) on CD3, thereby inducing the binding and activation of the kinase ZAP70. ZAP70 in turn phosphorylates the adaptor proteins LAT and SLP-76, which together with LCK and other proteins form a heteromultimeric signaling complex that activates PI3K and generates PIP3 on the plasma membrane. ITK binds to this signaling complex via the SH2 and SH3 domains and binds to PIP3 through its PH domain, resulting in LCK-dependent phosphorylation of ITK Y511 and subsequent ITK autophosphorylation of Y180. Activated ITK phosphorylates PLCγ1, which, once activated, hydrolyzes PIP2 into the second messengers IP3 and DAG. The cellular consequences of these events include calcium mobilization and flux, activation of the PKC and MEK / ERK pathways, and transcriptional activation of NFAT via AP1 and NFκ activation. As a key enzyme in the TCR activation pathway, ITK affects T cell function in a variety of ways, including positive and negative selection, cell differentiation, and cytokine production and release.
[0007] The role of ITK in T cell function has been described by genetic knockdown / kinase inactivation of the ITK gene in rodents and by characterization of individual human ITK mutants. Mice with null mutations in the itk gene express reduced numbers of mature T cells and a block in thymocyte development, as well as a reduced TCR-driven T cell proliferation response. Interestingly, IL2 and CD28 signaling and PMA / ionomycin-driven responses remain unchanged, indicating that the ITK response is membrane-proximal and stimulus-specific. It appears that ITK is responsible for the amplification of TCR signaling rather than an 'on / off' switch, as double knockout of T cells expressing TFTK, ITK and RLK in mice produces a more complete TCR inactivation phenotype compared to ITK gene deletion alone. Contrary to what appears to be a role for ITK in naive T cell activation ( In contrast to the regulatory effects of ITK on T helper cell activation, it plays a more prominent role in T helper cell differentiation. Several studies in ITK-deficient mice have demonstrated a reduction in the Th2 protective response to parasitic infection. This reduced Th2 response is associated with decreased concentrations of the Th2 cytokines IL4, IL5, IL13, and IL10, as well as reduced expression of RLK. In contrast to the requirement of ITK for mounting a Th2-driven response, it has little effect on the Th1 response. For example, IFNg production is partially inhibited in ITK knockout cells, while double ITK / RLK knockout has a more severe phenotype. Evaluation of Th17 T helper cells in vitro and in vivo studies of ITK knockout demonstrated a reduction in IL17A mRNA and protein, with little effect on IL17F. The role of ITK in cytotoxic CD8 + Role of ITK-deficient CD8 T cells + T cell stimulation resulted in decreased activation of PLCg1, ERK, and p38 MAPK, as well as Ca 2+ The loss of CD4 T cells results in a decreased proliferative response and production of effector cytokines (IL2, IL4, and IFNg) without affecting the cytolytic capacity of these cells. + T cells and CD8 + In addition to the defects observed in T cells, natural killer T cell development and responses to TCR stimulation are reduced in ITK knockout cells and animals.
[0008] Rodent knockout studies have revealed the effects of enzyme expression (not necessarily its catalytic activity) on biological responses. Since, in addition to its catalytic role, ITK also plays a role in scaffolding through its multidomain structure. It is important to describe the effects of blocking each of these functions on cell biology. ITK activities that are independent of kinase activity include recruitment of the guanine nucleotide exchange factor VAV to the cell membrane associated with actin polymerization (PH and SH2 domain dependence), antigen receptor stimulation, and receptor activation of SRF. However, ITK knockout mice expressing a transgenic deletion of the ITK kinase domain demonstrated that this kinase domain is essential for the induction of a normal Th2 response.
[0009] The relationship between ITK expression and activity and human disease has recently been documented in studies characterizing individuals who exhibit a correlation between mutations and / or expression in the gene encoding this protein and disease. The ITK gene was found to be elevated in peripheral blood T cells from patients with moderate to severe atopic dermatitis, a Th2-driven chronic inflammatory skin disease. An investigation into disease-associated single nucleotide polymorphisms (SNPs) in seasonal allergic rhinitis identified ITK as a significant risk factor. Human primary immunodeficiency was not found in siblings who died due to an immune disorder that causes lymphocyte proliferation following Epstein-Barr virus (EBV) infection. This disorder is associated with a missense (R335W) mutation in the SH2 domain of ITK that causes structural instability of the enzyme and reduced steady-state levels. This finding was confirmed and expanded in a study that identified three patients carrying the C1764G nonsense mutation in ITK that causes a premature stop codon and reduced protein expression and / or activity. These patients presented with EBV-positive Hodgkin lymphoma. These two reports show that mutational disruption of the ITK gene in humans causes an autosomal recessive lymphoproliferative disorder and identify this kinase as a key regulator in T cell biology.
[0010] In addition to the human genetic data summarized above, animal models also support ITK as a therapeutic target for autoimmune and inflammatory diseases. ITK knockout mice show reduced airway hypersensitivity and inflammation in a model of allergic asthma. In a mouse model of atopic dermatitis, ITK-deficient mice do not develop inflammation, while ITK inhibition reduces the response of wild-type mice. 2+ ITK-dependent regulation of mobilization and transcription factor induction makes it a key factor in protection against influenza A and HIV infection and viral replication. ITK inhibitors have been shown to alter HIV replication at multiple stages and have the potential to be effective HIV therapeutics.
[0011] From an oncology perspective, studies have demonstrated that ITK inhibitors selectively target and kill acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma, with minimal effect on normal T cells. ITK is highly expressed in transformed T-cell lines relative to normal T cells and other cancer cell lines. The effect of ITK inhibition on T-cell tumors was demonstrated in mouse xenograft models. Cancer evasion of the immune system due to induction (as opposed to priming) of tumor antigen tolerance is critical for tumor survival. Tumors that develop a microenvironment that induces T-cell anergy demonstrate altered T-cell gene expression, indicating a deviation from a Th2 phenotype. ITK inhibition will favor Th1 differentiation and may be used to enhance cancer immunotherapy.
[0012] The effectiveness of simultaneously suppressing the signal of both T cell receptor and cytokine receptor downstream is best exemplified by the field of organ transplantation (Halloran). The standard of care set up immediately after transplantation is to prevent immune transplant rejection by administering a cocktail of inhibitors that affect lymphocyte activation at different points. The most common drugs used in both the initial post-transplantation period and the discharge setting are calcineurin inhibitors (such as Prograf or Neoral) that block TCR signal conduction and antimetabolites (such as mycophenolate mofetil or rapamycin) downstream of the cytokines (such as IL-2 or IL-15) that block proliferation induction. These drugs cannot be used as monotherapy because they will need to cause higher doses of drug-specific toxicity. By using these drugs simultaneously with suboptimal doses, synergistic immunosuppression can be achieved with reduced toxicity. ITK is downstream of TCR, and JAK3 is downstream of the common g chain of cytokine receptors. By covalently modifying cysteine in the catalytic domains of the two kinases, the two enzymes can be inhibited with a single drug, thereby synergistically inhibiting the activation of T cells. Summary of the Invention
[0013] As described herein, embodiments are directed to compounds disclosed herein, pharmaceutical compositions of such compounds, methods of making such compounds, and methods of using such compounds.
[0014] Some embodiments disclosed herein are directed to compounds of formula (I):
[0015]
[0016] in:
[0017] X is N or CR3;
[0018] n is 0, 1, or 2;
[0019] m is 0, 1, or 2;
[0020] R1 is selected from COOR6, C1-C5 alkyl-COOR6, bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally substituted with one or more groups selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR6, or C1-C5-alkyl-COOR6;
[0021] R2 is selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, CN, OH, C1-C5 alkoxy and halogen, wherein two R2 groups on the same carbon may or may not be connected to a heteroatom to form a spirocyclic ring system;
[0022] R3 is selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0023] R4 is selected from H, C1-C6 alkyl;
[0024] R5 is selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy or C1-C6 alkyl-heterocyclyl;
[0025] R6 is selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0026] and derivatives of the compounds of formula (I).
[0027] Some embodiments disclosed herein are directed to compounds of formula (II):
[0028]
[0029] in:
[0030] X is N or CR 23 ;
[0031] n is 0, 1, or 2;
[0032] m is 0, 1, or 2;
[0033] R 21 Selected from COOR 26 、C1-C5 alkyl-COOR 26 , bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR26 , or C1-C5-alkyl-COOR 26 substituted with one or more groups;
[0034] R 22 is selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, CN, OH, C1-C5 alkoxy, halogen, and wherein two R2 groups on the same carbon may or may not be connected to a heteroatom to form a spirocyclic ring system;
[0035] R 23 Selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0036] R 24 Selected from H, C1-C6 alkyl;
[0037] R 25 is selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy or C1-C6 alkyl-heterocyclyl;
[0038] R 26 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0039] and derivatives of the compound of formula (II).
[0040] Some embodiments disclosed herein are directed to compounds of formula (III):
[0041]
[0042] in:
[0043] X is CR 33 or N;
[0044] n is 1 or 2;
[0045] When n is 1, m is 0, 1, or 2, and when n is 2, m is 1;
[0046] R 31 Selected from COOR 36 、C1-C5 alkyl-COOR 36, bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR 36 , or C1-C5-alkyl-COOR 36 substituted with one or more groups;
[0047] R 32 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl;
[0048] R 33 Selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0049] R 34 Selected from H, C1-C6 alkyl;
[0050] R 35 Selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy;
[0051] R 36 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0052] and derivatives of the compound of formula (III).
[0053] Some embodiments disclosed herein are directed to compounds of formula (IV):
[0054]
[0055] in:
[0056] X is CR 43 or N;
[0057] n is 1 or 2;
[0058] When n is 1, m is 0, 1, or 2, and when n is 2, m is 1;
[0059] R 41 Selected from COOR 46 、C1-C5 alkyl-COOR 46 , bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR 46 , or C1-C5-alkyl-COOR 46 substituted with one or more groups;
[0060] R 42 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl;
[0061] R 43 Selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0062] R 44 Selected from H, C1-C6 alkyl;
[0063] R 45 Selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy;
[0064] R 46 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0065] and derivatives of the compound of formula (IV).
[0066] In some embodiments, the compound of formula (I) or a derivative of the compound of formula (I) is selected from:
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080] as well as
[0081] In some embodiments, the compound of formula (III) or a derivative of the compound of formula (III) is selected from:
[0082]
[0083] as well as
[0084] Some embodiments disclosed herein are directed to a pharmaceutical composition comprising: one or more compounds and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein the one or more compounds are selected from a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and derivatives of the compound of formula (I), the compound of formula (II), the compound of formula (III), and the compound of formula (IV).
[0085] Some embodiments disclosed herein are directed to a method of inhibiting ITK activity or JAK3 activity in a cell population, the method comprising administering to the cell population one or more compounds in an amount effective to inhibit ITK activity or JAK3 activity in the cell population, the one or more compounds being selected from a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and derivatives of compounds of formula (I), formula (II), formula (III), and formula (IV).
[0086] In some embodiments, the cell population is a human cell population.
[0087] Some embodiments disclosed herein are directed to a method of treating an ITK-mediated or JAK3-mediated disorder in a subject in need thereof, the method comprising administering to the subject one or more compounds and derivatives of compounds in an amount effective for treating the ITK-mediated or JAK3-mediated disorder, the one or more compounds being selected from a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV).
[0088] In some embodiments, the subject is a human subject.
[0089] In some embodiments, the ITK-mediated or JAK3-mediated disorder is selected from an autoimmune disorder, a chronic and / or acute inflammatory disorder, an autoinflammatory disorder, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, systemic onset juvenile idiopathic arthritis, Still's disease, adult-onset Still's disease, seronegative spondyloarthropathy, osteoarthritis, enthesitis, terminal disease, infectious arthritis, Lyme disease, inflammatory arthritis, inflammatory bowel disease-associated arthritis, myositis, autoimmune myositis, carditis, myocarditis, dermatomyositis, juvenile dermatomyositis, idiopathic arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, ankylosing spondylitis, gout, scleroderma, juvenile Scleroderma, Reiter's syndrome, spondylitis, spondyloarthritis, spondyloarthropathies, lupus, systemic lupus erythematosus (SLE), juvenile systemic lupus erythematosus, cutaneous lupus, subacute cutaneous lupus, chronic cutaneous lupus, discoid lupus, psoriatic arthritis, reactive arthritis, Sjogren's syndrome, polymyositis, polymyalgia rheumatica, mixed connective tissue disease, vasculitis, large vessel vasculitis, small vessel vasculitis, vasculitis syndromes including Takayasu arteritis, Wegener's granulomatosis, giant cell arteritis, polyarteritis nodosa, sarcoidosis, familial Mediterranean fever, cold pyrin-associated periodic syndromes, Merkel-Weiss syndrome, familial cold autoinflammatory syndrome, neonatal-onset multisystem inflammatory disease, TNF receptor-associated periodic syndromes, gastrointestinal Gastrointestinal disorders, inflammatory bowel disease, irritable bowel syndrome, spastic colon, Crohn's disease, ulcerative colitis, acute and chronic pancreatitis, celiac disease, primary biliary cirrhosis, primary sclerosing cholangitis, periodontitis, gingivitis, esophagitis, gastritis, eosinophilic gastritis, gastric and duodenal ulcers, peritonitis, periodontitis, enteritis, colitis, pulmonary respiratory disorders, lung inflammation, sinusitis, rhinitis, pneumonia, bronchitis, pulmonary fibrosis, idiopathic pulmonary fibrosis, asthma, bronchial asthma, allergic asthma, eosinophilic asthma, Churg-Strauss syndrome, bronchiolitis, bronchiolitis obliterans, chronic obstructive pulmonary disease (COPD), interstitial lung disease, endocrine disorders, diabetes, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, Addison's disease, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, neurological disorders / neuromuscular disorders, neurodegenerative disorders, multiple sclerosis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), familial ALS, Alzheimer's disease, myasthenia gravis (Lang-Evans myasthenic syndrome (LEMS)), Guillain-Barré syndrome, meningitis, encephalitis, traumatic brain injury, kidney disease, immune-mediated glomerulonephropathy, autoimmune kidney disease, membranous glomerulopathy, chronic progressive kidney disease, diabetic nephropathy, renal fibrosis, kidney disease associated with ischemia / reperfusion injury,HIV-associated nephropathy, ureteral obstructive nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease, diabetic kidney disease, eye disorders, dry eye, uveitis, keratoconjunctivitis sicca, scleritis, episcleritis, keratitis, corneal disease, laryngitis, retinal vasculitis, optic neuritis, retinopathy, diabetic retinopathy, immune-mediated retinopathy, macular degeneration, wet macular degeneration, dry (age-related) macular degeneration, ocular malignancy, including hypersensitivity reactions, type I hypersensitivity reactions, allergies, type II hypersensitivity reactions, Goodpasture's disease, autoimmune hemolytic anemia, type III hypersensitivity disorders, Arthus reaction, serum sickness, type IV Hypersensitivity reactions, contact dermatitis, allergic and hypersensitivity reactions to allograft rejection, disorders of fibrosis and scarring, hepatic fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, low-grade scarring, scleroderma, increased fibrosis, keloids, postoperative scarring, skin diseases, psoriasis, atopy, atopic dermatitis, acne, acne vulgaris, acne comedonologica, inflammatory acne, nodulocystic acne, acne keloidalis, acne nuchal keloidalis, hidradenitis suppurativa, neutrophilic dermatosis, pyoderma gangrenosum, acute febrile neutrophilic dermatosis (Sweet's syndrome), erythema erecta ternata (EED), neutrophilic exocrine hidradenitis, histiocytic neutrophilic dermatosis, intestinal bypass syndrome dermatosis, Behçet's disease, palisade neutrophilic granuloma Dermatitis, neutrophilic urticaria, hair loss, non-scarring alopecia, alopecia areata (AA), plaque AA, alopecia totalis (AT), alopecia universalis (AU), androgenic alopecia (AGA), male and female pattern AGA, serpiginous alopecia, horseshoe alopecia, telogen effluvium, tinea capitis, hypotrichosis, simple hereditary hypotrichosis, scarring alopecia, lichen planus pilaris, central centrifugal scarring alopecia, frontal fibrosing alopecia, eyebrow loss, nasal hair loss, vitiligo, segmental vitiligo, single segmental vitiligo, two segmental vitiligo, multisegmental vitiligo, non-segmental vitiligo, acral vitiligo, facial vitiligo, acrofacial vitiligo, central facial vitiligo, mucosal vitiligo, shredded paper vitiligo, tricolor vitiligo, marginal Peripheral inflammatory vitiligo, four-color vitiligo, blue vitiligo, Kebner phenomenon, common vitiligo, generalized vitiligo, universal vitiligo, mixed vitiligo (non-segmental vitiligo with segmental vitiligo), localized vitiligo, isolated mucosal vitiligo, vitiligo with white hair, vitiligo without white hair, immune bullous diseases, bullous pemphigoid, cicatricial pemphigoid, pemphigus vulgaris, linear IgA disease, skin disease drug reaction, pruritus (itch), atopic pruritus, dry pruritus, pruritus associated with psoriasis (psoriatic pruritus), acute pruritus, chronic pruritus, idiopathic pruritus, chronic idiopathic pruritus, hepatobiliary-related pruritus, kidney-related pruritus, chronic simple lichen-related pruritus, nodular prurigo,Type II diabetes, hypophysitis, idiopathic thrombocytopenic purpura, metal-induced autoimmunity, autoimmune deafness, Meniere's disease, interstitial cystitis, enterocolitis, eye inflammation, non-small cell lung cancer, skin cancer, organ transplant rejection, bone marrow transplant rejection, graft-versus-host reaction, graft-versus-host disease, allograft rejection, acute allograft rejection, chronic allograft rejection, early transplantation, diabetes, myeloproliferative disorders, rejection, bone resorption disorders, asthma, bronchial asthma, atopy, autoimmune thyroid disorders, chronic atypical neutrophilic leukemia and hyperthermia syndrome (CANDLE syndrome), SAVI (stimulator of interferon genes (STING)-associated skin disease), and hyperthermia. Infantile-onset vasculopathy), nephropathy, myocarditis, secondary hematologic manifestations of autoimmune diseases, anemia, autoimmune hemolytic syndrome, autoimmune and inflammatory hepatitis, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, silicone implant-related autoimmune diseases, drug-induced autoimmunity, HIV-related autoimmune syndrome; acute and chronic infections, sepsis syndrome, sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, Gram-negative sepsis, Gram-positive sepsis, fungal sepsis, toxic shock syndrome; hyperoxia-induced inflammation, reperfusion injury, postoperative trauma, tissue damage, pain, acute pain, chronic pain , neuropathic pain, or fibromyalgia, autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, autoinflammatory disorders, fibrotic disorders, metabolic disorders, neoplasia, or cardiovascular disorders or cerebrovascular disorders, skin disorders, pruritus, hair loss disorders, cancer, neoplasms, inflammatory conditions, connective tissue diseases and autoimmune conditions, neoplasms, malignancies, myeloproliferative disorders, hematopoietic neoplasms, spinal cord neoplasms, myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia, acute leukemia and chronic leukemia, lymphoma, cutaneous lymphoma including mycosis fungoides, lymphoid neoplasms of other myeloid malignancies and myelodysplastic syndromes, atopic dermatitis, psoriasis, psoriasis vulgaris, Skin sensitization, skin irritation, rash, contact dermatitis, allergic contact sensitization, allergic dermatitis, inflammatory skin diseases, neutrophilic skin diseases, pruritus, atopic pruritus, atopic dermatitis-associated pruritus, autoimmune response, autoimmune connective tissue disease, bacterial infection, biliary pruritus, generalized activation of the immune response, body lice, bullous disease, brachioradialis pruritus, brain tumor, chronic idiopathic pruritus, contact dermatitis, cholestasis, cutaneous larva migrans, cutaneous T-cell lymphoma, nervous system damage, dandruff, delusional parasitosis, dermatomyositis, skin diseases of pregnancy, diabetes, drug eruption, dysregulation of neuronal processes and sensory perception, eczema, eosinophilic folliculitis, foreign body or device on the skin, fungal infection, pemphigoid gestationis, head lice, herpes,Hidradenitis suppurativa, pyoderma gangrenosum, urticaria, Hodgkin's disease, hyperparathyroidism, idiopathic chronic pruritus, inflammation, insect infestation, insect bites, insect stings, intrahepatic cholestasis of pregnancy, iron deficiency anemia, increased accumulation of exogenous opioids or synthetic opioids, internal cancer, jaundice, lichen planus, lichen sclerosus atrophicus, lupus erythematosus, lymphoma, lymphoma-associated pruritus, leukemia-associated pruritus, malignancy, mastocytosis, menopause, multiple sclerosis, neoplasms, nerve irritation, neurogenic pruritus, neuropathic pruritus, paresthesia back pain, obsessive-compulsive disorder back pain, parasitic infestation, papular urticaria, urticaria, pediculosis, peripheral neuropathy, photodermatitis, polycythemia vera, spermatorrhea Psychiatric disease, psychogenic itch, HIV-associated pruritic papules, pruritic urticarial papules and plaques of pregnancy (PUPP), psoriasis-associated itch, psoriatic itch, pubic lice, punctate palmoplantar keratoderma, renal itch, rheumatoid arthritis, scabies, scarring, shaving, seborrheic dermatitis, stasis dermatitis, sunburn, swimmer's itch, systemic immunosenescence, tactile hallucinations, Th17-related inflammation, thyroid disease, uremia, uremic itch, urticaria, urticarial itch, chickenpox, viral infection, wound or scab healing, xerosis, pernio lupus erythematosus, polychondritis, relapsing polychondritis, immune-mediated kidney disease, prostate cancer, kidney cancer, liver cancer, breast cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, Lymphoma, leukemia, multiple myeloma, polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), systemic mast cell disease (SMCD), systemic sclerosis / scleroderma, lupus nephritis, wound healing, surgical scarring, spinal cord injury, central nervous system scarring, acute lung injury, cystic fibrosis, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, chronic kidney disease, diabetic nephropathy, high Blood pressure-induced kidney disease, digestive or gastrointestinal fibrosis, liver fibrosis or bile duct fibrosis, liver fibrosis, nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma, cirrhosis, primary biliary cirrhosis or cirrhosis due to fatty liver disease, alcoholic steatosis, nonalcoholic steatosis, radiation-induced fibrosis, head and neck fibrosis, gastrointestinal fibrosis, pulmonary fibrosis, primary sclerosing cholangitis, restenosis, cardiac fibrosis, endomyocardial fibrosis, atrial fibrosis, ocular scarring, fibrosclerosis, fibrotic cancer, fibroma, fibroma, fibroadenoma, fibrosarcoma, transplant arteriopathy, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, obesity,Steroid resistance, glucose intolerance, metabolic syndrome, angiogenesis disorders, multiple myeloma, leukemia, acute lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, promyelocytic leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt lymphoma, mast cell tumor, Hodgkin's disease, non-Hodgkin's disease, myelodysplastic syndrome, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma and schwannoma; melanoma, seminoma, teratoma, osteosarcoma, Xeroderma pigmentosum, keratoacanthoma, follicular thyroid carcinoma, Kaposi's sarcoma, melanoma, teratoma, rhabdomyosarcoma, metastatic disorders and bone disorders, as well as bone cancer, oral / pharyngeal cancer, esophageal cancer, laryngeal cancer, stomach cancer, intestinal cancer, colon cancer, rectal cancer, liver cancer, nerve cancer, brain cancer, glioma, glioblastoma multiforme, head and neck cancer, pharyngeal cancer, ovarian cancer, uterine cancer, testicular cancer, bladder cancer, kidney cancer, gallbladder cancer, cervical cancer, atherosclerosis, atherosclerotic coronary artery restenosis, acute coronary syndrome, myocardial infarction, cardiac allograft vasculopathy, stroke, spinal cord injury, neuronal ischemia, peripheral neuropathy, and combinations thereof.
[0090] In some embodiments, the methods further comprise sequential administration or co-administration of pharmaceutical agents.
[0091] In some embodiments, the pharmaceutical agent is selected from a taxane, an inhibitor of bcr-abl, an inhibitor of EGFR, a DNA damaging agent, an antimetabolite, paclitaxel, imatinib, dasatinib, nilotinib, erlotinib, gefitinib, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC, 5-FU, camptothecin, doxorubicin, idarubicin, paclitaxel, docetaxel, vincristine, a MEK inhibitor, U0126, a KSP inhibitor, vorinostat, pembrolizumab, nivolumab, atezolizumab, avelumab, tesimumab, and durvalumab.
[0092] Some embodiments disclosed herein are directed to the use of compounds and derivatives of compounds for the manufacture of medicaments for treating ITK-mediated or JAK3-mediated diseases, wherein the compounds are selected from compounds of formula (I), compounds of formula (II), compounds of formula (III), and compounds of formula (IV).
[0093] In some embodiments, the compounds disclosed herein may have useful ITK inhibitory activity. Some embodiments herein are directed to using the compounds disclosed herein to treat or prevent diseases or conditions in which ITK plays an active role. In some embodiments, a method of treating an ITK-mediated disease or disorder in a subject comprises administering to the subject a compound of the embodiments herein.
[0094] Some embodiments provide methods for treating an ITK-mediated disorder in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound or composition according to the present disclosure. Also provided is the use of a compound disclosed herein in the manufacture of a medicament for treating a disease or condition that is ameliorated by inhibition of ITK.
[0095] definition
[0096] Before describing the compositions and methods of the present invention, it should be understood that the present invention is not limited to the specific processes, compositions, or methods described, because these can change. It should also be understood that the terms used in the specification are only for the purpose of describing a specific type or embodiment, and are not intended to limit the scope of the embodiments herein, and the scope of the embodiments herein will be limited only by the appended claims. Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art. Although any method and material similar or equivalent to those methods and materials described herein can be used in the practice or testing of the embodiments of the embodiments herein, preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated by reference in their entirety. Nothing herein should be construed as admitting that the embodiments herein are not entitled to be disclosed earlier than such disclosure by prior invention.
[0097] It must also be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to "an ITK inhibitor" is a reference to one or more ITK inhibitors known to those skilled in the art and equivalents thereof, etc.
[0098] As used herein, the term "about" is intended to qualify the numerical value it modifies, thereby representing such a value as a variable within a range of error. When no specific range of error is listed (such as the standard deviation of the mean value given in a chart or data table), the term "about" should be understood to mean the mean value of the numerical value with which it is used plus or minus 10%. Thus, about 50% means within the range of 45%-55%.
[0099] In embodiments or claims where the term "comprising" is used as a transition phrase, such embodiments are also contemplated as replacing the term "comprising" with the terms "consisting of" or "consisting essentially of.
[0100] As used herein, the term "consists of" or "consisting of" means that a pharmaceutical composition, composition, or method includes only those elements, steps, or ingredients specifically recited in a particular claimed embodiment or claim.
[0101] As used herein, the term "consisting essentially of" or "consists essentially of" means that a pharmaceutical composition or method contains only the elements, steps, or ingredients specifically recited in a particular claimed embodiment or claim, and may optionally contain additional elements, steps, or ingredients that do not materially affect the basic and novel characteristics of the particular embodiment or claim. For example, the only active ingredient or ingredients in a composition or method for treating a particular condition (e.g., nutrient depletion) are one or more therapeutic agents specifically recited in a particular embodiment or claim.
[0102] As used herein, two embodiments are "mutually exclusive" when one embodiment is defined as being different from another embodiment. For example, an embodiment in which two groups combine to form a cycloalkyl is mutually exclusive with an embodiment in which one group is ethyl and the other group is hydrogen. Similarly, an embodiment in which one group is CH2 is mutually exclusive with an embodiment in which the same group is NH.
[0103] The term "inhibit" means to limit, prevent or block the action or function of a target enzyme and / or prevent, alleviate or eliminate the onset of one or more symptoms associated with a disease, condition or disorder, or to prevent, alleviate or eliminate a disease, condition or disorder.
[0104] Unless otherwise specified, the term "skin" means the outer integument or covering of the body, consisting of the dermis and epidermis and overlying the subcutaneous tissue.
[0105] When a numerical range is disclosed and the notation "from n1 ... to n2" or "between n1 ... and n2" (where n1 and n2 are numbers) is used, then unless otherwise specified, the notation is intended to include the numbers themselves and the range between them. The range can be integer or continuous between the end values (inclusive of the end values). For example, the range "from 2 to 6 carbon atoms" is intended to include two, three, four, five, and six carbon atoms, because carbon atoms appear in integer units. In contrast, for example, the range "from 1 μM (micromolar) to 3 μM" is intended to include 1 μM, 3 μM, and all significant figures therebetween (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).
[0106] As used herein, alone or in combination, the term "acyl" refers to a carbonyl group attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety wherein the atom attached to the carbonyl group is carbon. An "acetyl" group refers to a -C(O)CH3 group. An "alkylcarbonyl" group or an "alkanoyl" group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl, and aroyl.
[0107] As used herein, alone or in combination, the term "alkenyl" refers to a straight or branched hydrocarbon group having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, the alkenyl group will include from 2 to 6 carbon atoms. The term "alkenylene" refers to a carbon-carbon double bond system connected at two or more positions, such as vinylene [(-CH=CH-), (-C::C-)]. Examples of suitable alkenyl groups include vinyl, propenyl, 2-methylpropenyl, 1,4-butadienyl, etc. Unless otherwise specified, the term "alkenyl" may include "alkenylene" groups.
[0108] As used herein, the term "alkoxy" refers to an alkyl ether group, wherein the term alkyl is as defined below. Examples of suitable alkyl ether groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, and the like.
[0109] As used herein, alone or in combination, the term "alkyl" refers to a straight or branched chain alkyl group containing from 1 to 20 carbon atoms. In certain embodiments, the alkyl group will include from 1 to 10 carbon atoms. In other embodiments, the alkyl group will include from 1 to 8 carbon atoms. Alkyl groups may be optionally substituted as defined herein.
[0110] Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, octyl, nonyl, etc. As used herein, alone or in combination, the term "alkylene" refers to a saturated aliphatic group derived from a straight or branched saturated hydrocarbon connected at two or more positions, such as methylene (-CH2-). Unless otherwise specified, the term "alkyl" may include "alkylene" groups.
[0111] The term "alkylamino," as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups can be monoalkylated or dialkylated groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino, and the like.
[0112]
[0046] The term "alkylidene," as used herein, alone or in combination, refers to an alkenyl group wherein one carbon atom of the carbon-carbon double bond belongs to the portion to which the alkenyl group is attached.
[0113] As used herein, the term "alkylthio" refers to an alkylthioether (RS-) group, wherein the term alkyl is as defined above, and wherein the sulfur may be mono- or di-oxidized. Examples of suitable alkylthioether groups include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, methanesulfinyl, ethanesulfinyl, and the like.
[0114] As used herein, alone or in combination, the term "alkynyl" refers to a straight or branched hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, the alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, the alkynyl comprises from 2 to 4 carbon atoms. The term "alkynylene" refers to a carbon-carbon triple bond connected at two positions, such as ethynylene (-C:::C-, -C≡C-).
[0115] Examples of alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, etc. Unless otherwise specified, the term "alkynyl" may include "alkynylene" groups.
[0116] As used herein, alone or in combination, the terms "amido" and "carbamoyl" refer to an amino group attached to the parent molecular moiety through a carbonyl group, as described below, or vice versa. As used herein, alone or in combination, the term "C-amido" refers to a -C(O)N(RR') group, where R and R' are as defined herein or as defined by a specific enumerated "R" group. As used herein, alone or in combination, the term "N-amido" refers to a RC(O)NH(R')- group, where R and R' are as defined herein or as defined by a specific enumerated "R" group. As used herein, alone or in combination, the term "amido" encompasses an acyl group attached to the parent moiety through an amino group. An example of an "amido" group is acetamido (CH3C(O)NH-).
[0117] As used herein, alone or in combination, the term "amino" refers to -NRR', wherein R and R' are independently selected from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. In addition, R and R' may combine to form heterocycloalkyl, any of which may be optionally substituted.
[0118] As used herein, alone or in combination, the term "aryl" means a carbocyclic aromatic system containing one, two or three rings, wherein such polycyclic ring systems are fused together. The term "aryl" includes aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthrenyl.
[0119]
[0066] The term "arylalkenyl" or "aralkenyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
[0120]
[0066] The term "arylalkoxy" or "aralkoxy," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
[0121]
[0046] The term "arylalkyl" or "aralkyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.
[0122]
[0066] The term "arylalkynyl" or "aralkynyl," as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
[0123] The term "arylalkanoyl" or "aralkanoyl" or "aroyl," as used herein, alone or in combination, refers to an acyl group derived from an aryl-substituted alkanecarboxylic acid (e.g., benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl(hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like).
[0124] The term aryloxy, as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an oxy group.
[0125]
[0026] The terms "benzo" and "benz," as used herein, alone or in combination, refer to a divalent radical C6H4= derived from benzene. Examples include benzothiophene and benzimidazole.
[0126] The term "carbamate," as used herein, alone or in combination, refers to an ester of a carbamic acid (-NHCOO-), which can be attached to the parent molecular moiety from either the nitrogen terminus or the acid terminus, and which can be optionally substituted as defined herein.
[0127] The term "O-carbamyl," as used herein, alone or in combination, refers to a -OC(O)NRR' group, where R and R' are as defined herein.
[0128] The term "N-carbamyl," as used herein, alone or in combination, refers to a ROC(O)NR'- group, where R and R' are as defined herein.
[0129] As used herein, the term "carbonyl" when used alone encompasses a formyl group [-C(O)H] and when used in combination, the term "carbonyl" is a -C(O)- group.
[0130] As used herein, the term "carboxyl" or "carboxy" refers to -C(O)OH or the corresponding "carboxylate" anion (e.g., in a carboxylate salt). An "O-carboxyl" group refers to a RC(O)O- group, where R is as defined herein. A "C-carboxyl" group refers to a -C(O)OR group, where R is as defined herein.
[0131] As used herein, the term "compound" is intended to encompass all stereoisomers, geometric isomers, tautomers, isotopes (eg, tritium, deuterium) of the depicted structure.
[0132] The term "cyano," as used herein, alone or in combination, refers to -CN.
[0133] As used herein individually or in combination, the term "cycloalkyl" or alternatively "carbocycle" refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group, wherein each ring portion contains from 3 to 12 carbon atom ring members, and can be alternatively a benzo-fused ring system as defined herein that is optionally substituted. In certain embodiments, the cycloalkyl will include from 5 to 7 carbon atoms. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl, etc. As used herein, "bicyclic" and "tricyclic" are intended to include fused ring systems, such as decalin, octahydronaphthalene, and polycyclic (multi-center) saturated or partially unsaturated types. The latter type of isomers are typically exemplified by bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.
[0134]
[0066] The term "ester," as used herein, alone or in combination, refers to a carboxyl group that bridges two moieties linked at carbon atoms.
[0135]
[0066] The term "ether," as used herein, alone or in combination, refers to an oxy group that bridges two moieties linked at carbon atoms.
[0136]
[0046] The term "halogen" or "halogen family," as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.
[0137] The term "haloalkoxy," as used herein, alone or in combination, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
[0138] As used herein individually or in combination, the term "haloalkyl" refers to an alkyl group with the meaning as defined above, in which one or more hydrogens are replaced by a halogen element. Specifically comprising a monohaloalkyl group, a dihaloalkyl group and a polyhaloalkyl group. For example, a monohaloalkyl group can have an iodine atom, a bromine atom, a chlorine atom or a fluorine atom within the group. A dihaloalkyl group and a polyhaloalkyl group can have a combination of two or more identical halogen atoms or different halogen groups. The example of a haloalkyl group comprises fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. A "haloalkylene" refers to a haloalkyl group connected at two or more positions. Example comprises fluoromethylene (-CFH-), difluoromethylene (-CF2-), chloromethylene (-CHCl-) etc.
[0139] As used herein individually or in combination, the term "halocycloalkyl" refers to a cycloalkyl group with the implication defined above, in which one or more hydrogens are replaced by halogen elements. Specifically comprising a monohalocycloalkyl group, a dihalocycloalkyl group and a polyhalocycloalkyl group. For example, a monohaloalkyl group can have an iodine atom, a bromine atom, a chlorine atom or a fluorine atom within the group. A dihaloalkyl group and a polyhaloalkyl group can have a combination of two or more identical halogen atoms or different halogen groups. The example of a haloalkyl group comprises fluorocyclopropyl, difluorocyclopropyl, fluorocyclobutyl, chlorocyclobutyl and chlorocyclopentyl.
[0140] As used herein, alone or in combination, the term "heteroalkyl" refers to a stable straight or branched chain, or a combination thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of a specified number of carbon atoms and one to three heteroatoms selected from N, O, and S, and wherein the N and S atoms may be optionally oxidized, and the N heteroatom may be optionally quaternized. One or more heteroatoms may be located at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive (such as, for example, -CH2-NH-OCH3).
[0141] As used herein, alone or in combination, the term "heteroaryl" refers to a 5- to 15-membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system, wherein at least one of the fused rings is aromatic, containing at least one atom selected from N, O, and S. In certain embodiments, the heteroaryl group will include from 1 to 4 heteroatoms as ring members. In further embodiments, the heteroaryl group will include from 1 to 2 heteroatoms as ring members. In certain embodiments, the heteroaryl group will include from 5 to 7 atoms. The term also encompasses fused polycyclic groups, wherein a heterocyclic ring is fused to an aryl ring, wherein a heteroaryl ring is fused to another heteroaryl ring, wherein a heteroaryl ring is fused to a heterocycloalkyl ring, or wherein a heteroaryl ring is fused to a cycloalkyl ring. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furanyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazole, Examples of the heterocyclic ring groups include benzoxazolyl, benzodioxolanyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuranyl, benzothiophenyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, etc. Exemplary tricyclic heterocyclic ring groups include carbazolyl, benzindolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl, etc.
[0142] As used herein, alone or in combination, the terms "heterocycloalkyl" and interchangeable "heterocycle" each refer to a saturated, partially unsaturated, or fully unsaturated (but non-aromatic) monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each of the heteroatoms can be independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, heterocycloalkyl will include from 1 to 4 heteroatoms as ring members. In other embodiments, the heterocycloalkyl will include from 1 to 2 heteroatoms as ring members. In certain embodiments, the heterocycloalkyl will include from 3 to 8 ring members in each ring. In other embodiments, the heterocycloalkyl will include from 3 to 7 ring members in each ring. In yet other embodiments, the heterocycloalkyl will include from 5 to 6 ring members in each ring. "Heterocycloalkyl" and "heterocycle" are intended to include sulfones, sulfoxides, N-oxides having a tertiary nitrogen ring member, and carbocyclic-fused ring systems and benzo-fused ring systems; in addition, both terms also include systems in which a heterocycle is fused to an aryl group as defined herein or an additional heterocyclic group. Examples of heterocyclic groups include aziridinyl, azetidinyl, 1,3-benzodioxolanyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. Unless expressly prohibited, heterocyclic groups may be optionally substituted.
[0143] The term "hydrazine," as used herein, alone or in combination, refers to two amino groups connected by a single bond (ie, -NN-).
[0144] The term "hydroxy," as used herein, alone or in combination, refers to -OH.
[0145] The term "hydroxyalkyl," as used herein, alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.
[0146] The term "imino," as used herein, alone or in combination, refers to =N-.
[0147] The term "iminohydroxy," as used herein, alone or in combination, refers to =N(OH) and =NO-.
[0148] The phrase "in the backbone" refers to the longest continuous or adjacent chain of carbon atoms starting at the point of attachment of a group to the compound having any of the formulae disclosed herein.
[0149] The term "isocyanato" refers to an -NCO group.
[0150] The term "isothiocyanato" refers to a -NCS group.
[0151] The phrase "linear chain of atoms" refers to the longest straight chain of atoms independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur.
[0152] As used herein, alone or in combination, unless specifically defined otherwise, the term "lower alkyl" means a group containing from 1 to 6 carbon atoms (inclusive) (ie, C1-C6 alkyl).
[0153] The term "lower aryl" as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as specified.
[0154] As used herein, the term "lower heteroaryl," alone or in combination, means: 1) a monocyclic heteroaryl comprising five or six ring members, wherein between one and four of the ring members may be heteroatoms selected from N, O, and S; or 2) a bicyclic heteroaryl wherein each of the fused rings comprises five or six ring members, wherein between the ring members there are one to four heteroatoms selected from N, O, and S.
[0155] As used herein, alone or in combination, the term "lower cycloalkyl" means a monocyclic cycloalkyl group having between three and six ring members (i.e., C3-C6 cycloalkyl). Lower cycloalkyl groups may be unsaturated. Examples of lower cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0156] As used herein, alone or in combination, the term "lower heterocycloalkyl" means a monocyclic heterocycloalkyl having between four and six ring members, one and four of which may be heteroatoms selected from N, O, and S (i.e., C3-C6 heterocycloalkyl). Examples of lower heterocycloalkyls include oxetane, azetidine, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower heterocycloalkyls may be unsaturated.
[0157] The term "lower amino," as used herein, alone or in combination, refers to -NRR', wherein R and R' are independently selected from hydrogen and lower alkyl, either of which may be optionally substituted.
[0158] The term "mercapto," as used herein, alone or in combination, refers to an RS- group, where R is as defined herein.
[0159] The term "nitro," as used herein, alone or in combination, refers to -NO2.
[0160] As used herein, "N-oxides" are formed from tertiary basic amines or imines present in the molecule using a convenient oxidizing agent.
[0161]
[00146] The term "oxy" or "oxa," as used herein, alone or in combination, refers to -O-.
[0162] The term "oxo," as used herein, alone or in combination, refers to =0.
[0163] The term "perhaloalkoxy" refers to an alkoxy group in which all of the hydrogen atoms are replaced by halogen atoms.
[0164] The term "perhaloalkyl," as used herein, alone or in combination, refers to an alkyl group in which all of the hydrogen atoms are replaced by halogen atoms.
[0165] As used herein, the term "substantially free," alone or in combination, refers to a compound that is free of all other compounds within the limits of detection as measured by any means, including nuclear magnetic resonance (NMR), gas chromatography / mass spectrometry (GC / MS), or liquid chromatography / mass spectrometry (LC / MS).
[0166] As used herein, the terms "sulfonate," "sulfonic acid," and "sulfonic," alone or in combination, refer to a -SO 3 H group, and as an anion of the sulfonic acid, used in salt form.
[0167] The term "sulfanyl," as used herein, alone or in combination, refers to -S-.
[0168] The term "sulfinyl," as used herein, alone or in combination, refers to -S(O)-.
[0169] The term "sulfonyl," as used herein, alone or in combination, refers to -S(O)2-.
[0170] The term "N-sulfonamido" refers to an RS(=O)2NR'- group, where R and R' are as defined herein.
[0171] The term "S-sulfonamido" refers to a -S(=O)2NRR' group, where R and R' are as defined herein.
[0172] As used herein, the terms "thia" and "thio" refer, alone or in combination, to an -S- group or an ether in which the oxygen is replaced by sulfur. Oxygenated derivatives of the thio group (ie, sulfinyl and sulfonyl) are included in the definitions of thia and thio.
[0173] The term "thiol," as used herein, alone or in combination, refers to a -SH group.
[0174] As used herein, the term "thiocarbonyl" when used alone encompasses the thioformyl group -C(S)H, and when used in combination, the term "thiocarbonyl" is a -C(S)- group.
[0175] The term "N-thiocarbamyl" refers to a ROC(S)NR'- group, where R and R' are as defined herein.
[0176] The term "O-thiocarbamyl" refers to a -OC(S)NRR' group, where R and R' are as defined herein.
[0177] The term "thiocyanato" refers to a -CNS group.
[0178] The term "trihalomethanesulfonamido" refers to a X3CS(O)2NR- group, where X is a halogen element and R is as defined herein.
[0179] The term "trihalomethanesulfinyl" refers to a X3CS(O)2- group, where X is a halogen element.
[0180] The term "trihalomethoxy" refers to a X3CO- group where X is a halogen element.
[0181] As used herein, the term "trisubstituted silyl" refers to a silicone group that is substituted at its three free valencies with groups as listed herein under the definition of amino. Examples include trimethylsilyl, tert-butyldimethylsilyl, triphenylsilyl, and the like.
[0182] Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is the element that is attached to the parent moiety. For example, the composite group alkylamido represents an alkyl group attached to the parent molecule via an amido group, and the term alkoxyalkyl represents an alkoxy group attached to the parent molecule via an alkyl group.
[0183] When a group is defined as "null", it means that the group does not exist.
[0184] The term "optionally substituted" means that the preceding group may be substituted or unsubstituted. When substituted, the substituents of the "optionally substituted" group may include, but are not limited to, one or more substituents independently selected from the following groups or groups of specifically designated groups (alone or in combination): lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, Lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxylate, lower formamido, cyano, hydrogen, halogen, hydroxyl, amino, lower alkylamino, arylamino, amide, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonic acid, sulfonic acid, trisubstituted silyl, N3, SH, SCH3, C(O)CH3, CO2CH3, CO2H, pyridyl, thiophene, furyl, lower carbamate, and lower urea. Where structurally feasible, two substituents can be linked together to form a fused five-membered, six-membered, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, such as methylenedioxy or ethylenedioxy. Optionally substituted groups can be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at any level between fully substituted and monosubstituted (e.g., -CH2CF3). Where substituents are listed without being characterized as substituted, both substituted and unsubstituted forms are encompassed. Where a substituent is characterized as "substituted," the substituted form is specifically intended. Furthermore, different groups of optional substituents for a particular moiety may be defined as desired; in these cases, the optional substitution will typically be defined immediately following the phrase as "optionally substituted with."
[0185] Unless otherwise defined, the term R or the term R', when appearing alone and without a numerical designation, refers to a portion selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycloalkyl (any of which may be optionally substituted). Such R and R' groups should be understood to be optionally substituted as defined herein. Regardless of whether the R group has a numerical designation, it should be understood that each R group (including R, R', and Rn (wherein n = (1, 2, 3, ... n)), each substituent, and each term are independent of one another in terms of selection from the group. If any variable, substituent, or term (e.g., aryl, heterocycle, R, etc.) appears more than once in a formula or family structure, its definition at each occurrence is independent of the definition at each other occurrence. Those skilled in the art will also recognize that certain groups can be connected to the parent molecule or can occupy a position in the chain of elements from either end as written. For example, an asymmetric group (e.g., -C(O)N(R)-) can be connected to the parent moiety at carbon or nitrogen.
[0186] Stereoisomeric source center is present in the compounds disclosed herein. According to the configuration of the substituents around the stereoisomerization source center, these centers are specified by the symbol "R" or "S". It should be understood that the present invention includes all stereoisomeric forms (including diastereomeric forms, enantiomeric forms and epimeric forms, as well as d-isomers and l-isomers, and mixtures thereof). The independent stereoisomers of the compound can be prepared synthetically by commercially available starting materials containing limited stereochemical configurations, or by separating or recrystallizing, chromatographic techniques, separating the mixture of stereoisomer products directly through conversion into a mixture of diastereoisomers, or any other suitable method preparation known in the art. The starting compound of a specific configuration is commercially available or can be manufactured and split by technology known in the art. In addition, compounds disclosed herein can exist as geometric isomers. The present invention includes all cis isomers, trans isomers, isomers, retro isomers, endo isomers, exo isomers, ipsilateral (E) isomers, and heterolateral (Z) isomers, and appropriate mixtures thereof. In addition, compounds may exist as tautomers; the present invention provides all tautomeric isomers. In addition, the compounds disclosed herein may exist in unsolvated forms, as well as in forms solvated with pharmaceutically acceptable solvents (such as water, ethanol, etc.). Generally, solvated forms are considered equivalent to unsolvated forms.
[0187] Compounds described herein can contain one or more stereoisomerism source centers, and therefore can exist as stereoisomers.Embodiments herein include all such possible stereoisomers as substantially pure stereoisomers, their racemic mixtures and mixtures of diastereomers through splitting.In some embodiments, the formula shown does not have definite stereochemistry at certain positions.In other embodiments, compounds are separated into single stereoisomers, but the absolute configuration of the stereoisomerism source center is unknown, or only relative stereochemical configuration (that is, cis isomerism or trans isomerism) is known.In such embodiments, formula is shown with the absolute designation of temporary allocation, to represent that they are single stereoisomers, and relative stereochemical configuration is described equally.Embodiments herein include all stereoisomers of such formula and pharmaceutically acceptable salts thereof. The diastereoisomer pairs of stereoisomers can be separated from a suitable solvent by, for example, fractional crystallization, and the enantiomer pairs thus obtained can be separated into individual stereoisomers by conventional means (e.g., by using an optically active acid or an optically active base as a resolving agent or on a chiral HPLC column). In addition, any stereoisomer of the general formula compound can be obtained by stereospecific synthesis or stereoselective synthesis using optically pure or enantiomerically enriched starting materials or reagents of known configuration. The scope of the embodiments described and claimed herein encompasses the racemic form of the compound as well as individual enantiomers, diastereomers, stereoisomers, and stereoisomerically enriched mixtures.
[0188] Conventional techniques for the preparation / separation of individual enantiomers include chiral synthesis from suitable enantiomerically enriched or optically pure precursors or separation of racemates using, for example, chiral high pressure liquid chromatography (HPLC). Alternatively, the racemate (or racemic precursor) can be reacted with a suitable optically active compound (e.g., alcohol, or acid or base (such as tartaric acid or 1-phenylethylamine) (when the compound contains an acidic or basic moiety). The resulting diastereomeric mixture can be separated by chromatography and / or fractional crystallization, and one or both of the diastereomers can be converted into corresponding one or more pure enantiomers by means well known to those skilled in the art. The chiral compounds of the embodiments herein (and chiral precursors thereof) can be obtained in enantiomerically enriched form on an asymmetric resin using chromatography (typically HPLC) wherein the mobile phase consists of a hydrocarbon (typically heptane or hexane) containing from 0 to 50% (typically from 2 to 20%) isopropanol and from 0 to 5% alkylamine (typically 0.1% diethylamine). Concentration of the eluent provides an enriched mixture. Stereoisomeric aggregates can be separated by conventional techniques known to those skilled in the art. See, for example, "Stereochemistry of Organic Compounds" by Ernest L. Eliel (Wiley, New York, 1994).
[0189] Atropisomers are stereoisomers arising from hindered rotation about a single bond, where the steric strain barrier to rotation is high enough to allow separation of the conformers. Oki (Oki, M; Topics in Stereochemistry 1983, 1) defines atropisomers as conformers that interconvert with a half-life of more than 1000 seconds at a given temperature. The scope of the embodiments described and claimed herein encompasses the racemic forms of the compounds as well as individual atropisomers (atropisomers that are "substantially free" of their corresponding enantiomers) and stereoisomerically enriched mixtures (i.e., mixtures of atropisomers).
[0190] Separation of atropisomers may be performed by chiral resolution methods such as selective crystallization. In atropisomer-enantioselective synthesis or atropisomer-selective synthesis, one atropisomer is formed at the expense of the other atropisomer. When the isomerization reaction favors one atropisomer over the other atropisomer, atropisomer-selective synthesis can be performed by using a chiral auxiliary such as a Corey-Bakshi-Shibata (CBS) catalyst (an asymmetric catalyst derived from proline) in the total synthesis of knipholone or by methods based on thermodynamic equilibrium.
[0191] As used herein, the term "derivative thereof" refers to a salt thereof, a pharmaceutically acceptable salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a cocrystal thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
[0192] By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.
[0193] As used herein, the term "pharmaceutically acceptable salt" refers to a salt prepared from a base or acid that is acceptable for administration to a patient (e.g., a mammal). The term "pharmaceutically acceptable salt" includes salts that are commonly used to form alkali metal salts and addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Such salts can be derived from pharmaceutically acceptable inorganic or organic bases as well as from pharmaceutically acceptable inorganic or organic acids.
[0194] Suitable pharmaceutically acceptable acid addition salts of the compounds of the embodiments herein may be prepared from inorganic or organic acids. All of these salts may be prepared from the corresponding compounds of the embodiments herein by conventional means, for example, by treating the compounds with an appropriate acid or base.
[0195] Pharmaceutically acceptable acids include inorganic acids (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid, phosphoric acid, and pyrophosphoric acid) and organic acids (e.g., formic acid, acetic acid, trifluoroacetic acid, propionic acid, succinic acid, glycolic acid, pamoic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, pantothenic acid, benzenesulfonic acid, toluenesulfonic acid, sulfanilic acid, mesylic acid, cyclohexylaminosulfonic acid, stearic acid, algenic acid, β-hydroxybutyric acid, malonic acid, galactic acid, galacturonic acid, citric acid, fumaric acid, gluconic acid, glutamic acid, lactic acid, maleic acid, malic acid, mandelic acid, mucic acid, ascorbic acid, oxalic acid, pantothenic acid, succinic acid, tartaric acid, benzoic acid, acetic acid, xinafoic acid (1-hydroxy-2-naphthoic acid), napadisulfonic acid (naphthalene disulfonic acid), benzoic acid, acetic acid, xinafoic acid (1-hydroxy-2-naphthoic acid), napadisulfonic acid), benzoic acid, acetic acid, ... acid) (1,5-naphthalenedisulfonic acid, etc.).
[0196] Salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines, including alkylamines, arylalkylamines, heterocyclic amines, cyclic amines, naturally occurring amines, and the like, such as arginine, betaine, caffeine, choline, chloroprocaine, diethanolamine, N-methylglucamine, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
[0197] Other preferred salts according to embodiments herein are quaternary ammonium compounds in which the equivalent weight of the anion (X-) is related to the positive charge of the N atom. X- can be an anion of various inorganic acids (such as, for example, chloride, bromide, iodide, sulfate, nitrate, phosphate) or an anion of an organic acid (such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulfonate and p-toluenesulfonate). X- is preferably an anion selected from chloride, bromide, iodide, sulfate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate. More preferably, X- is chloride, bromide, trifluoroacetate or methanesulfonate.
[0198] In some embodiments, the salt is a hydrochloride salt. In some embodiments, the salt is a benzenesulfonate salt. In some embodiments, the salt is a trifluoroacetate salt.
[0199] The compound of the present embodiment can exist in an unsolvated form and a solvated form. The term solvate is used herein to describe a molecular complex including a compound of the present embodiment and a certain amount of one or more pharmaceutically acceptable solvent molecules. When the solvent is water, the term hydrate is used. The example of solvate form includes, but is not limited to, compounds of the present embodiment associated with water, acetone, dichloromethane, 2-propanol, ethanol, methanol, dimethyl sulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or a mixture thereof. It is particularly contemplated that, in embodiments herein, a solvent molecule can be associated with a molecule of the compound of the present embodiment, such as a hydrate.
[0200] Furthermore, it is specifically contemplated that, in the embodiments herein, more than one solvent molecule may be associated with one molecule of a compound of the embodiments herein, such as a dihydrate. Furthermore, it is specifically contemplated that, in the embodiments herein, less than one solvent molecule may be associated with one molecule of a compound of the embodiments herein, such as a hemihydrate. Furthermore, the solvates of the embodiments herein are contemplated as solvates of the compounds of the embodiments herein that retain the biological effectiveness of the non-solvated form of the compound.
[0201] The embodiments herein also include isotopically labeled compounds of the embodiments herein, in which one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of suitable isotopes for inclusion in the compounds of the embodiments herein include isotopes of hydrogen (e.g., 2 H and 3 H), carbon isotopes (such as 11 C. 13 C and 14 C), isotopes of chlorine (such as 31 Cl), fluorine isotopes (such as 18 F), iodine isotopes (such as 123 I and 125 I), nitrogen isotopes (such as 13 N and 15 N), oxygen isotopes (such as 15 O. 17 O and 18 O), phosphorus isotopes (such as 32 P), and sulfur isotopes (such as 35 S). Certain isotopically labeled compounds of the embodiments herein (e.g., those incorporating a radioactive isotope) are useful in drug and / or substrate tissue distribution studies. 3 H) and carbon-14 ( 14 C) are easily incorporated and readily available detection means, which are particularly useful for this purpose. 2 F) substitution may offer certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and thus may be preferred in some circumstances. 11 C. 18 F. 15 O and 13 N) substitutions can be useful in positron emission tomography (PET) studies for examining substrate receptor occupancy.
[0202] Isotopically-labeled compounds of the embodiments herein can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
[0203] Preferred isotopically labeled compounds include deuterated derivatives of the compounds of the present embodiments. As used herein, the term deuterated derivatives includes compounds of the present embodiments wherein at least one hydrogen atom at a particular position is replaced by deuterium. Deuterium (D or 2 H) is a stable isotope of hydrogen that occurs at a natural abundance of 0.015 mol %.
[0204] A hydrogen-deuterium exchange (deuterium incorporation) is a chemical reaction in which a covalently bonded hydrogen atom is replaced by a deuterium atom. The exchange (incorporation) reaction may be complete or partial.
[0205] Typically, the deuterated derivatives of the compounds of the embodiments herein have an isotopic enrichment factor (the ratio between the abundance of an isotope and the natural abundance of that isotope, i.e., the percentage of deuterium incorporated in place of hydrogen at a given position in a molecule) of at least 3500 (52.5% deuterium incorporation) for each deuterium present at a site designated as a potential deuteration site on the compound.
[0206] In some embodiments, the isotopic enrichment factor is at least 5000 (75% deuterium). In some embodiments, the isotopic enrichment factor is at least 6333.3 (95% deuterium incorporation). In some embodiments, the isotopic enrichment factor is at least 6633.3 (99.5% deuterium incorporation). It should be understood that the isotopic enrichment factor of each deuterium present at a site designated as a deuteration site is independent of the other deuteration sites.
[0207] Isotopic enrichment factors can be determined using conventional analytical methods known to those of ordinary skill in the art, including mass spectrometry (MS) and nuclear magnetic resonance (NMR).
[0208] The term "prodrug" refers to a compound with higher activity in vivo. Prodrugs of the compounds described herein are also within the scope of the embodiments herein. Therefore, certain derivatives of the compounds of the embodiments herein (the derivatives themselves may have little or no pharmacological activity) can be converted into compounds of the embodiments herein with desired activity, for example, by hydrolytic cleavage, when administered to or on the body. Such derivatives are referred to as 'prodrugs'. Further information on the application of prodrugs can be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. EB Roche, American Pharmaceutical Association) or Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003).
[0209] The prodrug of the compound described herein is a structurally modified form of a compound that is easily subjected to chemical changes under physiological conditions and provides a compound. In addition, the prodrug can be converted into a compound by a chemical method or a biochemical method in an in vitro environment. For example, when the prodrug is placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent, the prodrug can be slowly converted into a compound. Prodrugs are generally useful because in some cases, prodrugs can be easier to apply than compounds or parent drugs. For example, prodrugs can be bioavailable by oral administration, while parent drugs are not. Compared with parent drugs, prodrugs can also have improved solubility in pharmaceutical compositions. Various prodrug derivatives are known in the art, such as those that rely on the hydrolytic cleavage or oxidative activation of prodrugs. Examples of prodrugs (not limited to) are compounds that are applied as esters ("prodrugs") but are then metabolically hydrolyzed into carboxylic acids, active entities. Other examples include peptidyl derivatives of compounds. Prodrugs according to the embodiments herein can be prepared, for example, by replacing appropriate functional groups present in the compounds of the embodiments herein with certain moieties known to those skilled in the art as 'pro-moieties', as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
[0210] As used herein, the terms "excipient" and "pharmaceutically acceptable excipient" are intended to be generally synonymous and are used interchangeably with the terms "carrier," "pharmaceutically acceptable carrier," "diluent," and "pharmaceutically acceptable diluent."
[0211] Where the compounds of the embodiments herein are solids, it will be understood by those skilled in the art that the compounds and salts of the invention may exist in different crystalline or polymorphic forms or in amorphous form, all of which are intended to be within the scope of the embodiments herein.
[0212] The compounds disclosed herein may exist as, and therefore encompass, all stereoisomers, conformers, and mixtures thereof in all ratios, as well as isotopic forms (e.g., deuterated compounds).
[0213] When atoms connected by a bond are considered to be part of a larger substructure, the term "bond" refers to a covalent bond between two atoms, or two moieties. Unless otherwise specified, a bond can be a single bond, a double bond, or a triple bond. A dotted line between two atoms in a molecular diagram indicates that an additional bond may or may not be present at that position.
[0214] As used herein, the term "disease" is intended to be generally synonymous with and used interchangeably with the terms "disorder," "symptom," and "condition" (as in medical condition), as all reflect an abnormal condition of the human or animal body or one of its parts that impairs normal function, usually manifests itself by distinctive signs and symptoms, and causes the human or animal to have a reduced lifespan or quality of life.
[0215] The term "combination therapy" means the administration of two or more therapeutic agents to treat the therapeutic conditions or disorders described in this disclosure. Such administration includes co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients, or in multiple separate capsules of each active ingredient. In addition, such administration also includes the use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide a beneficial effect of the drug combination in treating the conditions or disorders described herein.
[0216] The term "ITK inhibitor" is used herein to refer to an inhibitory agent that exhibits an IC for ITK activity of no more than about 100 μM and more typically no more than about 50 μM. 50 (as measured in the ITK enzyme assay generally described herein). 50 is the concentration of an inhibitor that reduces the activity of an enzyme (e.g., ITK) to half-maximal levels. Certain compounds disclosed herein have been found to exhibit inhibition against ITK. In certain embodiments, the compound will exhibit an IC against ITK of no more than about 10 μM. 50 In a further embodiment, the compound will exhibit an IC against ITK of no more than about 5 μM 50 In yet further embodiments, the compound will exhibit an IC against ITK of no more than about 1 μM 50 In yet further embodiments, the compound will exhibit an IC against ITK of no more than about 200 nM 50 (as measured in the ITK binding assay described herein).
[0217] The term "immune checkpoint inhibitor" means a compound or pharmaceutical composition that inhibits an immune checkpoint molecule.
[0218] When used in conjunction with a therapeutic approach, "administering" means administering a therapeutic agent directly into or onto a target tissue, or administering a therapeutic agent to a patient, whereby the therapeutic agent positively affects the tissue to which it is targeted. Thus, as used herein, when used in conjunction with the compounds of the embodiments herein, the term "administering" may include, but is not limited to: providing the compound into or onto a target tissue; providing the compound systemically to the patient, for example, by intravenous injection, whereby the therapeutic agent reaches the target tissue; providing the compound in a form encoding its sequence to the target tissue (e.g., by so-called gene therapy techniques). "Administering" a composition can be achieved by injection, topical, oral, or by any of these methods in combination with other known techniques.
[0219] The term "patient" is generally synonymous with the term "subject" and includes all mammals (including humans). Examples of patients include humans, livestock (such as cows, goats, sheep, pigs, and rabbits), and companion animals (such as dogs, cats, rabbits, and horses). Preferably, the patient is a human.
[0220] The phrase "therapeutically effective" is intended to qualify the amount of active ingredient used for the treatment of a disease or disorder or the effect of a clinical endpoint.
[0221] As used herein, the term "therapeutic" or "therapeutic agent" or "pharmaceutically active agent" means an agent used to treat, combat, modify, prevent or ameliorate an undesirable condition or disease in a patient. In part, embodiments of the present invention are directed to the treatment of ITK-mediated diseases.
[0222] The "therapeutically effective amount" or "effective amount" of a composition is a predetermined amount calculated to achieve the desired effect (e.g., inhibition, retardation, reversal of cell activation, migration, or proliferation). The activity expected by the present method includes (as the case may be) both medical therapeutic treatment and / or prophylactic treatment. The specific dosage of the compound administered according to the present invention to obtain a therapeutic effect and / or preventive effect will of course be determined by the specific circumstances surrounding the case, including, for example, the compound administered, the route of administration, and the condition being treated. The compound is effective over a wide dosage range, and for example, the daily dosage will typically be in the range of 0.001mg / kg to 10mg / kg, more typically in the range of 0.01mg / kg to 1mg / kg. However, it will be understood that the effective amount administered will be determined by the physician according to relevant circumstances (including the condition to be treated, the selection of the compound to be administered, and the selected route of administration), and therefore, the above dosage range is not intended to limit the scope of the present invention in any way. A therapeutically effective amount of a compound of the invention is generally an amount sufficient to achieve effective systemic or local concentrations in tissues when the compound is administered in a physiologically tolerable excipient composition.
[0223] The term "therapeutically acceptable" refers to those compounds or derivatives thereof that are suitable for use in contact with the tissues of patients without excessive toxicity, irritation and allergic response, commensurate with a reasonable benefit / risk ratio, and effective for their intended use.
[0224] As used herein, the terms "treat," "treated," "treating," or "treatment" refer to both therapeutic treatment and / or prophylactic measures or preventative measures, wherein the object is to prevent or slow down (lessen) an undesirable physiological condition, disorder, or disease, or to obtain a beneficial or desired clinical result. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; reduction in the extent of the condition, disorder, or disease; stabilization of the state of the condition, disorder, or disease (i.e., not worsening); delay in the onset of the condition, disorder, or disease or slowing of the progression of the condition, disorder, or disease; alleviation of the condition, disorder, or disease state; and remission (whether partial or complete, whether induced or maintained), whether detectable or undetectable, of the condition, disorder, or disease, or enhancement or improvement of the condition, disorder, or disease. Treatment encompasses eliciting a clinically significant response without excessive levels of side effects. Treatment also encompasses prolonging survival compared to expected survival if not receiving treatment. Treatment can also be preemptive in nature, that is, it can comprise the prevention of disease.The prevention of disease can relate to being free from disease (for example, as in the case of preventing pathogen infection) completely, or can relate to the prevention of disease progression.For example, the prevention of disease may not mean the complete elimination of any influence relevant with disease on any level, but may mean that the symptom of disease is prevented to clinically significant or detectable level.The prevention of disease can also mean preventing disease progression to late stage of disease, and prolonging disease-free survival compared with untreated disease-free survival, and prolonging disease-free survival compared with untreated disease-free survival.
[0225] Also provided are compounds selected from the examples disclosed herein. The compounds of the embodiments herein may also refer to salts thereof, esters thereof, free acid forms thereof, free base forms thereof, solvates thereof, cocrystals thereof, deuterated derivatives thereof, hydrates thereof, N-oxides thereof, clathrates thereof, prodrugs thereof, polymorphs thereof, stereoisomers thereof, geometric isomers thereof, tautomers thereof, mixtures of tautomers thereof, enantiomers thereof, diastereomers thereof, racemates thereof, mixtures of stereoisomers thereof, isotopes thereof (e.g., tritium, deuterium), or combinations thereof of the foregoing compounds of the embodiments herein.
[0226] The present disclosure relates to novel pyrrolopyrimidine compounds and compositions and their use as medicaments for treating diseases. Also provided are methods of inhibiting ITK activity in human or animal subjects for treating diseases, such as those caused by inflammation.
[0227] The Tec (Tyrosine kinase expressed in hepatocellular carcinoma) family of tyrosine kinases (TFTKs) consists of five family members: Tec, BTK (Bruton's tyrosine kinase), BMX (myeloid kinase on chromosome X, also known as ETK), RLK (resting lymphocyte kinase, also known as TXK), and ITK (interleukin-2-inducible T-cell kinase, also known as EMT and TSK). These kinases are central to the regulation of hematopoietic cell biology and, more specifically, the development and activity of lymphocytes and myeloid cells. TFTKs share structural similarities with other non-receptor tyrosine kinases while displaying some family-specific motifs, resulting in a diverse domain architecture associated with complex localization, scaffolding, and activation mechanisms. Typically, TFTKs contain an amino-terminal plekstrin homology domain (PH domain) involved in lipid interactions and membrane targeting, followed by a proline-rich domain that is typically involved in Zn binding. 2+ The BTK homology domain (BH) of the phosphotyrosine binding SH2 domain and the carboxyl-terminal ATP binding kinase domain form the TFTK structure. With the exception of ETK and TEC, which are expressed in hepatocytes and endothelial cells, respectively, TFTK expression is generally limited to hematopoietic lineage cells. BMX is expressed in monocytes, granulocytes, and cardiac endothelial cells, while BTK is expressed in B cells and mast cells, but not in plasma cells and T cells. TEC, RLK, and ITK are all expressed in T cells. To date, the TFTK with the most obvious biological effect in T cells is ITK.
[0228] It has been shown that antigen / MHC-dependent activation of the T cell receptor (TCR) transduces its signal through ITK. TCR stimulation causes the activation of the kinase LCK and the subsequent phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) on CD3, thereby inducing the binding and activation of the kinase ZAP70. ZAP70 in turn phosphorylates the adaptor proteins LAT and SLP-76, which together with LCK and other proteins form a heteromultimeric signaling complex that activates PI3K and generates PIP3 on the plasma membrane. ITK binds to this signaling complex via the SH2 and SH3 domains and binds to PIP3 through its PH domain, resulting in LCK-dependent phosphorylation of ITK Y511 and subsequent ITK autophosphorylation of Y180. Activated ITK phosphorylates PLCγ1, which, once activated, hydrolyzes PIP2 into the second messengers IP3 and DAG. The cellular consequences of these events include calcium mobilization and flux, activation of the PKC and MEK / ERK pathways, and transcriptional activation of NFAT via AP1 and NFκ activation. As a key enzyme in the TCR activation pathway, ITK affects T cell function in a variety of ways, including positive and negative selection, cell differentiation, and cytokine production and release.
[0229] The role of ITK in T cell function has been described by genetic knockdown / kinase inactivation of the ITK gene in rodents and by characterization of individual human ITK mutants. Mice with null mutations in the itk gene express reduced numbers of mature T cells and a block in thymocyte development, as well as a reduced TCR-driven T cell proliferation response. Interestingly, IL2 and CD28 signaling and PMA / ionomycin-driven responses remain unchanged, indicating that the ITK response is membrane-proximal and stimulus-specific. It appears that ITK is responsible for the amplification of TCR signaling rather than an 'on / off' switch, as double knockout of T cells expressing TFTK, ITK and RLK in mice produces a more complete TCR inactivation phenotype compared to ITK gene deletion alone. Contrary to what appears to be a role for ITK in naive T cell activation ( In contrast to the regulatory effects of ITK on T helper cell activation, it plays a more prominent role in T helper cell differentiation. Several studies in ITK-deficient mice have demonstrated a reduction in the Th2 protective response to parasitic infection. This reduced Th2 response is associated with decreased concentrations of the Th2 cytokines IL4, IL5, IL13, and IL10, as well as reduced expression of RLK. In contrast to the requirement of ITK for mounting a Th2-driven response, it has little effect on the Th1 response. For example, IFNg production is partially inhibited in ITK knockout cells, while double ITK / RLK knockout has a more severe phenotype. Evaluation of Th17 T helper cells in vitro and in vivo studies of ITK knockout demonstrated a reduction in IL17A mRNA and protein, with little effect on IL17F. The role of ITK in cytotoxic CD8 + Role of ITK-deficient CD8 T cells + T cell stimulation resulted in decreased activation of PLCg1, ERK, and p38 MAPK, as well as Ca 2+ The loss of CD4 T cells results in a decreased proliferative response and production of effector cytokines (IL2, IL4, and IFNg) without affecting the cytolytic capacity of these cells. + T cells and CD8 + In addition to the defects observed in T cells, natural killer T cell development and responses to TCR stimulation are reduced in ITK knockout cells and animals.
[0230] Rodent knockout studies have revealed the effects of enzyme expression (not necessarily its catalytic activity) on biological responses. Since, in addition to its catalytic role, ITK also plays a role in scaffolding through its multidomain structure. It is important to describe the effects of blocking each of these functions on cell biology. ITK activities that are independent of kinase activity include recruitment of the guanine nucleotide exchange factor VAV to the cell membrane associated with actin polymerization (PH and SH2 domain dependence), antigen receptor stimulation, and receptor activation of SRF. However, ITK knockout mice expressing a transgenic deletion of the ITK kinase domain demonstrated that this kinase domain is essential for the induction of a normal Th2 response.
[0231] The relationship between ITK expression and activity and human disease has recently been documented in studies characterizing individuals who exhibit a correlation between mutations and / or expression in the gene encoding this protein and disease. The ITK gene was found to be elevated in peripheral blood T cells from patients with moderate to severe atopic dermatitis, a Th2-driven chronic inflammatory skin disease. An investigation into disease-associated single nucleotide polymorphisms (SNPs) in seasonal allergic rhinitis identified ITK as a significant risk factor. Human primary immunodeficiency was not found in siblings who died due to an immune disorder that causes lymphocyte proliferation following Epstein-Barr virus (EBV) infection. This disorder is associated with a missense (R335W) mutation in the SH2 domain of ITK that causes structural instability of the enzyme and reduced steady-state levels. This finding was confirmed and expanded in a study that identified three patients carrying the C1764G nonsense mutation in ITK that causes a premature stop codon and reduced protein expression and / or activity. These patients presented with EBV-positive Hodgkin lymphoma. These two reports show that mutational disruption of the ITK gene in humans causes an autosomal recessive lymphoproliferative disorder and identify this kinase as a key regulator in T cell biology.
[0232] In addition to the human genetic data summarized above, animal models also support ITK as a therapeutic target for autoimmune and inflammatory diseases. ITK knockout mice show reduced airway hypersensitivity and inflammation in a model of allergic asthma. In a mouse model of atopic dermatitis, ITK-deficient mice do not develop inflammation, while ITK inhibition reduces the response of wild-type mice. 2+ ITK-dependent regulation of mobilization and transcription factor induction makes it a key factor in protection against influenza A and HIV infection and viral replication. ITK inhibitors have been shown to alter HIV replication at multiple stages and have the potential to be effective HIV therapeutics.
[0233] From an oncology perspective, studies have demonstrated that ITK inhibitors selectively target and kill acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma, with minimal effect on normal T cells. ITK is highly expressed in transformed T-cell lines relative to normal T cells and other cancer cell lines. The effect of ITK inhibition on T-cell tumors was demonstrated in mouse xenograft models. Cancer evasion of the immune system due to induction (as opposed to priming) of tumor antigen tolerance is critical for tumor survival. Tumors that develop a microenvironment that induces T-cell anergy demonstrate altered T-cell gene expression, indicating a deviation from a Th2 phenotype. ITK inhibition will favor Th1 differentiation and may be used to enhance cancer immunotherapy.
[0234] The effectiveness of simultaneously suppressing the signal of both T cell receptor and cytokine receptor downstream is best exemplified by the field of organ transplantation (Halloran). The standard of care set up immediately after transplantation is to prevent immune transplant rejection by administering a cocktail of inhibitors that affect lymphocyte activation at different points. The most common drugs used in both the initial post-transplantation period and the discharge setting are calcineurin inhibitors (such as Prograf or Neoral) that block TCR signal conduction and antimetabolites (such as mycophenolate mofetil or rapamycin) downstream of the cytokines (such as IL-2 or IL-15) that block proliferation induction. These drugs cannot be used as monotherapy because they will need to cause higher doses of drug-specific toxicity. By using these drugs simultaneously with suboptimal doses, synergistic immunosuppression can be achieved with reduced toxicity. ITK is downstream of TCR, and JAK3 is downstream of the common g chain of cytokine receptors. By covalently modifying cysteine in the catalytic domains of the two kinases, the two enzymes can be inhibited with a single drug, thereby synergistically inhibiting the activation of T cells.
[0235] The detailed description proposed herein is provided to help those skilled in the art to practice the present disclosure. However, the scope of the disclosure described and claimed herein is not limited by the specific embodiments disclosed herein, because these embodiments are intended to be illustrations of several aspects of the present disclosure. Any equivalent embodiments are intended to be within the scope of the present disclosure. In fact, in addition to those shown and described herein, various modifications of the present disclosure will become apparent to those skilled in the art from the foregoing description, and the modifications do not depart from the spirit or scope of the present invention. Such modifications are also intended to fall within the scope of the appended claims.
[0236] All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended only to summarize the assertions made by their authors and does not constitute an admission that any reference constitutes prior art relevant to patentability. Applicants reserve the right to challenge the accuracy and pertinence of the cited references. Specific implementation plan
[0237] Compound
[0238] In some embodiments, the compound has structural formula (I):
[0239]
[0240] in:
[0241] X is N or CR3;
[0242] n is 0, 1, or 2;
[0243] m is 0, 1, or 2;
[0244] R1 is selected from COOR6, C1-C5 alkyl-COOR6, bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally substituted with one or more groups selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR6, or C1-C5-alkyl-COOR6;
[0245] R2 is selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, CN, OH, C1-C5 alkoxy, and halogen, wherein two R2 groups on the same carbon may or may not be connected to a heteroatom to form a spirocyclic ring system;
[0246] R3 is selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0247] R4 is selected from H, C1-C6 alkyl;
[0248] R5 is selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy or C1-C6 alkyl-heterocyclyl;
[0249] R6 is selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0250] and derivatives of the compounds of formula (I).
[0251] In the embodiments of the compounds of formula (I), the compounds of the present disclosure are administered with a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[0252] Embodiments of the present disclosure are directed to compounds having structural formula (II):
[0253]
[0254] in:
[0255] X is N or CR 23 ;
[0256] n is 0, 1, or 2;
[0257] m is 0, 1, or 2;
[0258] R 21 Selected from COOR 26 、C1-C5 alkyl-COOR 26 , bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR 26 , or C1-C5-alkyl-COOR 26 substituted with one or more groups;
[0259] R 22 is selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, CN, OH, C1-C5 alkoxy, halogen, and wherein two R2 groups on the same carbon may or may not be connected to a heteroatom to form a spirocyclic ring system;
[0260] R 23 Selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0261] R 24 Selected from H, C1-C6 alkyl;
[0262] R 25is selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy or C1-C6 alkyl-heterocyclyl;
[0263] R 26 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0264] and derivatives of the compound of formula (II).
[0265] In the embodiment of the compound of formula (II), the compound of the present disclosure is administered with a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[0266] Embodiments of the present disclosure are directed to compounds having structural formula (III):
[0267]
[0268] in:
[0269] X is CR 33 or N;
[0270] n is 1 or 2;
[0271] When n is 1, m is 0, 1, or 2, and when n is 2, m is 1;
[0272] R 31 Selected from COOR 36 、C1-C5 alkyl-COOR 36 , bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR 36 , or C1-C5-alkyl-COOR 36 substituted with one or more groups;
[0273] R 32Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl;
[0274] R 33 Selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0275] R 34 Selected from H, C1-C6 alkyl;
[0276] R 35 Selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy;
[0277] R 36 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0278] and derivatives of the compound of formula (III).
[0279] In the embodiment of the compound of formula (III), the compound of the present disclosure is administered with a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[0280] Embodiments of the present disclosure are directed to compounds having structural formula (IV):
[0281]
[0282] in:
[0283] X is CR 43 or N;
[0284] n is 1 or 2;
[0285] When n is 1, m is 0, 1, or 2, and when n is 2, m is 1;
[0286] R 41 Selected from COOR 46 、C1-C5 alkyl-COOR 46, bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-C5-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, C(O)C3-C6 heterocyclyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN, halogen, COOR 46 , or C1-C5-alkyl-COOR 46 substituted with one or more groups;
[0287] R 42 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl;
[0288] R 43 Selected from H, CN, C1-C6 alkyl, C3-C6 cycloalkyl;
[0289] R 44 Selected from H, C1-C6 alkyl;
[0290] R 45 Selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6-alkyl-NH2, C1-C6 alkylNH(C1-C6 alkyl), C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl), C1-C5 alkyl-C1-C5 alkoxy;
[0291] R 46 Selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy, C1-C5 alkyl-OH, C1-C5 alkyl-NH2, C1-C5 alkyl-NH-C1-C5 alkyl, and C1-C5 alkyl-N-(C1-C5 alkyl)(C1-C5 alkyl);
[0292] and derivatives of the compound of formula (IV).
[0293] In the embodiment of the compound of formula (IV), the compound of the present disclosure is administered with a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[0294] In some embodiments, the compound of formula (I) or a derivative of the compound of formula (I) may be selected from:
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309] In some embodiments, the compound of formula (III) or a derivative of the compound of formula (III) may be selected from:
[0310]
[0311]
[0312] Pharmaceutical composition
[0313] Also provided are pharmaceutical compositions comprising a compound disclosed herein and a pharmaceutically acceptable excipient.
[0314] In certain embodiments, a pharmaceutical composition may include from about 0.01% to about 50% of one or more compounds disclosed herein. In some embodiments, the content of one or more compounds is from about 0.01% to about 50%, from about 0.01% to about 45%, from about 0.01% to about 40%, from about 0.01% to about 30%, from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.01% to about 5%, from about 0.05% to about 50%, from about 0.05% to about 45%, from about 0.05 ... .05% to about 30%, about 0.05% to about 20%, about 0.05% to about 10%, about 0.1% to about 50%, about 0.1% to about 45%, about 0.1% to about 40%, about 0.1% to about 30%, about 0.1% to about 20%, about 0.1% to about 10%, about 0.1% to about 5%, about 0.5% to about 50%, about 0.5% to about 45%, about 0.5% to about 40%, about 0.5% to about 30%, about 0.5% to about 20%, about 0.5% to about 10%, about 0.5% to about 5%, about 1% to about 50%, about 1% to about 45%, about 1% to about 40%, about 1% to about 35%, about 1% to about 30%, about 1% to about 25%, about 1% to about 20%, about 1% to about 15%, about 1% to about 10%, about 1% to about 5%, about 5% to about 45%, about 5 % to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 5% to about 10%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, or a value within one of these ranges. Specific examples can include about 0.01%, about 0.05%, about 0.1%, about 0.25%, about 0.5%, about 0.75%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 60%, about 70%, about 80%, about 90%, or a range between any two of these values. All of the foregoing represent percentages by weight of the pharmaceutical composition.
[0315] In some embodiments, the compound is in a therapeutically effective amount. In some embodiments, a therapeutically effective amount can be from about 1 mg to about 1000 mg, from about 1 mg to about 900 mg, from about 1 mg to about 800 mg, from about 1 mg to about 700 mg, from about 1 mg to about 600 mg, from about 1 mg to about 500 mg, from about 1 mg to about 400 mg, from about 1 mg to about 300 mg, from about 1 mg to about 200 mg, from about 1 mg to about 100 mg, from about 10 mg to about 1000 mg, from about 50 mg to about 1000 mg, from about 100 mg to about 1000 mg, from about 200 mg to about 1000 mg. g, about 300 mg to about 1000 mg, about 400 mg to about 1000 mg, about 500 mg to about 1000 mg, about 10 mg to about 500 mg, about 50 mg to about 500 mg, about 100 mg to about 500 mg, about 100 mg to about 300 mg, about 50 mg to about 300 mg, from about 100 mg to about 300 mg, about 10 mg to about 150 mg, about 50 mg to about 150 mg, about 60 mg to about 120 mg, about 50 mg to about 120 mg, or a range between any two of these values. Specific examples include, for example, about 1000 mg, about 900 mg, about 800 mg, about 700 mg, about 750 mg, about 600 mg, about 500 mg, about 400 mg, about 450 mg, about 300 mg, about 250 mg, about 200 mg, about 175 mg, about 150 mg, about 125 mg, about 120 mg, about 110 mg, about 100 mg, about 90 mg, about 80 mg, about 70 mg, about 60 mg, about 50 mg, about 30 mg, about 20 mg, or any value between the ranges disclosed above.
[0316] Although the compounds described herein may be administered in the form of raw materials, it is also possible to present them as pharmaceutical compositions. Therefore, pharmaceutical compositions are provided herein, and pharmaceutical compositions include one or more of some compounds disclosed herein, or derivatives thereof, and one or more pharmaceutically acceptable excipients and optional one or more other therapeutic ingredients. One or more excipients must be "acceptable" in the sense that they are compatible with the other ingredients of the preparation and harmless to the recipient. The appropriate formulation of the pharmaceutical composition depends on the selected route of administration. Any of the known techniques and excipients can be used as is suitable and understood in the art. Pharmaceutical compositions disclosed herein can be manufactured in any manner as known in the art, for example, by conventional mixing processes, dissolution processes, granulation processes, dragee manufacturing processes, grinding processes, emulsification processes, encapsulation processes, entrapping processes, or compression processes.
[0317] In some embodiments, pharmaceutical compositions for use in accordance with the embodiments herein may be formulated in conventional manner using one or more physiologically acceptable excipients.
[0318] When used as medicine, compound can be applied in the form of pharmaceutical composition.These compositions can be prepared in a manner known to the pharmaceutical field, and can be applied by various approaches according to whether local treatment or systemic treatment and the area to be treated are desired.The application of disclosed compound or composition can be oral administration, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular and intramedullary) application, pulmonary (for example, by inhalation or insufflation (including by nebulizer) of powder or aerosol; Intratracheal or intranasal) application, intraperitoneal application, intrathecal application, intradural application, transmucosal application, transdermal application, rectal application, local (including skin, cheek, sublingual and intraocular) application or intravaginal application. Parenteral administration includes intravenous application, intraarterial application, subcutaneous application, intraperitoneal application, intramuscular application or injection application or infusion application; or intracranial (for example, intrathecal or intraventricular) application. Parenteral administration can be in the form of a single dose, or can be carried out, for example, by continuous infusion pump. The pharmaceutical composition for topical application can include foams, transdermal patches, ointments, lotions, creams, gels, solutions, liquid emulsions, liquid suspensions, semisolids, pastes, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous powders or oily bases, thickeners etc. can be necessary or desirable. Coated condoms, gloves etc. can also be useful. In some embodiments, the compound can be contained in such a preparation pharmaceutical composition together with a pharmaceutically acceptable diluent, filler, disintegrant, binding agent, lubricant, surfactant, hydrophobic vehicle, water-soluble vehicle, emulsifier, buffer, wetting agent, humectant, solubilizing agent, preservative etc. The technician can refer to various pharmaceutical references as guidance. For example, one may consult Modern Pharmaceutics, 5th Edition, Banker & Rhodes, CRC Press (2009); and Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 13th Edition, McGraw Hill, New York (2018).
[0319] In some embodiments, the method of treating an ITK-mediated disease comprises administering a compound or pharmaceutical composition of the embodiments disclosed herein. In some embodiments, the compound is in a therapeutically effective amount. In some embodiments, the therapeutically effective amount is an amount disclosed herein.
[0320] Some embodiments disclosed herein also encompass pharmaceutical compositions containing, as active ingredients, one or more of the compounds disclosed herein in combination with one or more pharmaceutically acceptable carriers (excipients).
[0321] In some embodiments, the method of making a pharmaceutical composition comprises mixing the active ingredient with an excipient, diluting the active ingredient with the excipient, or enclosing the active ingredient in a carrier, such as in the form of a capsule, sachet, paper, or other container. When the excipient acts as a diluent, it can be a solid material, a semisolid material, or a liquid material that acts as a solvent, carrier, or medium for the active ingredient. Thus, the pharmaceutical composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments (containing, for example, up to 10% by weight of the active compound), soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
[0322] Some examples of suitable excipients include the following: lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, and methylcellulose containing a deep eutectic solvent, a deep eutectic ionic liquid, or an ionic liquid. The pharmaceutical composition may additionally contain: lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl hydroxybenzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents. By employing procedures known in the art, the pharmaceutical composition can be formulated to provide rapid, sustained, or delayed release of the active ingredient after administration to the patient.
[0323] Pharmaceutical composition can be formulated into unit dosage form.Term " unit dosage form " refers to the physically unrelated unit that is suitable as the unit dose for human subjects and other mammals, and each unit contains the active material of the predetermined amount of calculated therapeutic effect that produces expectation, in conjunction with suitable pharmaceutical excipient.Although the most suitable approach can depend on the patient's condition and disorder of for example recipient, composition comprises and is suitable for oral administration, parenteral (comprising subcutaneous, intradermal, intramuscular, intravenous, intraarticular and intramedullary) administration, intraperitoneal administration, intrathecal administration, intradural administration, transmucosal administration, transdermal administration, rectal administration, intranasal administration, local (comprising for example skin, cheek, sublingual and intraocular) administration, intravitreal administration or intravaginal administration those compositions.Composition can comprise those compositions that are suitable for injection by reservoir or by implantation administration.Composition can comprise those compositions that are suitable for by suction (as, for example, gas, steam or powder) administration.Composition can comprise those compositions that are suitable for, for example, via sprayer, humidifier, inhaler and vaporizer etc. and use in aerosol form. Compositions can be conveniently presented in unit dosage form and can be prepared by any method known in the pharmaceutical field. Typically, these methods include the step of combining a compound disclosed herein or a derivative thereof ("active ingredient") with a carrier constituting one or more auxiliary ingredients. Typically, the active ingredient is uniformly and closely combined with a liquid carrier or a finely ground solid carrier or both a liquid carrier and a finely ground solid carrier, and then the product is shaped into the desired composition (if necessary) to prepare the composition.
[0324] Compositions of the compounds disclosed herein suitable for oral administration can be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion. The active ingredient can also be presented as a bolus, electuary, or paste.
[0325] Pharmaceutical preparations that can be used orally include tablets, push-fit capsules made of gelatin, and sealed soft capsules made of gelatin and plasticizers (such as glycerol or sorbitol). Tablets can be made by compressing or molding with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing the active ingredient (such as powder or granules) in a free-flowing form (optionally mixed with a binder, inert diluent, or lubricant, surfactant or dispersant) in a suitable machine. Die-stamped tablets can be made by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. Tablets can be optionally coated or scored and can be formulated to provide a slow release or controlled release of the active ingredient therein. The entire composition for oral administration should be in a dosage suitable for such administration. Push-fit capsules can contain an active ingredient mixed with a filler (such as lactose), a binder (such as starch), and / or a lubricant (such as talc or magnesium stearate), and an optional stabilizer. In soft capsules, the active compound can be dissolved in or suspended in a suitable liquid (such as fatty oil, liquid paraffin or liquid polyethylene glycol). In addition, a stabilizing agent can be added. The dragee core is provided with a suitable coating. For this reason, concentrated sugar solution can be used, and concentrated sugar solution can contain gum arabic, talcum, polyvinyl pyrrolidone, carbomer gel, polyethylene glycol and / or titanium dioxide, lacquer solution and a suitable organic solvent or solvent mixture alternatively. Coloring agent or pigment can be added to tablet or the dragee coating to identify or characterize the different combinations of active compound dosage.
[0326] To prepare solid compositions (such as tablets), the main active ingredient can be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a uniform mixture of the compounds of the invention. When these preformulation compositions are referred to as uniform, the active ingredient is generally evenly dispersed throughout the pharmaceutical composition so that the pharmaceutical composition can be easily and evenly divided into therapeutically effective unit dosage forms (such as tablets, pills, and capsules). The solid preformulation is then further divided into unit dosage forms of the above type containing, for example, from about 0.1 mg to about 1000 mg of the active ingredient.
[0327] Tablet of the present invention or pill can be coated or otherwise compound to provide the dosage form of the advantage of giving prolonged effect.For example, tablet or pill can comprise inner dosage component and outer dosage component, and the latter is the form of the wrapper on the former.These two kinds of components can be separated by enteric layer, and enteric layer is used for resisting the disintegration in stomach, and allows inner component to enter duodenum intact or be delayed release.Various materials can be used for such enteric layer or coating, and such material comprises the mixture of many polymeric acids and polymeric acids and material (such as shellac, cetyl alcohol and cellulose acetate).
[0328] Liquid forms for oral administration or by injection in which the compounds and compositions of the present invention may be incorporated include aqueous solutions, appropriately flavored syrups, aqueous or oily suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
[0329] The compound can be formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). Compositions for injection can be present in unit dosage form, for example, in ampoules or multidose containers with added preservatives. Pharmaceutical compositions can be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles and can contain formulatory agents such as suspending agents, stabilizers, and / or dispersants. Compositions can be present in unit dose containers or multidose containers (e.g., sealed ampoules and vials) and can be stored in powder form or under freeze-dried (lyophilized) conditions requiring only the addition of a sterile liquid carrier (e.g., saline or sterile pyrogen-free water) prior to use. Extemporaneous injections and suspensions can be prepared from the aforementioned sterile powders, granules, and tablets.
[0330] Pharmaceutical compositions for parenteral administration include aqueous and non-aqueous (oily) sterile injections of the active compound (which may contain antioxidants, buffers, bacteriostats, and solutes that render the composition isotonic with the blood of the intended recipient); and aqueous and non-aqueous sterile suspensions (which may contain suspending agents and thickening agents). Suitable lipophilic solvents or vehicles include fatty oils (such as sesame oil), or synthetic fatty acid esters (such as ethyl oleate or triglycerides), or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension (such as sodium carboxymethylcellulose, sorbitol, or dextran). Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compound to allow the preparation of highly concentrated solutions.
[0331] In addition to the pharmaceutical composition described above, the compound can also be formulated into a depot preparation. Such a long-acting composition can be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Therefore, for example, the compound can be formulated with a suitable polymeric material or hydrophobic material (e.g., as an emulsion in an acceptable oil) or an ion exchange resin, or be formulated into a slightly soluble derivative (e.g., formulated into a slightly soluble salt).
[0332] For buccal or sublingual administration, the pharmaceutical compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may include the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
[0333] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
[0334] Certain compounds disclosed herein can be administered topically (i.e., by non-systemic administration). This includes applying the compounds disclosed herein externally to the epidermis or buccal cavity, as well as instilling such compounds into the ears, eyes, and nose, so that the compounds do not enter the bloodstream to a significant extent. In contrast, systemic administration refers to oral administration, intravenous administration, intraperitoneal administration, and intramuscular administration.
[0335] In some embodiments, the pharmaceutical composition is suitable for topical administration. In some embodiments, the pharmaceutical composition is suitable for oral administration. In some embodiments, the composition is suitable for oral administration, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular and intramedullary) administration, intraperitoneal administration, intrathecal administration, intradural administration, transmucosal administration, transdermal administration, rectal administration, intranasal administration, topical (including, for example, skin, buccal, sublingual and intraocular) administration, intravitreal administration, or intravaginal administration.
[0336] In some embodiments, the compounds disclosed herein can be administered ophthalmically. In some embodiments, the compounds disclosed herein can be administered in the form of ophthalmic compositions. The compounds of the embodiments herein can be administered in the form of, for example, liquid preparations (including eye lotions, sprays, or eye drops for topical administration). In some embodiments, the compounds disclosed herein can be administered (for example, applied to eyelids) in the form of semisolid preparations (such as creams, lotions, gels, ointments, or pastes). In some embodiments, the compounds disclosed herein can be administered (for example, applied to the eye surface) in the form of solid dosage forms (such as powders) to produce improved release. In some embodiments, the compounds of the embodiments herein are administered by devices for surgical implantation, parenteral products (for example, intracorneal products or intravitreal products), liquids for rinsing, etc. In some embodiments, the pharmaceutical compositions including the compounds disclosed herein are sterile and free of particulate matter. In some embodiments, the compounds disclosed herein can be administered by intraocular injection, intraorbital injection, or intravitreal injection. In some embodiments, intraocular injection can be for the anterior chamber of the eye, the posterior chamber of the eye, or a combination thereof. For example, the compounds disclosed herein can be administered to the posterior intraorbital region of the eye.
[0337] In some embodiments, pharmaceutical compositions suitable for topical administration comprise liquid or semi-liquid formulations (such as solutions, powders, liquid emulsions, liquid suspensions, semisolids, gels, liniments, lotions, creams, ointments, pastes, jelly, foams, and drops suitable for administration to the eye, ear, or nose) suitable for penetration through the skin to the site of inflammation. The active ingredient for topical administration can comprise, for example, from 0.001% w / w to 10% w / w (by weight) of the composition. In certain embodiments, the active ingredient can comprise up to 10% w / w. In other embodiments, it can comprise less than 5% w / w. In certain embodiments, the active ingredient can comprise from 2% w / w to 5% w / w. In other embodiments, it can comprise from 0.1% w / w to 1% w / w of the composition.
[0338] Gels for topical or transdermal administration can generally include a mixture of a volatile solvent, a non-volatile solvent, and water. In certain embodiments, the volatile solvent component of the buffered solvent system can include lower (C1-C6) alkyl alcohols, lower alkyl glycols, and lower glycol polymers. In other embodiments, the volatile solvent is ethanol. The volatile solvent component is considered to serve as a penetration enhancer and also produces a cooling effect on the skin when evaporated. The non-volatile solvent portion of the buffered solvent system is selected from lower alkylene glycols and lower glycol polymers. In certain embodiments, propylene glycol is used. The non-volatile solvent slows down the evaporation of the volatile solvent and reduces the vapor pressure of the buffered solvent system. The same as the volatile solvent, the amount of this non-volatile solvent component is determined by the pharmaceutical compound or medicine used. When the non-volatile solvent in the system is too little, the pharmaceutical compound may crystallize due to the evaporation of the volatile solvent, and excessive amounts may cause a lack of bioavailability due to poor release of the drug from the solvent mixture. The buffer component of the buffered solvent system can be selected from any buffer commonly used in the art; in certain embodiments, water is used. A common ratio of ingredients is about 20% non-volatile solvent, about 40% volatile solvent, and about 40% water. There are several optional ingredients that can be added to the topical composition. These include, but are not limited to, chelating agents and gelling agents. Suitable gelling agents may include, but are not limited to, semisynthetic cellulose derivatives (such as hydroxypropyl methylcellulose) and synthetic polymers, as well as cosmetic agents.
[0339] Lotions include those suitable for application to the skin or eyes. Eye lotions may include sterile aqueous solutions optionally containing bactericides and may be prepared by methods similar to those used for preparing drops. Lotions or liniments for application to the skin may also include agents that accelerate drying and cool the skin (such as alcohol or acetone), and / or humectants (such as glycerol) or oils (such as castor oil or peanut oil).
[0340] Creams, ointments or pastes are semisolid pharmaceutical compositions of active ingredients for external use. They can be made by mixing finely ground or powdered active ingredients (alone or in a solution or suspension in an aqueous or non-aqueous fluid) with an oily or non-oily base using a suitable machine. The base can include hydrocarbons such as hard paraffin, soft paraffin or liquid paraffin, glycerol, beeswax, metallic soaps; mucilage; oils of natural origin such as almond oil, corn oil, peanut oil, castor oil or olive oil; lanolin or its derivatives or fatty acids (such as stearic acid or oleic acid) and alcohols (such as propylene glycol) or macrogranular gels. The pharmaceutical composition can incorporate any suitable surfactant, such as anionic surfactants, cationic surfactants or nonionic surfactants (such as sorbitan esters or their polyethylene oxide derivatives). It can also contain suspending agents (such as natural gums), cellulose derivatives or inorganic materials (such as siliceous silica), and other ingredients (such as lanolin).
[0341] Drops can include aseptic aqueous or oily solutions or suspensions, and can be prepared by dissolving active ingredient in a suitable aqueous solution of bactericide and / or fungicide and / or any other suitable preservative (and comprising a surfactant in certain embodiments). The resulting solution can then be clarified by filtration, transferred to a container sealed after being suitable, and sterilized by autoclaving or keeping at 98°C-100°C for half an hour. Alternatively, the solution can be sterilized by filtration, and transferred to a container by aseptic technique. The example of the bactericide and fungicide suitable for being included in the drops is phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%), and chlorhexidine acetate (0.01%). The solvent suitable for preparing an oily solution comprises glycerol, diluted alcohol, and propylene glycol.
[0342] Pharmaceutical compositions for topical administration in the mouth, for example, buccal or sublingual, include lozenges comprising the active ingredient in a flavored base such as sucrose and acacia or tragacanth and pastilles comprising the active ingredient in a base such as gelatin and glycerin or sucrose and acacia.
[0343] For administration by inhalation, the compound can be conveniently delivered from an insufflator, a nebulizer pressurized package or other convenient means of delivering an aerosol spray. The pressurized package can include a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compound according to the present invention can be in the form of a dry powder composition (e.g., a powder mixture of the compound and a suitable powder base (e.g., lactose or starch)). The powder composition can be present in, for example, a capsule, a cartridge, a gelatin package or a blister pack in a unit dosage form from which the powder can be administered by means of an insufflator or insufflator.
[0344] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the pharmaceutical composition is administered orally or via the nasal respiratory route to produce a local or systemic effect. The composition can be atomized using an inert gas. The atomized solution can be breathed directly from the atomizing device, or the atomizing device can be connected to a face mask tent or intermittent positive pressure breathing machine. Solution compositions, suspension compositions, or powder compositions can be administered orally or nasally from a device that delivers the composition in an appropriate manner.
[0345] In some embodiments, the pharmaceutical composition used to the patient can be in the form of the above-mentioned pharmaceutical composition. In some embodiments, these compositions can be sterilized by conventional sterilization techniques, or can be aseptically filtered. Aqueous solutions can be packaged to use as is or lyophilized (lyophilized preparation is combined with sterile aqueous carrier before use). In some embodiments, the pH of the compound formulation is about 3 to about 11, about 5 to about 9, about 5.5 to about 6.5 or about 5.5 to about 7.5. It will be understood that the use of some of the aforementioned excipients, carriers or stabilizers will cause the formation of pharmaceutical salts.
[0346] Preferred unit dosage pharmaceutical compositions are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
[0347] It should be understood that in addition to the ingredients particularly mentioned above, the pharmaceutical compositions described above may include other agents conventional in the art having regard to the type of pharmaceutical composition in question, for example those suitable for oral administration may include flavoring agents.
[0348] In some embodiments, the therapeutically effective amount can vary according to, for example, the specific application being treated, the mode of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compound in the pharmaceutical composition can vary according to many factors (including dosage, chemical properties (e.g., hydrophobicity), and route of administration). For example, the compound can be provided in a physiological buffered aqueous solution containing about 0.1% w / v to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges of the compound are from about 1 μg / kg body weight per day to about 1g / kg body weight per day. In some embodiments, the dosage range is from about 0.01mg / kg body weight per day to about 100mg / kg body weight per day. The dosage may depend on variables such as the type and degree of progression of the disease or disorder, the overall health of a particular patient, the relative biological efficacy of the selected compound, the composition of the excipient, and its route of administration. The effective dose can be inferred from a dose-response curve derived from an in vitro or animal model test system.
[0349] The amount of compound or composition administered to a patient will vary depending on what is being administered, the purpose of the administration (e.g., prophylaxis or treatment), the state of the patient, the mode of administration, etc. In therapeutic applications, the composition can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications.
[0350] The active compound can be effective over a wide dosage range and can generally be administered in a therapeutically effective amount. However, it will be understood that the amount of compound actually administered will generally be determined by a physician based on the relevant circumstances (including the condition to be treated, the route of administration selected, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, etc.).
[0351] The compound can be administered orally or via injection at a dosage of from 0.1 mg / kg to 500 mg / kg per day. The dosage range for adults is generally from 5 mg / day to 2 g / day. The tablet or other presentation provided in discrete units can conveniently contain one or more compounds in such a dosage or as a multiple of an equal dose, for example, a unit containing 5 mg to 500 mg (usually about 10 mg to 200 mg).
[0352] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
[0353] The compound can be administered in various ways, for example, orally, topically, or by injection. The precise amount of the compound administered to the patient will be the responsibility of the visiting physician. The specific dosage level for any particular patient will depend on a variety of factors, including the activity, age, body weight, general health, sex, diet, time of administration, route of administration, excretion rate, drug combination, the exact disorder being treated, and the indication being treated or the severity of the patient's condition. In addition, the route of administration can vary depending on the patient's condition and its severity.
[0354] The composition may also contain one or more additional pharmaceutical agents (such as a chemotherapeutic agent, a steroid, an anti-inflammatory compound, or an immunosuppressant).
[0355] Treatment
[0356] Some embodiments herein are directed to methods of modulating ITK-mediated function in a subject, the methods comprising administering a therapeutically effective amount of a compound disclosed herein. In some embodiments, a method of inhibiting ITK in a subject comprises administering to the subject a compound of the embodiments herein.
[0357] The present invention also relates to methods for inhibiting the function of at least one ITK, comprising contacting an ITK with a compound described herein. Cell phenotype, cell proliferation, ITK activity, changes in the biochemical output of active ITK, ITK expression, or binding of ITK to its natural binding partner can be monitored. Such methods can include therapeutic modalities for disease, biological assays, cell-based assays, biochemical assays, and the like.
[0358] The compounds of the present invention can be used as JAK3 kinase inhibitors and inhibitors of ITK. The dual purpose of a single compound inhibiting the ITK pathway or the JAK3 pathway alone or simultaneously inhibiting both pathways can lead to beneficial effects. Therefore, the compounds of the present invention can be used to treat a variety of diseases or conditions mediated by ITK activity, JAK3 activity, or both. Therefore, some embodiments herein are directed to using the compounds disclosed herein to treat or prevent diseases or conditions in which JAK (particularly JAK3) plays an active role. In some embodiments, the method for treating a JAK3-mediated disease or disorder in a subject includes administering a compound of the embodiments herein to the subject. Some embodiments provide a method for treating a JAK3-mediated disease in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a compound or composition according to the present disclosure to the subject. Also provided is the use of compounds disclosed herein in the preparation of a medicament for treating a disease or condition alleviated by inhibiting JAK3, ITK, or a combination thereof. The embodiments of the methods of treating the conditions or diseases mediated by ITK discussed herein can also be applied to methods of treating the conditions or diseases mediated by JAK3.
[0359] Also provided herein are methods for treating ITK-mediated or JAK3-mediated diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, a derivative of a compound disclosed herein, or a combination thereof. In certain embodiments, a therapeutically effective amount of a compound disclosed herein, a derivative of a compound disclosed herein, or a combination thereof may be in the form of a pharmaceutical composition. In embodiments, the pharmaceutical composition may comprise a pharmaceutically acceptable excipient.
[0360] Also provided herein are methods of inhibiting ITK activity or JAK3 activity in a cell population, comprising administering to the cell population one or more compounds disclosed herein, derivatives thereof, or combinations thereof in an amount effective to inhibit ITK activity or JAK3 activity in the cell population. In some embodiments, the cell population is a human cell population.
[0361] In some embodiments, the present invention provides a method for treating an ITK-mediated or JAK3-mediated disease or disorder in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of the embodiments herein, or a composition thereof. Such ITK-mediated diseases or disorders include, but are not limited to, those described herein.
[0362] In some embodiments, diseases or disorders associated with ITK kinase or JAK3 kinase treated by the compounds of the present invention include autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, autoinflammatory disorders, fibrotic disorders, metabolic disorders, neoplasia, cardiovascular disorders or cerebrovascular disorders, respiratory diseases, allergic reactions and allergic diseases and allergic hypersensitivity disorders, immune disorders, proliferative disorders, transplant rejection, graft-versus-host disease, HIV, aplastic anemia, pain (including inflammatory pain), and other diseases and disorders associated with ITK.
[0363] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is selected from a skin disorder, pruritus, hair loss disorder, cancer, a neoplasm, Alzheimer's disease, an inflammatory condition, a connective tissue disease, an autoimmune condition, asthma, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, contact hypersensitivity, and inflammatory bowel disease.
[0364] In some embodiments, the compounds and pharmaceutical compositions of the present disclosure may be administered in therapeutically effective amounts to prevent or treat HIV.
[0365] In certain embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a neoplasm, a malignancy, a myeloproliferative disorder, a hematopoietic neoplasm, a spinal cord neoplasm, a lymphoid neoplasm (including myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia, leukemia, childhood leukemia, acute leukemia, acute lymphocytic T-cell leukemia, acute leukemia and chronic leukemia, lymphoma (including systemic lymphoma, T-cell lymphoma, B-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, cutaneous lymphoma (including but not limited to cutaneous T-cell lymphoma (CTCL), mycosis fungoides and cutaneous B-cell lymphoma)), other myeloid malignancies, and myelodysplastic syndrome. In certain embodiments, the ITK-mediated or JAK3-mediated disease or disorder is resistant to prior therapy (e.g., a cancer that is resistant to or has failed chemotherapy).
[0366] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is an autoimmune disorder, a chronic and / or acute inflammatory disorder, and / or an autoinflammatory disorder. Exemplary autoimmune and / or inflammatory disorders and / or autoinflammatory disorders include: arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, systemic onset juvenile idiopathic arthritis, Still's disease, adult-onset Still's disease, seronegative spondyloarthropathies, osteoarthritis, enthesitis, terminal disease, infectious arthritis, Lyme disease, inflammatory arthritis, inflammatory bowel disease-associated arthritis, myositis, autoimmune myositis, carditis, myocarditis, dermatomyositis, juvenile dermatomyositis, idiopathic arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, ankylosing spondylitis, gout, scleroderma, juvenile scleroderma, Lyme disease, inflammatory arthr ... syndrome, spondylitis, spondyloarthritis, spondyloarthropathies, lupus, systemic lupus erythematosus (SLE), juvenile systemic lupus erythematosus, cutaneous lupus, subacute cutaneous lupus, chronic cutaneous lupus, discoid lupus, psoriatic arthritis, reactive arthritis, Sjögren's syndrome, polymyositis, polymyalgia rheumatica, mixed connective tissue disease, vasculitis, large vessel vasculitis, small vessel vasculitis, vasculitic syndromes including Takayasu arteritis, Wegener's granulomatosis, giant cell arteritis, polyarteritis nodosa, sarcoidosis, familial Mediterranean fever, cold pyrin-associated periodic syndromes (e.g., Merkel-Weiss syndrome), familial cold autoinflammatory syndrome, neonatal-onset multisystem inflammatory disease , TNF receptor-associated periodic syndromes; gastrointestinal disorders, such as, inflammatory bowel disease, irritable bowel syndrome, spastic colon, Crohn's disease, ulcerative colitis, acute and chronic pancreatitis, celiac disease, primary biliary cirrhosis, primary sclerosing cholangitis, periodontitis, gingivitis, esophagitis, gastritis, eosinophilic gastritis, gastric and duodenal ulcers, peritonitis, periodontitis, enteritis, colitis; pulmonary respiratory disorders (e.g.), lung inflammation, sinusitis, rhinitis, pneumonia, bronchitis, pulmonary fibrosis, idiopathic pulmonary fibrosis, asthma, bronchial asthma, allergic asthma, eosinophilic asthma, Churg-Strauss syndrome, bronchiolitis, bronchiolitis obliterans, chronic obstructive pulmonary disease COPD, interstitial lung disease; endocrine disorders (e.g., diabetes mellitus type 1, Hashimoto's thyroiditis, Graves' disease, Addison's disease); autoimmune hemolytic anemia, pernicious anemia, autoimmune atrophic gastritis, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia; neurological disorders / neuromuscular disorders (e.g., neurodegenerative disorders, multiple sclerosis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), familial ALS, Alzheimer's disease, myasthenia gravis (Lang-Evans myasthenic syndrome (LEMS)), Guillain-Barré syndrome, meningitis, encephalitis,Traumatic brain injury; renal diseases including, for example, immune-mediated glomerulonephropathy, autoimmune nephropathy, membranous glomerulopathy, chronic progressive nephropathy, diabetic nephropathy, renal fibrosis, ischemia / reperfusion injury-related nephropathy, HIV-related nephropathy, ureteral obstructive nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease, diabetic kidney disease; ocular disorders including, for example, dry eye, uveitis, keratoconjunctivitis sicca, scleritis, episcleritis, keratitis, corneal disease, laryngitis, retinal vasculitis, optic neuritis, retinopathy, diabetic retinopathy, immune-mediated retinopathy, macular degeneration , wet macular degeneration, dry (age-related) macular degeneration, and ocular malignancies; allergic and allergic reactions, including hypersensitivity reactions (such as type I hypersensitivity reactions (e.g., including anaphylaxis), type II hypersensitivity reactions (e.g., Goodpasture's disease, autoimmune hemolytic anemia), type III hypersensitivity diseases (e.g., Arthus reaction, serum sickness), and type IV hypersensitivity reactions (e.g., contact dermatitis, allograft rejection); disorders of fibrosis and scarring (e.g., liver fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, low-grade scarring (e.g., scleroderma, increased fibrosis, keloids, postoperative scars); skin diseases (e.g., psoriasis, atopy, atopic dermatitis, acne Acne vulgaris, acne comedonae, inflammatory acne, nodulocystic acne, acne keloidae, acne keloidae, hidradenitis suppurativa, neutrophilic dermatosis, pyoderma gangrenosum, acute febrile neutrophilic dermatosis (Sweet's syndrome), erythema elevating persevere (EED), neutrophilic exocrine hidradenitis, histiocytic neutrophilic dermatosis, intestinal bypass syndrome dermatosis, Behçet's disease, palisade neutrophilic granulomatosis, neutrophilic urticaria dermatosis, hair loss, non-scarring alopecia, alopecia areata (AA) (including plaque AA, alopecia totalis (AT), alopecia universalis (AU), androgenic alopecia (AGA), male and female type AGA, alopecia areata serpiginosa, alopecia areata horseshoe, telogen effluvium, tinea capitis, hypotrichosis, simple hereditary Hereditary hypotrichosis, cicatricial alopecia, lichen planus hairis, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, eyebrow loss, nasal hair loss; vitiligo, the vitiligo includes segmental vitiligo, single segmental vitiligo, double segmental vitiligo, or multi-segmental vitiligo, non-segmental vitiligo (including acrofacial vitiligo, facial vitiligo, or acrofacial vitiligo, central facial vitiligo, mucosal vitiligo, shredded paper vitiligo, tricolor vitiligo, marginal inflammatory vitiligo, four-color vitiligo, blue vitiligo, Cabner phenomenon, common vitiligo, generalized vitiligo, universal vitiligo), mixed vitiligo (non-segmental vitiligo accompanied by segmental vitiligo), localized vitiligo, isolated mucosal vitiligo,or vitiligo with or without white hair (body hair involvement); immune bullous diseases such as, for example, bullous pemphigoid, cicatricial pemphigoid, pemphigus vulgaris, linear IgA disease; dermatological drug reactions, and pruritus (itch), including, for example, atopic pruritus, dry pruritus, pruritus associated with psoriasis ("psoriatic pruritus"), acute pruritus, chronic pruritus, idiopathic pruritus, chronic idiopathic pruritus, hepatobiliary-related pruritus, renal-related pruritus, pruritus associated with chronic simple lichen simplex, prurigo nodularis, type II diabetes mellitus, hypophysitis, idiopathic thrombocytopenic purpura, metal-induced autoimmunity, autoimmune deafness (including, for example, Meniere's disease), interstitial cystitis, enterocolitis, ocular Inflammation, non-small cell lung cancer, small cell lung cancer, skin cancer, organ transplant rejection, bone marrow transplant rejection, graft-versus-host reaction (e.g., graft-versus-host disease), allogeneic transplant rejection (e.g., acute allogeneic transplant rejection or chronic allogeneic transplant rejection), early transplantation, diabetes, myeloproliferative disorders, rejection reactions (e.g., allogeneic transplant rejection), bone resorption disorders, asthma (e.g., bronchial asthma), atopy, autoimmune thyroid disorders, chronic atypical neutrophilic lipodystrophy and hyperthermia syndrome (CANDLE syndrome), SAVI (stimulator of interferon genes (STING)-associated vasculopathy of infancy), kidney disease, myocarditis, sequelae of autoimmune diseases hematologic manifestations (e.g., anemia), autoimmune hemolytic syndrome, autoimmune hepatitis and inflammatory hepatitis, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, silicone implant-related autoimmune disease, drug-induced autoimmunity, HIV-related autoimmune syndrome; acute and chronic infections, sepsis syndromes (e.g., sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, Gram-negative sepsis, Gram-positive sepsis, fungal sepsis, toxic shock syndrome; hyperoxia-induced inflammation, reperfusion injury, postoperative trauma, tissue damage, pain (e.g., acute pain, chronic pain, neuropathic pain, or fibromyalgia), autoimmune disorders , chronic inflammatory disorders, acute inflammatory disorders, autoinflammatory disorders, fibrotic disorders, metabolic disorders, neoplasia, or cardiovascular or cerebrovascular disorders, skin disorders, pruritus, hair loss disorders, cancer, neoplasms, inflammatory conditions, connective tissue diseases and autoimmune conditions, neoplasms, malignancies, myeloproliferative disorders, hematopoietic neoplasms, spinal cord neoplasms, myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia, acute leukemia and chronic leukemia, lymphoma, lymphoma of the skin including mycosis fungoides, other myeloid malignancies and myelodysplastic syndromes, atopic dermatitis, psoriasis, psoriasis vulgaris, skin sensitization, skin irritation, rash, contact dermatitis,Allergic contact sensitization, allergic dermatitis, inflammatory skin diseases, neutrophilic skin diseases, pruritus, atopic pruritus, atopic dermatitis-associated pruritus, autoimmune response, autoimmune connective tissue disease, bacterial infection, biliary pruritus, generalized activation of the immune response, body lice, bullous disease, brachioradialis pruritus, brain tumor, chronic idiopathic pruritus, contact dermatitis, cholestasis, cutaneous larva migrans, cutaneous T-cell lymphoma, nervous system damage, dandruff, delusional parasitosis, dermatomyositis, skin diseases of pregnancy, diabetes, drug eruption, dysregulation of neuronal processes and sensory perception, eczema, eosinophilic folliculitis, foreign body or device on the skin, fungal infection, pemphigoid gestationis, head lice, herpes, hidradenitis suppurativa, pyoderma gangrenosum, urticaria, choriocarcinoma Chikin's disease, hyperparathyroidism, idiopathic chronic pruritus, inflammation, insect infestation, insect bites, insect stings, intrahepatic cholestasis of pregnancy, iron deficiency anemia, increased accumulation of exogenous opioids or synthetic opioids, internal cancer, jaundice, lichen planus, lichen sclerosus atrophicus, lupus erythematosus, lymphoma, lymphoma-associated pruritus, leukemia-associated pruritus, malignancy, mastocytosis, menopause, multiple sclerosis, neoplasms, nerve irritation, neurogenic pruritus, neuropathic pruritus, back pain with paresthesia, back pain, obsessive-compulsive disorder, parasitic infestation, papular urticaria urticaria, pediculosis, peripheral neuropathy, photodermatitis, polycythemia vera, mental illness, psychogenic pruritus, HIV-associated pruritus papulosa rash, pruritic urticarial papules and plaques of pregnancy (PUPP), psoriasis-associated pruritus, psoriatic pruritus, pubic lice, guillotine palmoplantar keratoderma, renal pruritus, rheumatoid arthritis, scabies, scarring, shaving, seborrheic dermatitis, stasis dermatitis, sunburn, swimmer's itch, systemic immunosenescence, tactile hallucinations, Th17-related inflammation, thyroid disease, uremia, uremic pruritus, urticaria, urticarial pruritus, chickenpox, viral infection, wound or scab healing, xerosis, pernio lupus erythematosus, polychondritis, relapsing polychondritis, immune-mediated kidney disease, prostate cancer, kidney cancer, liver cancer, breast cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, lymphoma, leukemia, multiple myeloma, polycythemia vera Polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), systemic mast cell disease (SMCD), systemic sclerosis / scleroderma, lupus nephritis, wound healing, surgical scarring, spinal cord injury, central nervous system scarring, acute lung injury, cystic fibrosis, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, chronic kidney disease (e.g., diabetic nephropathy), hypertension-induced nephropathy, digestive or gastrointestinal fibrosis,Liver fibrosis or bile duct fibrosis, liver fibrosis (e.g., nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma), liver cirrhosis (e.g., primary biliary cirrhosis or cirrhosis due to fatty liver disease (e.g., alcoholic steatosis and nonalcoholic steatosis)), radiation-induced fibrosis (e.g., head and neck fibrosis, gastrointestinal fibrosis, or pulmonary fibrosis), primary sclerosing cholangitis, restenosis, cardiac fibrosis (e.g., endomyocardial fibrosis or atrial fibrosis), ocular scarring, fibrosclerosis, fibrosis fibrotic cancer, fibroids, fibromas, fibroadenomas, fibrosarcomas, transplant arteriopathy, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, obesity, steroid resistance, glucose intolerance, metabolic syndrome, angiogenic disorders, multiple myeloma, leukemias (e.g., acute lymphoblastic leukemia, acute myeloid leukemia and chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, leukemia, or promyelocytic leukemia), lymphoma (e.g., B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt lymphoma, mast cell tumor, Hodgkin's disease, or non-Hodgkin's disease), myelodysplastic syndrome, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma, and schwannoma; melanoma, seminoma, teratoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, follicular thyroid carcinoma, Kaposi's sarcoma, melanoma, teratoma, rhabdomyosarcoma, Metastatic disorders and bone disorders, as well as bone cancer, oral / pharyngeal cancer, esophageal cancer, laryngeal cancer, stomach cancer, intestinal cancer, colon cancer, rectal cancer, liver cancer, neurological cancer, brain cancer (e.g., glioma or glioblastoma multiforme), head and neck cancer, pharyngeal cancer, ovarian cancer, uterine cancer, testicular cancer, bladder cancer, kidney cancer, gallbladder cancer, cervical cancer, atherosclerosis, atherosclerotic coronary artery restenosis, acute coronary syndrome, myocardial infarction, cardiac allograft vasculopathy, stroke, spinal cord injury, neuronal ischemia, and peripheral neuropathy.
[0367] In some embodiments, additional exemplary disorders include, but are not limited to, complications from organ transplantation (including xenotransplantation), such as graft-versus-host reaction (e.g., graft-versus-host disease), allogeneic transplant rejection (e.g., acute allogeneic transplant rejection or chronic allogeneic transplant rejection), early transplantation, diabetes, myeloproliferative disorders, rejection (e.g., acute allogeneic transplant rejection); bone resorption diseases, asthma (e.g., bronchial asthma), atopy, autoimmune thyroid disorders, chronic atypical neutrophilic lipodystrophy and hyperthermia syndrome (CANDLE syndrome), SAVI (stimulator of interferon genes (STING)-associated vasculopathy of infancy), ulcerative colitis, inflammatory bowel disease, Crohn's disease, celiac disease, ulcerative colitis , Behçet's disease, myasthenia gravis, nephropathy, and myocarditis, secondary hematologic manifestations of autoimmune diseases (e.g., anemia), autoimmune hemolytic syndrome, autoimmune hepatitis and inflammatory hepatitis, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, silicone implant-related autoimmune diseases, drug-induced autoimmunity, HIV-related autoimmune syndrome; acute and chronic infections, sepsis syndromes (e.g., sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, Gram-negative sepsis, Gram-positive sepsis, fungal sepsis, toxic shock syndrome); hyperoxia-induced inflammation, reperfusion injury, postoperative trauma, tissue damage, pain (e.g., acute pain, chronic pain, neuropathic pain, or fibromyalgia).
[0368] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is asthma. In embodiments, the asthma is allergic asthma, non-allergic asthma, allergic bronchopulmonary fungal disease, aspirin-induced asthma, adult-onset asthma, fixed airflow obstruction asthma, exercise-induced asthma, cough variant asthma, work-related asthma, nocturnal asthma, asthma complicated by obesity, eosinophilic asthma, steroid-resistant asthma / severe asthma, extrinsic asthma, or intrinsic asthma / cryptogenic asthma.
[0369] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is vitiligo. In embodiments, the vitiligo is segmental vitiligo (including single segmental vitiligo, double segmental vitiligo or multi-segmental vitiligo), non-segmental vitiligo (including acrofacial vitiligo, facial vitiligo, or acrofacial vitiligo, central facial vitiligo, mucosal vitiligo, paper-like vitiligo, tricolor vitiligo, marginal inflammatory vitiligo, four-color vitiligo, blue vitiligo, Kebney phenomenon, common vitiligo, generalized vitiligo, universal vitiligo), mixed vitiligo (non-segmental vitiligo with segmental vitiligo), localized vitiligo, isolated mucosal vitiligo, or vitiligo with or without white hair (body hair involvement), or any type of vitiligo shown in Table 1 below:
[0370] Table 1 Classification of vitiligo
[0371]
[0372] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a skin disorder. In embodiments, the skin disorder is atopic dermatitis, psoriasis, psoriasis vulgaris, skin sensitization, skin irritation, rash, contact dermatitis, allergic contact sensitization, allergic dermatitis, inflammatory skin disease, or neutrophilic dermatosis.
[0373] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is pruritus. As used herein, "pruritus" and "itch" are interchangeable. In some embodiments, pruritus comprises chronic idiopathic pruritus, as well as the itch component of other itch disorders. In some embodiments, pruritus may be a symptom of a disease or condition selected from the group consisting of: allergy, arthropod bite, athlete's foot, atopic dermatitis (AD), atopic pruritus, atopic dermatitis-associated pruritus, autoimmune response, autoimmune connective tissue disease, bacterial infection, biliary pruritus, generalized activation of the immune response, body lice, bullous disease, brachioradialis pruritus, brain tumor, chronic idiopathic pruritus, contact dermatitis, cholestasis, cutaneous larva migrans, cutaneous T-cell lymphoma, nervous system damage dermatosis, dandruff, delusional parasitosis, dermatomyositis, skin disorders of pregnancy, diabetes, drug eruptions, dysregulation of neuronal processes and sensory perception, eczema, eosinophilic folliculitis, foreign bodies or devices on the skin, fungal infections, pemphigoid gestationis, head lice, herpes, hidradenitis suppurativa, urticaria, Hodgkin's disease, hyperparathyroidism, idiopathic chronic pruritus, inflammation, insect infestations, insect bites, insect stings, intrahepatic cholestasis of pregnancy, iron deficiency anemia, increased accumulation of exogenous opioids or synthetic opioids , internal cancer, jaundice, lichen planus, lichen sclerosus atrophicus, lupus erythematosus, lymphoma, lymphoma-associated pruritus, leukemia-associated pruritus, malignant tumor, mastocytosis, menopause, multiple sclerosis, neoplasms, nerve irritation, neurogenic pruritus, neuropathic pruritus, paresthesia, paresthesia, obsessive-compulsive disorder, parasitic infestation, papular urticaria, pediculosis, peripheral neuropathy, photodermatitis, polycythemia vera, mental illness, psychogenic pruritus, HIV-associated pruritus Papules, pruritic urticarial papules and plaques of pregnancy (PUPPP), psoriasis, psoriasis-associated pruritus, psoriatic pruritus, pubic lice, palmoplantar keratoderma punctata, renal pruritus, rheumatoid arthritis, scabies, scarring, shaving, seborrheic dermatitis, stasis dermatitis, sunburn, swimmer's itch, systemic immunosenescence, tactile hallucinations, Th17-related inflammation, thyroid disease, uremia, pruritus or uremic pruritus, urticaria, urticarial pruritus, chickenpox, viral infection, wound or scab healing, and xerosis.
[0374] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a hair loss disorder. In embodiments, the hair loss disorder is selected from alopecia, alopecia areata, alopecia areata patchy, alopecia totalis, alopecia universalis, alopecia ophiopogonidum, alopecia areata equinus, androgenetic alopecia (male and female pattern hair loss), telogen effluvium, tinea capitis, hypotrichosis, simple hereditary hypotrichosis, cicatricial alopecia, lichen planus pilaris, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, eyebrow loss, folliculitis alopeciae, or intranasal hair loss.
[0375] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a connective tissue disease. In embodiments, the connective tissue disease is selected from SLE (systemic lupus erythematosus), cutaneous lupus (e.g., SCLE, discoid lupus), pernio-like lupus erythematosus, myositis, polymyositis, dermatomyositis, scleroderma, Sjogren's syndrome, polychondritis (relapsing polychondritis), vasculitis, or large vessel vasculitis.
[0376] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a kidney disease. In embodiments, the kidney disease is selected from immune-mediated kidney disease, autoimmune kidney disease, chronic progressive kidney disease, diabetic nephropathy, renal fibrosis, ischemia / reperfusion injury-related kidney disease, HIV-related kidney disease, ureteral obstructive nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease, or diabetic kidney disease.
[0377] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is cancer. In embodiments, the cancer is a solid tumor.
[0378] In embodiments, the cancer is prostate cancer, genitourinary cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, skin cancer, bone cancer, ovarian cancer, liver cancer, non-small cell lung cancer, brain cancer, laryngeal cancer, gallbladder cancer, cancer of pancreas, rectal cancer, parathyroid cancer, adrenal cancer, cancer of nervous tissue, head and neck cancer, colon cancer, stomach cancer, bronchial cancer, kidney cancer, cancer), basal cell carcinoma, squamous cell carcinoma, metastatic skin cancer, osteosarcoma, Ewing sarcoma, myeloma, giant cell tumor, small cell lung tumor, pancreatic islet cell tumor, primary brain tumor, lymphocytic and granulocytic tumors, hairy cell tumors, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuroma, intestinal ganglioma, ovarian tumor, cervical dysplasia, neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid tumor, localized skin lesions, rhabdomyosarcoma, Kaposi sarcoma, osteosarcoma, malignant hypercalcemia, adenocarcinoma, glioblastoma multiforma, leukemia, lymphoma, malignant melanoma, and epidermoid carcinoma.
[0379] In embodiments, the cancer is lymphoma, leukemia, or multiple myeloma.
[0380] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a myeloproliferative disorder (MPD). In embodiments, the MPD is polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD).
[0381] In embodiments, the myeloproliferative disorder is myelofibrosis.
[0382] In embodiments, the myeloproliferative disorder is primary myelofibrosis (PMF).
[0383] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a bone resorption disease. In embodiments, the bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormone imbalance, bone resorption associated with hormone therapy, bone resorption associated with autoimmune disease, or bone resorption associated with cancer.
[0384] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a fibrotic disorder. Exemplary fibrotic disorders include systemic sclerosis / scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, central nervous system scarring, acute lung injury, pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis or cystic fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, chronic kidney disease (e.g., diabetic nephropathy), hypertension-induced nephropathy, digestive or gastrointestinal fibrosis, renal fibrosis, liver fibrosis or bile duct fibrosis, liver fibrosis (e.g., nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma), cirrhosis ( For example, primary biliary cirrhosis or cirrhosis due to fatty liver disease (e.g., alcoholic steatosis and nonalcoholic steatosis), radiation-induced fibrosis (e.g., head and neck, gastrointestinal tract, or lung), primary sclerosing cholangitis, restenosis, cardiac fibrosis (e.g., endomyocardial fibrosis or atrial fibrosis), ocular scarring, fibrosclerosis, fibrotic cancers, fibroids, fibromas, fibroadenomas, fibrosarcomas, transplant arteriopathy, keloids, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, and nephrogenic systemic fibrosis.
[0385] In some embodiments, the ITK-mediated or JAK3-mediated disease or disorder is a metabolic disorder. Exemplary metabolic disorders include obesity, steroid resistance, glucose intolerance, and metabolic syndrome. In some embodiments, the ITK-mediated disease or disorder is a neoplasia. Exemplary neoplasia includes cancer. In some embodiments, exemplary neoplasia includes angiogenesis disorders, multiple myeloma, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, or promyelocytic leukemia), lymphoma (e.g., B cell lymphoma, T cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt lymphoma, mast cell tumor, Hodgkin's disease or non-Hodgkin's disease), myelodysplastic syndrome, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma, and schwannoma; melanoma, seminoma and skin cancers.
[0386] In some embodiments, the ITK-mediated or JAK3-mediated disorder is a cardiovascular disorder and a cerebrovascular disorder. Exemplary cardiovascular disorders include atherosclerosis, atherosclerotic coronary artery restenosis, acute coronary syndrome, myocardial infarction, cardiac allograft vasculopathy, and stroke. Exemplary cerebrovascular diseases include central nervous system disorders with an inflammatory component or an apoptotic component, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, neuronal ischemia, and peripheral neuropathy.
[0387] Also provided herein are compounds disclosed herein for use as medicaments. Also provided herein are compounds disclosed herein for use as medicaments for treating ITK-mediated or JAK3-mediated diseases. Also provided herein are uses of the compounds disclosed herein as medicaments. Also provided herein are uses of the compounds disclosed herein as medicaments for treating ITK-mediated or JAK3-mediated diseases. Also provided herein are compounds disclosed herein for use in the manufacture of medicaments for treating ITK-mediated or JAK3-mediated diseases. Also provided herein are uses of the compounds disclosed herein for treating ITK-mediated or JAK3-mediated diseases. Also provided herein are methods of inhibiting ITK, comprising contacting ITK with a compound disclosed herein. Also provided herein are methods of inhibiting JAK3, comprising contacting JAK3 with a compound disclosed herein.
[0388] Also provided herein are methods for achieving an effect in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound disclosed herein, wherein the effect is selected from cognitive enhancement.
[0389] In certain embodiments, the ITK-mediated or JAK3-mediated disease is selected from pruritus, alopecia, alopecia areata, vitiligo, male pattern androgenic alopecia, female pattern androgenic alopecia, atopic dermatitis, and psoriasis.
[0390] In certain embodiments, the ITK-mediated or JAK3-mediated disease is selected from arthritis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, adult-onset Still's disease, and a seronegative spondyloarthropathy.
[0391] In certain embodiments, the ITK-mediated or JAK3-mediated disease is selected from inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, enteritis, colitis, gastritis, and eosinophilic gastritis.
[0392] In certain embodiments, the ITK-mediated or JAK3-mediated disease is selected from asthma, allergic asthma, eosinophilic asthma, sinusitis, and rhinitis.
[0393] In certain embodiments, the ITK-mediated or JAK3-mediated disease is selected from lymphoma, T-cell lymphoma, cutaneous T-cell lymphoma, and leukemia.
[0394] In certain embodiments, the ITK-mediated or JAK3-mediated disease is selected from organ transplant rejection or bone marrow transplant rejection, and graft-versus-host disease (GVHD).
[0395] Some embodiments are directed to methods of inhibiting ITK activity or JAK3 activity in a biological sample, the method comprising contacting the biological sample with a compound or pharmaceutical composition described herein.
[0396] In addition to being useful for human treatment, the compounds and compositions disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals, and farm animals, including mammals, rodents, etc. More preferred animals include horses, dogs, and cats.
[0397] Combination therapy
[0398] The compounds of the present invention can be used (alone or in combination with another pharmaceutically active ingredient) to treat conditions (such as those previously described above). One or more compounds of the present invention and one or more other pharmaceutically active compounds are administered simultaneously (in the same dosage form or in a separate dosage form) or sequentially. Therefore, in one embodiment, the present invention includes methods of treating a condition by administering to a subject a therapeutically effective amount of one or more compounds of the present invention and one or more other pharmaceutically active compounds.
[0399] In an embodiment, the composition further includes additional pharmaceutical agents, which are selected from chemotherapeutic agents or antiproliferative agents, antiviral agents, antibiotics, antihistamines, lubricants, systemic phototherapy, psoralen photochemotherapy, laser therapy, hormone replacement therapy, anti-inflammatory agents, immunomodulators or immunosuppressants, neurotrophic factors, agents for treating cardiovascular diseases, agents for treating diabetes, agents for treating immunodeficiency disorders, and immune checkpoint inhibitors. The compounds of the present disclosure and pharmaceutically acceptable compositions can be used in combination therapy, that is, compounds and pharmaceutically acceptable compositions can have the potential utility of being combined with other therapies for treating immune disorders, inflammatory disorders, proliferative disorders, and allergic disorders. Examples include, but are not limited to, co-administered with steroids, leukotriene antagonists, antihistamines, anticancer agents, protein kinase inhibitors, cyclosporine, rapamycin, or immune checkpoint inhibitors.
[0400] Cancer cells often use immune checkpoint molecules to evade or suppress the immune system's attack. Therefore, the expression of immune checkpoint molecules on the surface of cancer cells prevents immune cells (such as T cells) from identifying them as "foreign" or "abnormal." Therefore, immune checkpoint inhibitors are compounds that block inhibitory immune checkpoint molecules, thereby leading to immune system activation via T cell recognition.
[0401] Since two checkpoint inhibitor drugs initially indicated for advanced melanoma—ipilimumab (eg, YERVOY YM ; a monoclonal antibody that works by targeting CTLA-4 to activate the immune system) and pembrolizumab (e.g., KEYTRUDA YM; a humanized antibody targeting the programmed cell death 1 (PD-1) receptor), inhibitory checkpoint molecules have been increasingly considered as novel targets for cancer immunotherapy. Another checkpoint inhibitor called nivolumab (e.g., OPDIVO YM ) blocks the interaction between PD-1 and programmed cell death ligand 1 (PD-L1), thereby preventing immune suppression.
[0402] Any molecule capable of inhibiting one or more immune checkpoint molecules can be used as an additional pharmaceutical agent in the methods disclosed herein. Such immune checkpoint inhibitors include (but are not limited to) antibodies or functional fragments of antibodies, inhibitory polypeptides, small molecule chemical compounds, and / or inhibitory nucleic acids (such as (but not limited to) antisense oligonucleotides, small inhibitory RNA (siRNA), small hairpin RNA (shRNA), and / or catalytic nucleic acids (such as ribozymes)). Any immune checkpoint molecule targeted by a checkpoint inhibitor suitable for use in the methods disclosed herein includes (but is not limited to) one or more of the following: adenosine A 2Areceptor (A2AR), B7-H3 (also known as CD276; e.g., MGA271), cytotoxic T-lymphocyte-associated protein 4 (CTLA4; also known as CD152; e.g., ipilimumab; AGEN-1884 (Agenus), programmed cell death ligand 1 (PD-L1; also known as CD274; e.g., MDX-1105 (Bristol Myers Squibb), WBP-3155 (C-stone), LY3300054 (Eli Lilly), programmed cell death protein 1 (PD-1; also known as CD279; for example, pembrolizumab, SHR-1210 (Incyte), STI-A1110 (Sorrento), REGN2810 (Regeneron), CT-011 (pidilizumab; Curetech), PDR-001 (Novartis), BGB-A317 (BeiGene), TSR-042 (Tesaro), ENUMC-8 (Enumeral), MGD-013 (Macrogenics; a bispecific antibody against PD1 and Lag3), B7- H4 (also known as VTCN1), T cell immunoglobulin mucin domain-containing 3 (TIM3; also known as HAVCR2), B and T lymphocyte attenuator (BTLA; also known as CD272), indoleamine-pyrrole 2,3-dioxygenase (IDO), killer cell immunoglobulin-like receptor (KIR; e.g., lirilumab), lymphocyte activation gene 3 (LAG-3; e.g., BMS-986016), T cell immunoreceptor with Ig domain and ITIM domain (TIGIT; also known as WUCAM and Vstm3), ILT-3, ILT-4, and / or V-domain Ig suppressor of T cell activation (VISTA).
[0403] In some embodiments, the immune checkpoint inhibitor is an antagonist antibody, such as, but not limited to, one or more of ipilimumab (Bristol-Myers Squibb), nivolumab (Bristol-Myers Squibb), pembrolizumab (Merck), durvalumab (Medimmune), atezolizumab (Genentech / Roche), tesitumumab (Medimmune), and / or avelumab (Pfizer).
[0404] The compounds and pharmaceutical compositions of the present disclosure can be used to prevent or treat ITK-mediated disorders by sequential administration or co-administration with additional pharmaceutical agents.
[0405] In some cases, it may be appropriate to administer at least one of the compounds described herein or a derivative of the compound in combination with another pharmaceutical agent. By way of example only, if one of the side effects a patient experiences when receiving one of the compounds herein is hypertension, it may be appropriate to administer an antihypertensive agent in combination with the initial pharmaceutical agent. Alternatively, by way of example only, the therapeutic effect of one of the compounds described herein may be enhanced by the administration of an adjuvant (i.e., the adjuvant itself may only have minimal therapeutic benefit, but when combined with another pharmaceutical agent, enhances the overall therapeutic benefit to the patient). Alternatively, by way of example only, the benefit experienced by the patient may be increased by administering one of the compounds described herein together with another pharmaceutical agent (which also comprises a treatment regimen) that also has a therapeutic benefit. By way of example only, in a treatment for diabetes involving the administration of one of the compounds described herein, an increased therapeutic benefit may also be generated by providing the patient with another pharmaceutical agent for diabetes. In any case, regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the patient may be merely the sum of the two pharmaceutical agents, or the patient may experience a synergistic benefit.
[0406] Specific non-limiting examples of possible combination therapies include the use of a compound of the embodiments herein with a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating an immunodeficiency disorder.
[0407] Specific non-limiting examples of possible combination therapies for inflammation include the use of certain compounds of the present disclosure with: (1) corticosteroids, including but not limited to cortisone, dexamethasone, and methylprednisolone; (2) nonsteroidal anti-inflammatory drugs (NSAIDs), including but not limited to ibuprofen, naproxen, acetaminophen, aspirin, fenoprofen, and acetaminophen. TM ), Flurbiprofen (ANSAID TM ), ketoprofen, oxaprozin (DAYPRO TM ), Diclofenac Sodium (VOLTAREN TM ), diclofenac potassium (CATAFLAM TM ), etodolac (LODINE TM ), Indomethacin (INDOCIN TM ), TORADOL TM ), sulindac (CLINORIL TM ), TOLECTIN TM ), meclofenamic acid (MECLOMEN TM ), mefenamic acid (PONSTELTM ), nabumetone (RELAFEN TM ) and piroxicam (FELDENE TM ); (3) immunosuppressants, including but not limited to methotrexate (RHEUMATREX TM ), leflunomide (ARAVA TM ), azathioprine (IMURAN TM ), cyclosporine (NEORAL TM 、SANDIMMUNE TM ), tacrolimus and cyclophosphamide (CYTOXAN TM ); (4) CD20 blockers, including but not limited to rituximab (RITUXAN TM ); (5) tumor necrosis factor (TNF) blockers, including but not limited to etanercept (ENBREL TM ), infliximab (REMICADE TM ) and adalimumab (HUMIRA TM ); (6) interleukin-1 receptor antagonists, including but not limited to anakinra (KINERET TM ); (7) interleukin-6 inhibitors, including but not limited to tocilizumab (ACTEMRA TM ); (8) interleukin-17 inhibitors, including but not limited to AIN457; (9) Janus kinase inhibitors, including but not limited to tasocitinib; and (10) SYK inhibitors, including but not limited to fostamatinib.
[0408] Specific non-limiting examples of possible combination therapies for the treatment of cancer include the use of certain compounds of the present disclosure with: (1) alkylating agents, including but not limited to cisplatin (PLATIN TM ), carboplatin (PARAPLATIN TM ), oxaliplatin (ELOXATIN TM ), ZANOSAR TM ), busulfan (MYLERAN TM ) and cyclophosphamide (ENDOXAN); (2) antimetabolites, including but not limited to mercaptopurine (PURINETHOL TM ), thioguanine, pentostatin (NIPENT TM ), cytosine arabinoside (ARA-C TM ), gemcitabine (GEMZAR TM ), fluorouracil (CARAC TM ), folinic acid (FUSILEVTM ) and methotrexate (RHEUMATREX TM ); (3) plant alkaloids and terpenoids, including but not limited to vincristine (ONCOVIN TM ), vinblastine and taxol (TAXOL TM ); (4) topoisomerase inhibitors, including but not limited to irinotecan (CAMPTOSAR TM ), Topotecan (HYCAMTIN TM ) and etoposide (EPOSIN TM ); (5) cytotoxic antibiotics, including but not limited to actinomycin D (COSMEGEN TM ), adriamycin (ADRIAMYCIN TM ), bleomycin (BLENOXANE TM ) and mitomycin (MITOSOL TM ); (6) angiogenesis inhibitors, including but not limited to sunitinib (SUTENT TM ) and bevacizumab (AVASTIN TM ); (7) tyrosine kinase inhibitors, including but not limited to imatinib (GLEEVEC TM ), erlotinib (TARCEVA TM ), lapatinib (TYKERB TM ) and axitinib (INLYTA TM ); and (8) immune checkpoint inhibitors, including but not limited to atezolizumab (TECENTRIQ TM ), avelumab (BAVENCIO TM ), durvalumab (IMFINZI TM ), ipilimumab (YERVOY TM ), pembrolizumab (KEYTRUDA TM ), nivolumab (OPDIVO TM ), and tremelimumab.
[0409] In some embodiments, the compounds disclosed in the embodiments herein may also be co-administered (simultaneously or sequentially) with various other pharmaceutical agents or treatments, e.g., pharmaceutical agents or treatments that are administered systemically (e.g., orally or parenterally). Examples of such systemic treatments include topical or systemic corticosteroids (e.g., prednisone), antibiotics (e.g., erythromycin, tetracycline, and dicloxacillin), antifungals (e.g., those sold under the trade name Diflucan), and steroids. TM ketoconazole and fluconazole), antivirals (such as those sold under the brand name Valtrex TM Valacyclovir, acyclovir, and Famvir are sold under the brand name TM famciclovir, sold under the brand name Cytoxan, corticosteroids, immunosuppressants TM Cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, biologics (such as those sold under the brand name Rituxan TM Rituximab is sold under the brand name Enbrel TM Etanercept, sold under the brand name Humira TM Adalimumab is sold under the brand name Remicade TM Infliximab is sold under the brand name Stelara TM Ustekinumab, sold under the brand name Amevive TM alefacept (sold as alefacept), and / or thyroid hormone replacement.
[0410] In some embodiments, other therapies that can be used in combination with the compounds disclosed herein include, for example, mercaptopurine, topical or systemic corticosteroids (e.g., prednisone, methylprednisolone, and prednisolone), alkylating agents (e.g., cyclophosphamide), calcineurin inhibitors (e.g., cyclosporine, sirolimus, and tacrolimus), inhibitors of inosine monophosphate dehydrogenase (IMPDH) (e.g., mycophenolate mofetil, mycophenolate mofetil, azathioprine), various antibodies (e.g., antilymphocyte globulin (ALG), antithymocyte globulin (ATG), monoclonal anti-T cell antibody (OKT3)), and radiation. These various agents can be used according to their standard or commonly used doses (as specified in the prescribing information accompanying the commercially available drug form (see also the prescribing information in The Physician's Desk Reference (2006 edition)). In some embodiments, the standard doses of these agents can be reduced when used in combination with the compounds of the embodiments herein. Without limiting the scope of the present disclosure, it is believed that such combinations can produce synergistic results with better efficacy, less toxicity, longer duration of action, or faster response to therapy. In some embodiments, the combination therapy described herein can be administered in the form of a subtherapeutic amount of a compound of the embodiments herein, or an additional pharmaceutical agent, or both a compound of the embodiments herein and an additional pharmaceutical agent. Azathioprine is currently available under the brand name Azasan TM Available from Salix Pharmaceuticals, Inc.; mercaptopurine is currently available under the brand name Purinethol TM Available from Gate Pharmaceuticals, Inc.; prednisone and prednisolone are currently available from Roxane Laboratories, Inc.; methylprednisolone is currently available from Pfizer; sirolimus (rapamycin) is currently available under the brand name Rapamune TM Available from Wyeth-Ayerst; tacrolimus is currently available under the brand name Prograf TM Obtained from Fujisawa; cyclosporine is currently available under the brand name Sandimmune TM Acquired from Novartis and under the brand name Gengraf TM Obtained from Abbott; IMPDH inhibitors (such as mycophenolate mofetil and mycophenolic acid) are currently available under the brand name Cellcept TM Obtained from Roche and under the brand name Myfortic TM Obtained from Novartis; azathioprine is currently available under the brand name Imuran TMobtained from Glaxo Smith Kline; and the antibody is currently available under the brand name Orthoclone TM Obtained from Ortho Biotech under the brand name Simulect TM (basiliximab) is available from Novartis and under the brand name Zenapax TM (daclizumab) was obtained from Roche.
[0411] In some embodiments, the compounds of the present invention are administered in combination with, concomitantly with, or adjunctively with the above pharmaceutical agents or therapies and / or with pharmaceutical agents or therapies for other diseases. For example, the compounds of the present invention can be combined with thyroid hormone replacement therapy or with anti-inflammatory therapy or immunomodulatory therapy.
[0412] In any case, multiple drug agents (at least one of which is a compound disclosed herein) can be administered in any order or even simultaneously. If administered simultaneously, multiple drug agents can be provided in a single, unified form or in multiple forms (for example only, as a single pill or as two separate pills). One of the drug agents can be administered in multiple doses, or both drug agents can be administered in multiple doses. If not administered simultaneously, the time between multiple doses can be any duration from a few minutes to eight weeks, or at any interval suitable for maintaining the desired therapeutic efficacy. In some embodiments, the time between multiple doses can be one minute, one hour, six hours, one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, or eight weeks.
[0413] Thus, in another aspect, certain embodiments provide methods for treating an ITK-mediated disorder in a human or animal subject in need of such treatment, the method comprising administering to the subject an amount of a compound disclosed herein in combination with at least one additional agent known in the art for treating the disorder that is effective to reduce or prevent the disorder in the subject. In a related aspect, certain embodiments provide therapeutic compositions comprising at least one compound disclosed herein in combination with one or more additional agents for treating an ITK-mediated disorder.
[0414] In further embodiments, pharmaceutical compositions are provided that include one or more compounds of the present invention, one or more additional pharmaceutically active compounds, and a pharmaceutically acceptable carrier.
[0415] In further embodiments, the one or more additional pharmaceutically active compounds are selected from the group consisting of anti-inflammatory drugs, anti-atherosclerotic drugs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, antiproliferative agents, angiogenesis inhibitors, kinase inhibitors, cytokine blockers, and inhibitors of cell adhesion molecules.
[0416] In additional embodiments, the pharmaceutical composition may further comprise one or more additional pharmaceutical agents (eg, chemotherapeutic agents, steroids, anti-inflammatory compounds, or immunosuppressants).
[0417] The ITK inhibitor compositions described herein are also optionally used in combination with other therapeutic agents, which are selected based on the therapeutic value of the condition to be treated. Generally, in embodiments employing combination therapy, the pharmaceutical compositions described herein and other agents do not have to be administered in the same pharmaceutical composition and may be administered by different routes due to different physical and chemical properties. Initial administration is typically performed according to an established regimen, and the dosage, mode of administration, and time of administration are then modified based on the observed effects. In some cases, it is appropriate to administer the ITK inhibitor compositions described herein in combination with additional therapeutic agents. By way of example only, if one of the side effects experienced by a patient when receiving the ITK inhibitor compositions described herein is a rash, it is appropriate to administer an antihistamine in combination with the initial therapeutic agent. Alternatively, by way of example only, the therapeutic effect of the ITK inhibitor may be enhanced by the administration of an additional pharmaceutical agent (which also comprises a therapeutic regimen) that also has therapeutic benefit. In any case, regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the patient is simply the sum of the two therapeutic agents, or the patient experiences a synergistic benefit.
[0418] When drugs are used in combination therapy, the therapeutically effective doses vary. Methods for experimentally determining the therapeutically effective doses of drugs and other agents used in combination therapy regimens are documented methodologies. Combination therapy also includes periodic treatments that are started and stopped at various times to assist in the clinical management of the patient. In any case, the multiple therapeutic agents (one of which is an ITK inhibitor as described herein) are administered in any order or even simultaneously. If administered simultaneously, the multiple therapeutic agents are optionally provided in a single, unified form or in multiple forms (by way of example only, as a single pill or as two separate pills).
[0419] In some embodiments, one of the therapeutic agents is administered in multiple doses, or both therapeutic agents are administered in multiple doses. If not administered simultaneously, the time between multiple doses optionally varies from more than zero weeks to less than twelve weeks.
[0420] In addition, combination methods and compositions are not limited to using only two medicaments, and the use of multiple therapeutic combinations is also contemplated. It should be understood that the dosage regimen for treating, preventing or improving one or more conditions for which relief is sought may be optionally changed based on a variety of factors. These factors include the disorder that the subject suffers from, as well as the subject's age, weight, sex, diet, and physical condition. Therefore, in some embodiments, the dosage regimen actually employed varies widely and is therefore different from the dosage regimen set forth herein.
[0421] The pharmaceutical agent that forms the combination therapy disclosed herein is optionally a combination dosage form or a separate dosage form that is intended to be administered substantially simultaneously. The pharmaceutical agent that forms the combination therapy is also optionally administered sequentially, wherein any one of the agents is administered by requiring a two-step administration regimen. The two-step administration regimen optionally requires the sequential administration of the active agent or the interval administration of the active agent alone. According to the properties of each pharmaceutical agent (such as the effectiveness, solubility, bioavailability, plasma half-life and kinetic properties of the pharmaceutical agent), the scope of the time period between the multiple administration steps is from a few minutes to a few hours. The circadian rhythm variation of the target molecule concentration is optionally used to determine the optimal dose interval.
[0422] In other embodiments, ITK inhibitors are optionally used in conjunction with procedures that provide additional benefits or synergistic benefits to the patient. The ITK inhibitor and one or more additional therapies are optionally administered before the onset of the disease or condition, during the onset of the disease or condition, or after the onset of the disease or condition, and in some embodiments, the time of administration of the pharmaceutical composition containing the ITK inhibitor is different. Thus, for example, the ITK inhibitor is used as a prophylactic and is continuously administered to a subject with a tendency to develop a condition or disease to prevent the onset of the disease or condition. The ITK inhibitor and composition are optionally administered to the subject during or immediately after the onset of symptoms. Although embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Many variations, changes, and substitutions will then occur to those skilled in the art without departing from the present invention. It should be understood that in some embodiments of the present invention, various alternatives to the embodiments described herein are employed in practicing the present invention.
[0423] ITK inhibitors can be administered in combination with drugs from the following classes: NSAIDs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, antiproliferative agents, angiogenesis inhibitors, biologics, steroids, vitamin D3 analogs, retinoids, other kinase inhibitors, cytokine blockers, corticosteroids, and inhibitors of cell adhesion molecules. Where the subject has atherosclerosis or a condition associated with atherosclerosis or is at risk of developing atherosclerosis or a condition associated with atherosclerosis, the ITK inhibitor compositions described herein are optionally used in any combination with one or more agents or methods for treating atherosclerosis or a condition associated with atherosclerosis. Examples of therapeutic agents / treatments for treating atherosclerosis or conditions associated with atherosclerosis include, but are not limited to, any of the following: torcetrapib, aspirin, niacin, HMG CoA reductase inhibitors (e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin), colesevelam, cholestyramine, colestipol, gemfibrozil, probucol, and clofibrate.
[0424] Where the subject has or is at risk of having an inflammatory condition, the ITK inhibitor compositions described herein are optionally used in any combination with one or more agents or methods for treating the inflammatory condition.
[0425] One or more additional pharmaceutical agents (such as, for example, anti-inflammatory agents, steroids, immunosuppressants, and one or more other ITK kinase inhibitors and / or other kinase inhibitors (such as JAK3 kinase inhibitors, JAK1 kinase inhibitors, JAK1 / 2 kinase inhibitors, or JAK2 kinase inhibitors (such as those described in, for example, WO 99 / 65909, WO 00 / 00202 and / or WO / 2004 / 099205)) or other agents) can be used in combination with the compounds of the invention for the treatment of ITK-related diseases, disorders or conditions.
[0426] In certain embodiments, the additional pharmaceutical agent is selected from a taxane, an inhibitor of bcr-abl, an inhibitor of EGFR, a DNA damaging agent, an antimetabolite, paclitaxel, imatinib, dasatinib, nilotinib, erlotinib, gefitinib, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC, 5-FU, camptothecin, doxorubicin, idarubicin, paclitaxel, docetaxel, vincristine, a MEK inhibitor, U0126, a KSP inhibitor, vorinostat, pembrolizumab, nivolumab, atezolizumab, avelumab, tesimumab, and durvalumab.
[0427] In some embodiments, the composition further comprises an additional pharmaceutical agent selected from the group consisting of a chemotherapeutic or antiproliferative agent, an antiviral agent, an antibiotic, an antihistamine, a lubricant, systemic phototherapy, psoralen photochemotherapy, laser therapy, hormone replacement therapy, an anti-inflammatory agent, an immunomodulator or immunosuppressant, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, and an agent for treating an immunodeficiency disorder.
[0428] In some embodiments, one or more compounds of the embodiments herein can be used in combination with one or more other therapeutic agents used in the treatment of ITK-mediated disorders, and the therapeutic response can be improved compared to the response to the other therapeutic agents alone without exacerbating their toxic effects. In some embodiments, the compounds of the embodiments herein can be used in combination with one or more other ITK inhibitors, and / or JAK1 and / or JAK2 and / or JAK3 inhibitors, and / or TYK2 inhibitors for the treatment of ITK-mediated disorders. An additive effect or a synergistic effect is the desired result of such a combination. The additional agent can be combined with the compounds of the present invention in a single dosage form or a continuous dosage form, or the agent can be administered simultaneously or sequentially as a separate dosage form. In some embodiments, one or more additional agents can be administered to a patient in combination with at least one ITK inhibitor described herein, wherein the additional agent is administered intermittently (rather than continuously).
[0429] For example, in certain embodiments, topically or orally administered ITK inhibitors / antagonists described herein can be used alone for the treatment of alopecia areata (e.g., alopecia areata patchy, alopecia totalis, alopecia universalis) or in combination with topical or intralesional corticosteroids, topical minoxidil, oral finasteride, oral dutasteride, contact sensitization therapy (such as with dibutyl squarate, dinitrochlorobenzene, diphenylcyclopropenone), topical or oral methoxalen and ultraviolet A (PUVA), topical anthralin, hair transplantation, or other therapies known to have a beneficial effect on the condition.
[0430] For example, in certain embodiments, topically or orally administered ITK inhibitors / antagonists described herein can be used alone or in combination with topical minoxidil, oral finasteride (in men), oral dutasteride (in men), topical antiandrogens, hair transplantation, or other therapies known to have a beneficial effect on the condition for the treatment of male pattern baldness or female pattern baldness (androgenetic alopecia).
[0431] For example, in certain embodiments, the compounds can be used alone for vitiligo (e.g., localized vitiligo, focal vitiligo, vitiligo), generalized vitiligo, segmental vitiligo, acrofacial vitiligo, facial vitiligo, acrofacial vitiligo, mucosal vitiligo, shredded paper vitiligo, tricolor vitiligo, marginal inflammatory vitiligo, tetracolor vitiligo, blue vitiligo, Kebner phenomenon, vitiligo vulgaris, mixed acrofacial and vulgaris, or universal vitiligo), or in combination with topical corticosteroids, topical tacrolimus, topical pimecrolimus, phototherapy (e.g., ultraviolet therapy with UVB, narrow-band UVB, oral or topical psoralen plus ultraviolet A (PUVA), calcipotriene or other topical vitamin D analogs, excimer laser phototherapy), systemic immunosuppressants, surgical treatment (e.g., skin micrografts, transplantation of autologous epidermal suspensions, concealing agents (e.g., with cosmetics or dihydroxyacetone), or other therapies known to have a beneficial effect on the condition, for vitiligo (e.g., localized vitiligo). vitiligo), focal vitiligo, generalized vitiligo, segmental vitiligo, acrofacial vitiligo, facial vitiligo, acrofacial vitiligo, mucosal vitiligo, tattered paper vitiligo, tricolor vitiligo, marginal inflammatory vitiligo, tetracolor vitiligo, blue vitiligo, Cabner phenomenon, vitiligo vulgaris, mixed acrofacial and vulgaris, or universal vitiligo).
[0432] In certain embodiments, the compounds of the present disclosure can be used in combination with one or more agents that act by the same mechanism or by different mechanisms to achieve treatment of gastrointestinal disorders. The different agents can be administered sequentially or simultaneously (in separate compositions or in the same composition). Useful classes of agents for combination therapy include, but are not limited to, aminosalicylates, steroids, systemic immunosuppressants, anti-TNFα antibodies, TNFα ligand inhibitors, TNF binders, anti-VLA-4 antibodies, anti-integrin Cv37 antibodies, antibacterial agents, glucocorticoid agonists, nuclear factor kappa B inhibitors, 5-lipoxygenase inhibitors, integrin α-4 / β-7 antagonists, cyclooxygenase inhibitors, IL-23 antagonists, leukotriene BLT receptor antagonists, IL-6 antagonists, IL-8 antagonists, integrin antagonists agents, nicotinic acetylcholine receptor agonists, PPARγ agonists, sphingosine-1-phosphate receptor-1 modulators, B lymphocyte antigen CD20 inhibitors, calcineurin inhibitors, CD3 antagonists, cell adhesion molecule inhibitors, eosinophil peroxidase inhibitors, heparin agonists, ICAM1 gene inhibitors, IL-13 antagonists, IL-2 receptor α subunit inhibitors, insulin sensitizers, interferon beta ligands, interferon gamma receptor antagonists, interleukin-1 beta ligand modulators, MAdCAM inhibitors, PDE4 inhibitors, sphingosine-1-phosphate receptor 1 agonists, TLR-9 agonists, acetylcholinesterase inhibitors, ACTH receptor agonists, activin receptor antagonists, CCR5 chemokine antagonists, CCR9 chemokine antagonists, and antidiarrheal drugs.
[0433] Aminosalicylates that can be used in combination with the compounds of the present disclosure include, but are not limited to, aminosalicylic acid, osalazine, and sulfasalazine. Examples of steroids include, but are not limited to, prednisone, prednisolone, hydrocortisone, budesonide, beclomethasone, and fluticasone. Systemic immunosuppressants useful for the treatment of inflammatory disorders include, but are not limited to, cyclosporine, azathioprine, methotrexate, 6-mercaptopurine, and tacrolimus. In addition, anti-TNFα antibodies including, but not limited to, infliximab, adalimumab, golimumab, and certolizumab can be used in combination therapy. Useful compounds that act through other mechanisms include anti-VLA-4 antibodies (such as natalizumab), anti-integrin α4β7 antibodies (such as vedolizumab), antibacterial agents (such as rifaximin), and antidiarrheal drugs (such as loperamide) (Mozaffari et al. Expert Opin. Biol. Ther. 2014, 14, 583-600; Danese, Gut, 2012, 61, 918-932; Lam et al., Immunotherapy, 2014, 6, 963-971).
[0434] Other compounds that can be used in combination with the compounds of the present disclosure include, but are not limited to, opaganib, abatacept, mongersen, filgotinib, LYC-30937, BI-655130, mirikizumab, adalimumab, tacrolimus, rituximab, GSK-2982772, andecaliximab, naltrexone, risankizumab, sankizumab), QBECO, alicaforsen, etrolizumab, foralumab, crelizumab, edolizumab, amiselimod, ozanimod, olcanatide, catridecacog, budesonide, STNM-01, cannabidiol, telotristat etiprate, SHP-647, carotegrast methylmethyl), peg-ilodecakin, TOP-1288, iberogast N, PF-06480605, peficitinib, beclomethasone, recombinant interferon beta-1a, infliximab, golimumab, tralokinumab, ustekinumab, certolizumab pegol, thalidomide, upadacitinib, apremilast, natalizumab, interferon beta-1a, rifaximin, RBX-2660, etrasimod, zileuton, fingolimod, cobitolimod, ropivacaine , ABX-464, PF-06700841, prednisolone, GLPG-0974, valganciclovir, ciclosporin, VB-201, tulinercept, MDGN-002, PTG-100, dexamethasone, GED-0507-34-Levo, bertilimumab, brazikumab, KHK-4083, rosiglitazone, mocravimod, sotrastaurin, KAG-308, PUR-0110, E-6007, balsalazide, basiliximab, LP-02, ASP-3291, Trichuris suis eggs suis ova), K(D)PT, midismase, DNVX-078, vatelizumab, alequel, low molecular weight heparin, metenkefalin, tridecactide, HMPL-004, SB-012, olsalazine, balsalazide, propionyl-L-carnitine, Clostridium butyricum, beclomethasone, and acemannan.
[0435] General synthetic methods for preparing compounds
[0436] The compounds of the present invention can be prepared using the methods described in the general synthesis schemes and experimental procedures described in detail below. The general synthesis schemes and experimental procedures are presented for illustrative purposes and are not intended to be restrictive. The starting materials for preparing the compounds of the present invention are commercially available or can be prepared using conventional methods known in the art. Representative procedures for preparing the compounds of the present invention are outlined in Schemes 1 and 2 below. Solvents and reagents for the synthesis preparations not described below can be purchased from Sigma-Aldrich or Fisher Scientific.
[0437] Scheme 1 highlights the general synthesis of 3,4-disubstituted pyrrolopyrimidines and pyrrolopyridines. Protection of 1a as 2-(trimethylsilyl)ethoxymethyl (SEM) amine is carried out with SEM chloride and a strong base such as sodium hydride in a solvent such as DMF or THF, which provides 1b. 1b is reacted with the desired R as a boronate ester or other coupling partner using a transition metal catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (Pd(dppf)Cl2) in the presence of a weak base such as potassium carbonate in a dioxane / water solvent mixture. 3 Suzuki coupling of the group or related transition metal-mediated couplings provides 1c. In some cases, R can be further modified after the coupling reaction by methods known to those skilled in the art. 3 Schemes 6-8 show the desired R 3 Further illustration of the incorporation of groups into the heterocyclic core. An amino-heterocycle can be added to 1c via nucleophilic aromatic substitution in dioxane / water in the presence of potassium hydroxide under thermal conditions to produce 1d. Deprotection of the carbamate and SEM ether can be achieved by treating 1d with an acid such as trifluoroacetic acid (TFA) in dichloromethane to produce 1e. Treatment of 1e with acrylic acid and a peptide coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in DMF in the presence of a weak base such as diisopropylethylamine (DIEA) or reaction with acryloyl chloride in the presence of a tertiary amine base such as triethylamine in a solvent such as tetrahydrofuran provides acrylamide 1f.
[0438] Scheme 1. Preparation of 3,4-disubstituted pyrrolopyrimidines and pyrrolidines
[0439]
[0440] Scheme 2 highlights the general synthesis of 3,4-disubstituted pyrrolopyrimidines and pyrrolopyridines. Protection of 1a as 2-(trimethylsilyl)ethoxymethyl(SEM)amine is carried out with SEM chloride and a strong base such as sodium hydride in a solvent such as DMF or THF, which provides 2a. 1b is reacted with the desired R as the boronic ester using a palladium catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (Pd(dppf)Cl2) in dioxane / water as a solvent mixture in the presence of a weak base such as potassium carbonate. 3 Suzuki coupling or related coupling of the group provides 1c. In some cases, R can be further modified after the coupling reaction by methods known to those skilled in the art. 3 The amino-heterocycle is added to 2b via nucleophilic aromatic substitution via thermal conditions in dioxane / water in the presence of potassium hydroxide to produce 2c. Deprotection of the carbamate and SEM ether is achieved by treating 2c with an acid such as trifluoroacetic acid (TFA) in dichloromethane to produce 2d. Treatment of 2d with acrylic acid and a peptide coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in DMF in the presence of a weak base such as diisopropylethylamine (DIEA) or reaction with acryloyl chloride in the presence of a tertiary amine base such as triethylamine in a solvent such as tetrahydrofuran provides acrylamide 2e.
[0441] Scheme 2. Preparation of 3,4-disubstituted pyrrolopyrimidines and pyrrolidines
[0442]
[0443] Scheme 3 highlights the general synthesis of 3-ester 4-substituted pyrrolopyrimidines and pyrrolopyridines. Amino-heterocycles are added to 3a using thermal conditions in dioxane / water in the presence of potassium carbonate to produce 3b. Deprotection of the carbamate is achieved by treating 3b with an acid such as trifluoroacetic acid (TFA) in dichloromethane to produce 3c. Treatment of 3c with acrylic acid and a peptide coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in DMF in the presence of a weak base such as diisopropylethylamine (DIEA) provides acrylamide 3d. Alternatively, 3c can be acylated using acryloyl chloride in the presence of a weak base such as triethylamine in dichloromethane to produce 3d.
[0444] Scheme 3. Preparation of 3-ester 4-substituted pyrrolopyrimidines and pyrrolopyridines.
[0445]
[0446] Scheme 4 highlights the general synthesis of 3-ester 4-substituted pyrrolopyrimidines and pyrrolopyridines. Amino-heterocycles are added to 3a via nucleophilic aromatic substitution in dioxane / water in the presence of potassium carbonate under thermal conditions to produce 4a. Deprotection of the carbamate is achieved by treating 4a with an acid such as trifluoroacetic acid (TFA) in dichloromethane to produce 4b. Treatment of 4b with acrylic acid and a peptide coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in the presence of a weak base such as diisopropylethylamine (DIEA) in DMF provides acrylamide 4c. Alternatively, 4b can be acylated using acryloyl chloride in the presence of a weak base such as triethylamine in dichloromethane to produce 4c.
[0447] Scheme 4. Preparation of 3-ester 4-substituted pyrrolopyrimidines and pyrrolopyridines.
[0448]
[0449] Scheme 5 highlights the general synthesis of 3,5-disubstituted pyrrolopyrimidines and pyrrolopyrazines. Protected 5a was synthesized according to Scheme 1. 5a was reacted with the desired R as a boronic ester using a palladium catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (Pd(dppf)Cl2) in dioxane / water as a solvent mixture in the presence of a weak base such as potassium carbonate. 3 Suzuki coupling or related coupling of the group provides 5b. In some cases, R can be further modified after the coupling reaction by methods known to those skilled in the art. 3 Group. The amino-heterocycle is added to 5b using Buchwald conditions or Hartwig conditions in the presence of palladium acetate as a catalyst, a ligand such as Xantphos, a base such as cesium carbonate in toluene to produce 5c. Deprotection of the carbamate and SEM protecting groups is achieved by treating 5c with an acid such as trifluoroacetic acid (TFA) in dichloromethane followed by sodium acetate in ethanol to produce 5d. Treatment of 5d with acrylic acid and a peptide coupling agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in DMF in the presence of a weak base such as diisopropylethylamine (DIEA) provides acrylamide 5e. Addition of R 3 Substituents and R 5The order of substituents can be reversed. In this case, the amino-heterocycle is added to 5f using Buchwald conditions or Hartwig conditions in the presence of palladium acetate as a catalyst, a ligand (such as Xantphos), a base (such as cesium carbonate) in toluene to produce 5g. Halogenation of 5g with NBS in DMF provides bromine 5h. 5h is reacted with the desired R as the boronate ester using a palladium catalyst (such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) in dioxane / water as a solvent mixture in the presence of a weak base (such as potassium carbonate). 3 Suzuki coupling or related coupling of the groups affords 5c.
[0450] Scheme 5: Preparation of 3,5-disubstituted pyrrolopyrimidines and pyrrolopyrazines.
[0451]
[0452] Scheme 6 highlights the selection of R attached to the heteroaromatic core. 3 Synthesis of Keto and Alkyl Groups. In this order, metal halogen exchange of iodine-substituted 5a (or Br) is performed and the desired R 3 The intermediate anion is treated with Weinreb amides of the substituent. Following this general procedure, 6a is treated with n-butyllithium in ether at -78°C and then with the appropriate Weinreb amide to produce ketone 6b, keto-cycloalkyl 6f, or keto-heterocycle 6d. If desired, these ketone products can be further processed. For example, ketone 6f can be treated with methylmagnesium bromide in THF to produce an intermediate alcohol, which can be further reduced using triethylsilane in a mixture of TFA / DCM to produce alkyl 6g. Alternatively, the anion of 6a can react with an aldehyde (rather than Weinreb amide) to directly produce the alcohol. In this case, the anion of 6a can react with various aldehydes (such as 6i) to produce alcohol 6j. If desired, the alcohol can be removed using triethylsilane in a mixture of TFA / DCM to produce 6k. In all cases, those skilled in the art can select the protecting group of 6a as needed. (SEM) or benzenesulfonate protecting groups are generally preferred. The chemical process outlined in Scheme 6 is intended to represent more options available to those skilled in the art.
[0453] Scheme 6. R in the heteroaromatic core 3 Detailed description of the location.
[0454]
[0455] Scheme 7 emphasizes that R 3The synthesis of substituted cyclopropyl groups attached to a heterocyclic core is described. 7a (X = Cl or OMe) is reacted with the desired R as the boronic ester using a palladium catalyst (e.g., [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) in a dioxane / water solvent mixture in the presence of a weak base (e.g., potassium carbonate). 3 Suzuki coupling or related coupling of group (7b) provides 7c. Cyclopropanation of 7c can be achieved via a variety of methods (including CH2I2 and Et2Zn, TMSCF3 with NaI, and NMU KOH and Pd(OAc)2) to produce the desired substituted cyclopropyl 7d. In many cases, the R substituent or R can be modified by conventional procedures known in the art. 3-1 substituent.
[0456] Plan 7.R 3 The positions become substituted cyclopropyl analogs for elaboration.
[0457]
[0458] Scheme 8 emphasizes that R 3 The synthesis of substituted cycloalkyl groups outside the heteroaromatic core is carried out. 6a is reacted with the desired R as a boronic ester using a palladium catalyst (such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) in a dioxane / water solvent mixture in the presence of a weak base (such as potassium carbonate). 3 Suzuki coupling or related coupling of group (8a) provides 8b. Hydrogenation of 8b using hydrogen, Pd / C in a solvent such as ethanol provides 8c. Alternatively, 8b can be treated with CH2I2 and Et2Zn under Simmons-Smith conditions to form the bicyclic analog 8d.
[0459] Plan 8.R 3 The positions become substituted cycloalkyl analogs for elaboration.
[0460]
[0461] The present disclosure is further illustrated by the following examples.
[0462] Example 1: Preparation of (R)-4-((1-acryloylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid ethyl ester
[0463]
[0464] Step 1: Preparation of (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidinecarboxylic acid ethyl ester
[0465]
[0466] By 4- chloro- 7-H- pyrrolo [2,3-d] pyrimidine -5- carboxylic acid ethyl ester (0.150g, 0.665mmol), (3R) -3- aminopiperidine -1- carboxylic acid tert-butyl ester (0.146g, 0.731mmol) and N, N- diisopropylethylamine (0.346mL, 1.99mmol) in n-butanol (2mL) mixture was heated at 135 DEG C for 1 hour in a sealed container. Now, the cooling reaction, and distributed between ethyl acetate and water. The ethyl acetate layer was washed with salt water, dried over sodium sulfate, filtered and concentrated in vacuo. On silica gel, the resulting oily matter was subjected to chromatography (eluting with methanol and ethyl acetate). Pure fractions were combined and concentrated to give (R)-ethyl 4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidinecarboxylate (0.256 g, 99% yield) as a clear oil: MS (ES) m / z 390.3 (M+H).
[0467] Step 2: Preparation of (R)-ethyl 4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0468]
[0469] To a solution of (R)-ethyl 4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidinecarboxylate (0.256 g, 0.657 mmol) in dichloromethane (3 mL) at 0° C. was added trifluoroacetic acid (1 mL, 13.1 mmol). The solution was stirred at ambient temperature for 1 hour. The reaction was concentrated in vacuo to give (R)-ethyl 4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate as an oil in quantitative yield. The material was carried forward without further purification: MS (ES) m / z 290.2 (M+H).
[0470] Step 3: Preparation of (R)-ethyl 4-((1-acryloylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0471]
[0472] To a solution of (R)-4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid ethyl ester (0.190 g, 0.657 mmol) in dichloromethane (2 mL) was added N,N-diisopropylethylamine (0.340 mL, 1.96 mmol). A solution of prop-2-enoic acid (0.066 mg, 0.919 mmol) in dichloromethane (2 mL) was treated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.190 g, 0.985 mmol) and N,N-diisopropylethylamine (0.340 mL, 1.96 mmol), respectively. After 15 minutes at ambient temperature, a solution of the activated acid was added to the amine solution, and the mixture was stirred at ambient temperature for 1.5 hours. The reaction was then absorbed in ethyl acetate and washed with water and then brine. The ethyl acetate layer was then dried over sodium sulfate, filtered and concentrated in vacuo. The resulting material was chromatographed on silica gel (eluting with methanol and ethyl acetate). Pure fractions were combined and concentrated to yield (R)-ethyl 4-((1-acryloylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (90 mg, 40% yield): 1 H-NMR(400MHz,DMSO-d6)δ12.48(br s,1H),8.58(br d,J=7.04Hz,1H),8.21(br d,J=11.35Hz,1H),7.92(s,1H),6.49-6.89(m,1H),5.91-6.12(m,1H),5.42-5.72(m,1H),4.11-4.35(m,3H),3.83-4.08 (m,1H),3.38-3.72(m,3H),1.87-2.10(m,1H),1.63-1.86(m,2H),1.47-1.62(m,1H),1.30(t,J=7.04Hz,3H); MS(ES)m / z 344.3(M+H).
[0473] Example 2: Preparation of ethyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0474]
[0475] Step 1: Preparation of ethyl 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0476]
[0477] To a stirred solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid ethyl ester (4.00 g, 17.7 mmol) in DCM (40 mL) was added triethylamine (7.48 mL, 53.3 mmol) and N,N-dimethylaminopyridine (0.210 g, 1.77 mmol) at room temperature. Benzenesulfonyl chloride (4.00 g, 22.9 mmol) was then added dropwise over 10 min. The resulting reaction mixture was stirred at room temperature for another 30 min. After the reaction was complete, the reaction mixture was diluted with DCM (50 mL) and washed with water. The organic layer was then washed with salt water and dried over anhydrous sodium sulfate. The organic layer was filtered and concentrated under vacuum to provide the crude material, which was then purified by Combi-flash purifier with 20% ethyl acetate in hexanes as eluent to yield ethyl 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate as a light yellow solid (5.3 g, 82% yield): MS (ES) m / z 366.3 (M+H) +1 .
[0478] Step 2: Preparation of ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0479]
[0480] To the stirred solution of 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo-[2,3-d] pyrimidine-5-carboxylate (5.30g, 14.5mmol) in n-butanol (50mL) add (2S, 5R)-5-amino-2-methylpiperidine-1-carboxylic acid benzyl ester (4.53g, 15.9mmol) and N, N-diisopropylethylamine.Reaction mixture is heated to 130 DEG C, 16h in a sealed tube.After the reaction is complete, reaction mixture is allowed to cool and is under reduced pressure concentrated.Then, thick residue is dissolved in ethyl acetate, and washed with water and saline solution.The organic layer is dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude material was purified by Combi-flash purifier with 50% ethyl acetate in hexanes as eluent to yield benzylethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (6.5 g, 78% yield) as a light brown solid: MS (ES) m / z 578.1 (M+H) +1 .
[0481] Step 3: Preparation of ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0482]
[0483] To a stirred solution of benzylethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (6.50 g, 11.7 mmol) in tetrahydrofuran (100 mL) was added potassium tert-butoxide (3.9 g, 35 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (3.4 g, 69% yield) as a pale yellow solid: MS (ES) m / z 438.1 (M+H) +1 .
[0484] Step 4: Preparation of ethyl 4-(((3R,6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0485]
[0486] To a nitrogen-purged solution of ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (3.4 g, 7.8 mmol) in tetrahydrofuran (100 mL) was added 10% Pd / C (3 g). The reaction mixture was stirred at room temperature for 16 h under hydrogen atmosphere. After completion of the reaction, the mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to yield the desired crude compound. The crude product obtained was used in the next step without any purification (2.35 g, 100% yield): MS (ES) m / z 304.1 (M+H) +1 .
[0487] Step 5: Preparation of tert-butyl 4-((3-(1-cyclopropyl-2-methoxyethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)amino)piperidine-1-carboxylate
[0488]
[0489] To a stirred solution of ethyl 4-(((3R, 6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (2.4 g, 7.92 mmol) in THF / water (60 / 40 mL) at 0°C was added triethylamine (3.3 mL, 23.7 mmol). Then, acryloyl chloride (0.76 mL, 9.5 mmol) was slowly added at 0°C. The resulting reaction mixture was stirred at the same temperature for 20 min. After completion of the reaction, the mixture was quenched with saturated NaHCO solution and extracted with ethyl acetate. The organic layer was washed with water, brine, and dried over anhydrous sodium sulfate. The organic layer was concentrated under vacuum to provide a crude material, which was purified by silica gel chromatography (20% MeOH in DCM) to produce the pure title compound (1.14 g, 40% yield) as a white solid: 1 H NMR (400MHz, DMSO-d6) δ12.43(s,1H),8.42(d,J=6.8Hz,1H),8.19(s,1H),7.9(s ,1H),6.81-6.74(m,1H),6.1-6.05(dd,J1=2Hz,J2=16.8Hz,1H),5.67-5.64(m,1 H),4.51(bs,2H),4.29(q,J1=6.8Hz,2H),3.93(bs,1H),2.64(bs,1H),1.92(bs, 1H),1.71-1.64(m,3H),1.30(t,J=7.2Hz,3H),1.17(d,J=6.4Hz,3H); MS(ES)m / z 358.0(M+H).
[0490] Example 3: Preparation of 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid isopropyl ester
[0491]
[0492] The title compound was prepared by the method described in Scheme 9.
[0493] Scheme 9. Preparation of 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid isopropyl ester
[0494]
[0495] Step 1: Preparation of propyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0496]
[0497] To a suspension of potassium carbonate (0.153 g, 1.1 mmol) in N,N-dimethylformamide (10 mL) was added benzylethyl-4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid (prepared by the method described in Example 4, Step 5, 0.2 g, 0.37 mmol) and n-propyl bromide (0.22 g, 1.85 mmol), and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (30% ethyl acetate / hexanes) to afford propyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.2 g, 93% yield) as a yellow solid: MS (ES) m / z 582.5 (M+H).
[0498] Step 2: Preparation of propyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0499]
[0500] To a solution of propyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)-methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.2 g, 0.34 mmol) in tetrahydrofuran (5 mL) was added tetrabutylammonium fluoride (5 mL, 1 M in tetrahydrofuran) and the solution was heated to 80° C. for 16 hours. The reaction was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (70% ethyl acetate / hexanes) to afford propyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.09 g, 58% yield) as a white solid: MS (ES) m / z 452.4 (M+H).
[0501] Step 3: Preparation of propyl 4-(((3R,6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0502]
[0503] To a solution of isopropyl 4-(((3R, 6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.09 g, 0.2 mmol) in tetrahydrofuran (10 mL) was added palladium on carbon (0.05 g, 10 w (wet) / w) under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated in vacuo to provide propyl 4-(((3R, 6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.06 g, crude) as a white solid: MS (ES) m / z 318.1 (M+H).
[0504] Step 4: Preparation of propyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0505]
[0506] To a stirred solution of 4-(((3R, 6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid propyl ester (0.06 g, 0.188 mmol) in tetrahydrofuran:water (3:2 mL) at 0 ° C was added triethylamine (0.08 mL, 0.56 mmol), followed by a solution of acryloyl chloride (0.02 mL, 0.22 mmol) in tetrahydrofuran (0.5 mL) and stirred for 20 minutes. The reaction mixture was quenched with sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (20% methanol / dichloromethane) to afford propyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate as a white solid (0.02 g, 20% yield): 1 H NMR(400MHz,DMSO-d6)δ12.44(s,1H),8.42(d,J=6.8Hz,1H),8.18(s,1H),7.91 (s,1H),6.74-6.81(m,1H),6.07(d,J=16.8Hz,1H),5.65(d,J=10Hz,1H),4.5(br s,3H),4.2(t,J=6.4Hz,2H),3.93(bs,1H),1.91(br s,1H),1.67-1.78(m,4H),1.14-1.46(m,J=7.2Hz,5H),0.95(t,J=7.2Hz,2H); MS(ES)m / z371.1.0(M+H).
[0507] Example 4: Preparation of 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid isopropyl ester
[0508]
[0509] The title compound was prepared by the method described in Scheme 10.
[0510] Scheme 10. Preparation of Isopropyl 4-(((3R,6S)-1-Acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0511]
[0512] Step 1: Preparation of ethyl 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0513]
[0514] To a stirred solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid ethyl ester (4.0 g, 17.7 mmol) in dichloromethane (40 mL) was added triethylamine (7.48 mL, 53.28 mmol), N, N-dimethylaminopyridine (0.21 g, 1.77 mmol) dropwise over a 10-minute period, followed by dropwise addition of benzenesulfonyl chloride (4 g, 22.88 mmol), and the mixture was stirred at ambient temperature for 0.5 hour. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, salt water, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (20% ethyl acetate / hexanes) to afford ethyl 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (5.3 g, 82% yield) as a light yellow solid: MS (ES) m / z 366.3 (M+H).
[0515] Step 2: Preparation of ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-(phenylsulfonyl)-7H-pyrrolo-[2,3-d]pyrimidine-5-carboxylate
[0516]
[0517] To a stirred solution of 4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid ethyl ester (5.3 g, 14.5 mmol) in n-butanol (50 mL) was added (2S, 5R)-5-amino-2-methylpiperidine-1-carboxylic acid benzyl ester (4.53 g, 15.9 mmol), N, N-diisopropylethylamine (10.1 mL, 58 mmol), and the mixture was heated at 130 ° C for 16 hours in a sealed tube. The mixture was cooled to ambient temperature, poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (50% ethyl acetate / hexanes) to afford benzylethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)6-methyl-piperidin-3-yl)amino)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (6.5 g, 77.6% yield) as a light brown solid: MS (ES) m / z 578.1 (M+H).
[0518] Step 3: Preparation of ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0519]
[0520] To a stirred solution of benzylethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (6.5 g, 11.69 mmol) in tetrahydrofuran (100 mL) was added potassium tert-butoxide (3.9 g, 35 mmol), and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (3.4 g, 69% yield) as a light yellow solid: MS (ES) m / z 438.1 (M+H).
[0521] Step 4: Preparation of ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0522]
[0523] To a suspension of sodium hydride (0.12 g, 3.29 mmol) in N,N-dimethylformamide (30 mL) was added ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (1.2 g, 2.74 mmol) at 0 ° C. The suspension was stirred for 15 minutes, and then 2-(trimethylsilyl)ethoxymethyl chloride (0.55 g, 3.29 mmol) was added at 0 ° C. The reaction mixture was warmed to ambient temperature and stirred for 2 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (20% ethyl acetate / hexanes) to afford ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.9 g, 58% yield) as a white solid: MS (ES) m / z 568.2 (M+H).
[0524] Step 5: Preparation of 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid
[0525]
[0526] To a stirred solution of ethyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.85 g, 1.49 mmol) in tetrahydrofuran:methanol (10:10 mL) was added lithium hydroxide monohydrate (0.63 g, 14.9 mmol), and the mixture was stirred at ambient temperature for 16 hours. The volatiles were removed in vacuo, and the residue was diluted with water and acidified with 1 N hydrochloric acid (pH = ~4). The aqueous layer was extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid (0.75 g, 93.7% yield) as a white solid: MS (ES) m / z 540.2 (M+H).
[0527] Step 6: Preparation of isopropyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0528]
[0529] To a suspension of potassium carbonate (0.19 g, 1.39 mmol) in N,N-dimethylformamide (10 mL) was added 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid (0.25 g, 0.46 mmol) and isopropyl bromide (0.13 mL, 1.39 mmol), and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (30% ethyl acetate / hexanes) to afford isopropyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxylate (0.2 g, 74.3% yield) as a light yellow solid: MS (ES) m / z 582.5 (M+H).
[0530] Step 7: 4-(((3 R Preparation of isopropyl 1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0531]
[0532] To a solution of isopropyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.2 g, 0.34 mmol) in tetrahydrofuran (5 mL) was added tetrabutylammonium fluoride (5 mL, 1 M in tetrahydrofuran) and the solution was heated to 80° C. for 16 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (70% ethyl acetate / hexanes) to afford isopropyl 4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.1 g, 64% yield) as a white solid: MS (ES) m / z 452.2 (M+H).
[0533] Step 8: Preparation of isopropyl 4-(((3R,6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0534]
[0535] To a solution of isopropyl 4-(((3R, 6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.1 g, 0.22 mmol) in tetrahydrofuran (10 mL) was added palladium on carbon (0.05 g, 10 w (wet) / w) under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours under a hydrogen atmosphere. The reaction mixture was filtered through celite, and the filtrate was concentrated in vacuo to provide isopropyl 4-(((3R, 6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.08 g, crude) as a white solid: MS (ES) m / z 318.3 (M+H).
[0536] Step 9: Preparation of isopropyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
[0537]
[0538] To a solution of 4-(((3R, 6S)-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid isopropyl ester (0.08 g, 0.25 mmol) in tetrahydrofuran:water (3:2 mL) was added triethylamine (0.1 mL, 0.75 mmol) at 0 ° C., followed by addition of a solution of acryloyl chloride (0.018 mL, 0.22 mmol) in tetrahydrofuran (0.5 mL), and stirred for 20 minutes. The reaction mixture was quenched with saturated sodium bicarbonate aqueous solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (20% methanol / dichloromethane) to afford isopropyl 4-(((3R,6S)-1-acryloyl-6-methylpiperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (0.02 g, 19% yield) as a white solid. 1 H NMR (400MHz, DMSO-d6): δ12.41(s,1H),8.43(d,J=7.2Hz,1H),8.18(s,1H),7.85(s,1H),6.74-6.81(dd,J1=10. 8Hz,J2=16.8Hz,1H),6.05-6.09(dd,J1=2Hz,J2=16.8Hz,1H),5.66(d,J=10.4Hz,1H),5.10-5.16(m,1H),4.5(br s,3H),3.93(br s,1H),1.92(br s, 1H), 1.71-1.68 (m, 3H), 1.31 (d, J = 6Hz, 6H), 1.16-1.21 (m, 3H); MS (ES) m / z 372.3 (M+H).
[0539] Example 5: Preparation of (R)-1-(3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0540]
[0541] The title compound was prepared by the method described in Scheme 34.
[0542] Plan 34
[0543]
[0544] Step 1: Preparation of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanol
[0545]
[0546] To a stirred solution of 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (prepared by the method described in Example 7, 2 g, 5.52 mmol) in diethyl ether (30 mL) was added n-butyl lithium (5.17 mL, 8.28 mmol, 1 M in hexane) at -78 ° C and stirred for 0.5 hours. Then, a solution of cyclopropanecarboxaldehyde (0.64 mL, 8.28 mmol) in diethyl ether (3 mL) was added at -78 ° C, and the mixture was stirred for 30 minutes. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and extracted with diethyl ether (2×100 mL). The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (40% ethyl acetate / hexanes) to afford (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-(cyclopropyl)methanol (1.2 g, 53% yield) as a brown liquid. 1 H NMR (400MHz, DMSO-d6): δ8.61(s,1H),7.76(s,1H),5.61(s,2H),5.11(s,1H),4.76(s,1H),3.50(t ,J=7.6Hz,2H),1.31-1.32(m,1H),0.82(t,J=8Hz,2H),0.34-0.44(m,4H),0.03(s,9H); MS(ES)m / z 354.0(M+H).
[0547] Step 2: Preparation of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone
[0548]
[0549] To a stirred solution of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)-methanol (1.2 g, 3.39 mmol) in dichloromethane (20 mL) was added Dess-Martin reagent (2.1 g, 5.09 mmol) at 0 ° C., and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was quenched with saturated aqueous sodium bicarbonate and sodium thiosulfate and extracted with dichloromethane (2×100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (20% ethyl acetate / hexanes) to afford (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone (0.5 g, 45% yield) as a brown liquid: 1 H NMR (400MHz, DMSO-d6) δ8.66(s,1H),8.02(s,1H),5.62(s,2H),3.52(t,J=8Hz,2H) ,1.50-1.54(m,1H),0.80(t,J=8Hz,2H),0.48-0.59(m,4H),0.08(s,9H);MS(ES)m / z 352.1(M+H).
[0550] Step 3: Preparation of (R)-tert-butyl 3-((5-(cyclopropanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate
[0551]
[0552] To a stirred solution of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone (0.5 g, 1.42 mmol) in N-methyl-2-pyrrolidone (30 mL) was added (R)-tert-butyl 3-aminopiperidine-1-carboxylate (0.34 g, 1.70 mmol) and the mixture was heated in a sealed tube at 180 ° C for 4 hours. The reaction mixture was cooled to ambient temperature, poured into water, and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (27% ethyl acetate / hexanes) to afford (R)-tert-butyl 3-((5-(cyclopropanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.6 g, crude) as a brown liquid: MS (ES) m / z 516.2 (M+H).
[0553] Step 4: Preparation of tert-butyl (R)-3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate
[0554]
[0555] To a stirred solution of (R)-tert-butyl 3-((5-(cyclopropanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.6 g, 1.16 mmol) in tetrahydrofuran (4 mL) was added tetrabutylammonium fluoride (10 mL, 1 M in tetrahydrofuran) and the solution was heated to 80° C. for 16 hours. The reaction mixture was cooled to ambient temperature, poured into ice water, and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (4% methanol / dichloromethane) to afford (R)-tert-butyl 3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.17 g, 39% yield) as a yellow liquid: MS (ES) m / z 386.2 (M+H).
[0556] Step 5: Preparation of (R)-cyclopropyl(4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone hydrochloride
[0557]
[0558] To a stirred solution of (R)-tert-butyl 3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.17 g, 0.44 mmol) in dichloromethane (2 mL) at 0° C. was added hydrogen chloride (1.1 mL, 4.41 mmol, 4 M in dioxane), and the mixture was stirred at ambient temperature for 16 hours. The reaction was concentrated in vacuo, and the residue was washed with diethyl ether to provide (R)-cyclopropyl(4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone hydrochloride (0.17 g, crude) as an off-white solid: MS (ES) m / z 286.1 (M+H).
[0559] Step 6: Preparation of (R)-1-(3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0560]
[0561] To a stirred solution of (R)-cyclopropyl(4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone hydrochloride (0.17 g, 0.52 mmol) in tetrahydrofuran:water (10:6 mL) was added triethylamine (0.22 mL, 1.58 mmol) at 0 ° C., followed by acryloyl chloride (0.04 g, 0.42 mmol) and stirred for 15 minutes. The reaction mixture was quenched with sodium bicarbonate and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (3% methanol / dichloromethane) to afford (R)-1-(3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one as a white solid (0.03 g, 18% yield): 1H NMR (400 MHz, DMSO-d6, at 90 ° C): δ 12.2 (s, 1H), 9.07-9.09 (m, 1H), 8.34 (s, 1H), 8.17 (s, 1H), 6.59 (br s,1H),5.93-5.97(m,1H),5.50-5.53(m,1H),4.15(b,1H),3.91-3.95(m,1H),3.60-3.64(m,1H),3.37-3.47(m,2H),2.75-2.76(m, 1H),1.98-2.01(m,1H),1.78-1.79(m,1H),1.66-1.68(m,1H),1.51-1.57(m,1H),1.01-1.02(m,2H),0.92-0.95(m,2H); MS(ES)m / z 340.0(M+H).
[0562] Example 6: Preparation of (R)-1-(3-((5-(cyclopentanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0563]
[0564] The title compound was prepared by the method described in Scheme 11.
[0565] Scheme 11. Preparation of (R)-1-(3-((5-(cyclopentanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0566]
[0567] Step 1: Preparation of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopentyl)methanone
[0568]
[0569] To a stirred solution of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopentyl)methanol (prepared by the method described in Example 13, 1.5 g, 3.93 mmol) in dichloromethane (20 mL) cooled to 0° C. was added pyridinium chlorochromate (1.48 g, 5.90 mmol), and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was quenched with saturated sodium bicarbonate and saturated sodium thiosulfate and extracted with dichloromethane (2×100 mL). The combined organic layers were washed with water, brine, and dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (22% ethyl acetate / hexanes) to afford (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopentyl)methanone (1 g, 72% yield) as a brown liquid: MS (ES) m / z 380 (M+H).
[0570] Step 2: Preparation of (R)-tert-butyl 3-((5-(cyclopentanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate
[0571]
[0572] To a solution of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopentyl)methanone (1 g, 2.63 mmol) in ethanol (30 mL) was added (R)-tert-butyl 3-aminopiperidine-1-carboxylate (0.789 g, 3.94 mmol) and the mixture was heated in a sealed tube to 180 ° C for 4 hours. The reaction mixture was allowed to cool to ambient temperature, poured into water, and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (25% ethyl acetate / hexanes) to give (R)-tert-butyl 3-((5-(cyclopentanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.5 g, 38.46% yield) as a brown liquid: MS (ES) m / z 530 (M+H).
[0573] Step 3: Preparation of tert-butyl (R)-3-((5-(cyclopentanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate
[0574]
[0575] To a stirred solution of (R)-tert-butyl 3-((5-(cyclopentanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.5 g, 0.94 mmol) in tetrahydrofuran (6 mL) was added tetrabutylammonium fluoride (8 mL, 1 M in tetrahydrofuran) and the solution was heated to 80° C. for 16 hours. The reaction mixture was allowed to cool to ambient temperature, poured into ice water, and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (4% methanol / dichloromethane) to afford (R)-tert-butyl 3-((5-(cyclopentanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.25 g, 63% yield) as a yellow liquid: MS (ES) m / z 414 (M+H).
[0576] Step 4: Preparation of (R)-cyclopentyl(4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone hydrochloride
[0577]
[0578] To a stirred solution of (R)-tert-butyl 3-((5-(cyclopentanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.25 g, 0.60 mmol) in dichloromethane (2 mL) was added hydrogen chloride (2.5 mL, 6.05 mmol, 4 M in dioxane) at 0° C., and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo, and the residue was washed with diethyl ether to afford (R)-cyclopentyl(4-(piperidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone hydrochloride (0.15 g, crude) as an off-white solid: MS (ES) m / z 314 (M+H).
[0579] Step 5: Preparation of (R)-1-(3-((5-(cyclopentanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0580]
[0581] To a solution of (R)-cyclopentyl (4- (piperidin-3-ylamino) -7H- pyrrolo [2,3-d] pyrimidin-5-yl)methanone hydrochloride (0.15 g, 0.47 mmol) in tetrahydrofuran: water (10: 6 mL) cooled to 0 ° C was added triethylamine (0.1 mL, 0.96 mmol), a solution of acryloyl chloride (0.07 mL, 0.86 mmol) in tetrahydrofuran (0.5 mL) and stirred for 15 minutes. The reaction mixture was quenched with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol / dichloromethane) to afford (R)-1-(3-((5-(cyclopentane-carbonyl)-7H-pyrrolo[2,3-2015]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one as a white solid (0.04 g, 23% yield): 1 H NMR (400MHz, DMSO-d6, at 90℃) δ12.2(s,1H),9.07(d,J=7.2Hz,1H),8.16(d,J= 3.2Hz,2H),6.62(t,J=15.2Hz,1H),5.93-5.98(m,1H),5.51(d,J=10Hz,1H),4 .16(s,1H),3.94(d,J=13.2Hz,1H),3.61-3.72(m,2H),3.03-3.49(m,2H),2.0 0-2.05(m,1H),1.81-1.85(m,3H),1.53-1.79(m,8H); MS(ES)m / z368.4(M+H).
[0582] Example 7: Preparation of 1-(3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidin-1-yl)prop-2-en-1-one
[0583]
[0584] The title compound was prepared by the method described in Scheme 12.
[0585] Scheme 12. Preparation of 1-(3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidin-1-yl)prop-2-en-1-one
[0586]
[0587] Step 1: Preparation of 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine
[0588]
[0589] To a stirred solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (5 g, 32.67 mmol) in dichloromethane (50 mL) was added N-bromosuccinimide (6.9 g, 39.21 mmol) and the mixture was stirred at ambient temperature for 2 hours. The reaction was concentrated in vacuo. The resulting solid was filtered, washed with water and dried to provide 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (7.7 g, crude) as a brown solid: 1 H NMR (400MHz, DMSO-d6) δ 12.93 (s, 1H), 8.60 (s, 1H), 7.92 (s, 1H); MS (ES) m / z 231.9 (M+2H).
[0590] Step 2: Preparation of 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
[0591]
[0592] 5-bromo-4-chloro-7H-pyrrolo-[2,3-d] pyrimidine (5g, 21.55mmol) was added to a suspension of sodium hydride (5g, 21.55mmol) in dimethylformamide (20mL) at 0°C, and stirred at ambient temperature for 30 minutes, then 2-(trimethylsilyl)ethoxymethyl chloride (4.58mL, 25.86mmol) was added after being cooled to 0°C. The reaction mixture was heated to ambient temperature and stirred for 1 hour. The reaction mixture was quenched with ice water and extracted with ethyl acetate. The organic layer was washed with water and salt water, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (15% ethyl acetate / hexane), to provide 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo-[2,3-d] pyrimidine (4.5g, 58% yield) as an off-white solid: 1 H NMR (400MHz, DMSO-d6) δ8.71 (s, 1H), 8.14 (s, 1H), 5.60 (s, 2H), 3.51 (t, J = 7.6Hz, 2H), 0.81 (t, J = 8Hz, 2H), 0.08 (s, 9H); MS (ES) m / z 362.0 (M + H).
[0593] Step 3: Preparation of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanol
[0594]
[0595] To a stirred solution of 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (2 g, 5.52 mmol) in diethyl ether (30 mL) was added n-butyllithium (5.17 mL, 8.28 mmol, 1.6 M in hexane) at -78 ° C and stirred for 10 minutes. Then, a solution of cyclopropanecarboxaldehyde (0.64 mL, 8.28 mmol) in diethyl ether (3 mL) was added at -78 ° C, and the resulting mixture was stirred for 0.5 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and extracted with diethyl ether (2 × 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (32% ethyl acetate / hexanes) to afford (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanol (1.2 g, 61% yield) as a brown liquid: 1 H NMR(400MHz,DMSO-d6)δ8.61(s,1H),7.76(s,1H),5.61(s,2H),5.11(s,1H),4.76(s,1H),3.50(t ,J=7.6Hz,2H),1.31-1.32(m,1H),0.82(t,J=8Hz,2H),0.34-0.44(m,4H),0.03(s,9H); MS(ES)m / z 354.1(M+H).
[0596] Step 4: Preparation of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone
[0597]
[0598] To a stirred solution of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanol (1.2 g, 3.39 mmol) in dichloromethane (20 mL) was added Dess-Martin reagent (2.1 g, 5.09 mmol) at 0°C, and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was quenched with saturated aqueous sodium bicarbonate, sodium thiosulfate, and extracted with dichloromethane (2 x 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (20% ethyl acetate / hexanes) to afford (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone (0.5 g, 45% yield) as a brown liquid: 1 H NMR (400MHz, DMSO-d6) δ8.66(s,1H),8.02(s,1H),5.62(s,2H),3.52(t,J=8Hz,2H) ,1.50-1.54(m,1H),0.80(t,J=8Hz,2H),0.48-0.59(m,4H),0.08(s,9H);MS(ES)m / z 352.1(M+H).
[0599] Step 5: Preparation of tert-butyl 3-((5-(cyclopropanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidine-1-carboxylate
[0600]
[0601] To a stirred solution of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone (0.45 g, 1.28 mmol) in N-methyl-2-pyrrolidone (30 mL) was added tert-butyl 3-aminoazetidine-1-carboxylate (0.33 g, 1.92 mmol) and the mixture was heated in a sealed tube at 120 ° C for 2 hours. The reaction mixture was cooled to ambient temperature, poured into water, and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (50% ethyl acetate / hexanes) to afford tert-butyl 3-((5-(cyclopropanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidine-1-carboxylate (0.4 g, 65% yield) as a brown liquid:1 H NMR (400MHz, DMSO-d6) δ9.46(s,1H),8.74(s,1H),8.25(s,1H),5.56(s,2H),4.72-4.76(m,1H),4.22-4.24(m,2H),3.70-3.71(m,2H),3. 56(t,J=7.2Hz,2H),2.78-2.82(m,1H),1.44(s,9H),1.14-1.17(m,2H),1.01-1.09(m,2H),0.83(t,J=7.6Hz,2H),0.08(s,9H); MS(ES)m / z 488.2(M+H).
[0602] Step 6: Preparation of tert-butyl 3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidine-1-carboxylate
[0603]
[0604] To a stirred solution of tert-butyl 3-((5-(cyclopropanecarbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidine-1-carboxylate (0.4 g, 0.82 mmol) in tetrahydrofuran (2 mL) was added tetrabutylammonium fluoride (8 mL, 1 M solution in tetrahydrofuran) and the solution was heated to 80 ° C for 16 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (4% methanol / dichloromethane) to afford tert-butyl 3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidine-1-carboxylate (0.2 g, 69% yield) as an off-white solid: 1 H NMR(400MHz,DMSO-d6)δ12.60(s,1H),9.47(s,1H),8.52(s,1H),8.17(s,1H),4.70(br s,1H),4.21-4.22(m,2H),3.68-3.70(m,2H),1.56-157(m,1H),1.37(s,9H),1.06-1.08(m,2H),0.90-0.96(m,2H); MS(ES)m / z 358.1(M+H).
[0605] Step 7: Preparation of (4-(azetidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone hydrochloride
[0606]
[0607] To a stirred solution of tert-butyl 3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidine-1-carboxylate (0.2 g, 0.56 mmol) in dichloromethane (2 mL) was added hydrogen chloride (1.4 mL, 56.02 mmol, 4 M in dioxane) at 0° C., and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo, and the residue was washed with diethyl ether to afford (4-(azetidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone hydrochloride (0.15 g, 94% yield) as an off-white solid: MS (ES) m / z 258.1 (M+H).
[0608] Step 8: Preparation of 1-(3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidin-1-yl)prop-2-en-1-one
[0609]
[0610] To a stirred solution of (4-(azetidin-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(cyclopropyl)methanone hydrochloride (0.15 g, 0.51 mmol) in tetrahydrofuran:water (10:6 mL) was added triethylamine (0.22 mL, 1.53 mmol) at 0 ° C., followed by acryloyl chloride (0.04 g, 0.40 mmol) and stirred for 15 minutes. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (3% methanol / dichloromethane) and further purified by using preparative HPLC to provide 1-(3-((5-(cyclopropanecarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)azetidin-1-yl)prop-2-en-1-one as a white solid (0.04 g, 27%): 1H NMR (400MHz, DMSO-d6) δ12.60 (s, 1H), 9.51 (d, J = 5.6Hz, 1H), 8.52 (s, 1H), 8.1 8(s,1H),6.33-6.36(m,1H),6.29-6.31(m,1H),5.64-5.66(m,1H),4.76-4.83( m,1H),4.59(t,J=8.4Hz,1H)4.31(t,J=10Hz,1H),4.04-4.07(m,1H),3.74-3. 78(m,1H),2.81-2.86(m,1H),1.01-1.06(m,2H),0.94-0.97(m,2H); MS(ES)m / z 312.1(M+H).
[0611] Preparative HPLC method:
[0612] Column: ZORBAX XDB C-18 (150mm×4.6mm×5μm)
[0613] Mobile phase (A): 0.1% ammonia in water
[0614] Mobile phase (B): ACN
[0615] Flow rate: 1.0 mL / min
[0616] Retention time: 3.129 minutes.
[0617] Example 8: Preparation of (R)-1-(3-((3-(3-methoxypropanoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0618]
[0619] The title compound was prepared by the method described in Scheme 13.
[0620] Scheme 13. Preparation of (R)-1-(3-((3-(3-methoxypropanoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0621]
[0622] Step 1: Preparation of 1-(4-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-chloropropane-1-one
[0623]
[0624] To a solution of 4-bromo-1H-pyrrolo[2,3-b]pyridine (5.0 g, 25.37 mmol) in dichloromethane (100 mL) was added aluminum chloride (10.12 g, 50.74 mmol) in batches at 0 ° C (at the same temperature over 50 minutes). 3-chloropropionyl chloride (4.8 mL, 76.11 mmol) was then added dropwise at 0 ° C, warmed to ambient temperature, and the mixture was stirred for 16 hours. The reaction mixture was quenched with ice water and extracted with dichloromethane. The organic layer was washed with brine and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo. The solid obtained was dissolved in methanol, and triethylamine (30 mL) was added, and the solution was stirred at 65 ° C for 16 hours. The reaction was concentrated in vacuo, and the white solid was washed with saturated aqueous sodium bicarbonate solution, water, and dried to provide 1-(4-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-chloropropan-1-one (4.5 g, 61.8%) as a brown solid: MS (ES) m / z 286.9 (M+H).
[0625] Step 2: Preparation of 1-(4-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-methoxypropan-1-one
[0626]
[0627] To a suspension of 1- (4- bromo -1H- pyrrolo [2,3-b] pyridin-3-yl) -3- chloropropane -1- ketone (3.0 g, 10.43 mmol) in methanol (50 mL) was added potassium iodide (2.6 g, 15.64 mmol) and stirred at 70 ° C for 5 hours. The reaction mixture was concentrated in vacuo, and the residue was dissolved in 10% methanol in dichloromethane. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude product was washed with diethyl ether and n-pentane to provide 1- (4- bromo -1H- pyrrolo [2,3-b] pyridin-3-yl) -3- methoxypropane -1- ketone (1.4 g, 47% yield) as a yellow solid: MS (ES) m / z 285.0 (M + H).
[0628] Step 3: Preparation of tert-butyl 4-bromo-3-(3-methoxypropionyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate
[0629]
[0630] To a suspension of 1-(4-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-methoxypropane-1-one (1.4 g, 4.94 mmol) in tetrahydrofuran (30 mL) was added triethylamine (2.0 mL, 14.83 mmol), 4-dimethylaminopyridine (0.06 g, 0.49 mmol) and di-tert-butyl dicarbonate (1.7 mL, 7.41 mmol) at 0 ° C. The mixture was stirred at ambient temperature for 16 hours. The reaction mixture was quenched with ice and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (20% ethyl acetate / hexanes) to afford tert-butyl 4-bromo-3-(3-methoxypropanoyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (0.8 g, 42% yield) as a brown viscous oil: MS (ES) m / z 385.0 (M+H).
[0631] Step 4: Preparation of (R)-tert-butyl 4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-3-(3-methoxypropionyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate
[0632]
[0633] To the stirred solution of 4-bromo-3-(3-methoxypropionyl)-1H-pyrrolo-[2,3-b]pyridine-1-carboxylic acid tert-butyl esters (0.3g, 0.78mmol) in N, N-dimethyl sulfoxide (3mL) was added (R)-3-aminopiperidine-1-carboxylic acid tert-butyl esters (0.62g, 3.14mmol), and the mixture was heated at 100 DEG C for 16 hours in a sealed tube. The reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with salt water, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol / dichloromethane) to afford (R)-tert-butyl 4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-3-(3-methoxy-propionyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (0.2 g, 50% yield) as a light brown sticky material: MS (ES) m / z 403.2 (M+H).
[0634] Step 5: Preparation of (R)-3-methoxy-1-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-3-yl)propan-1-one hydrochloride
[0635]
[0636] To a stirred solution of (R)-tert-butyl 4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-3-(3-methoxypropanoyl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (0.4 g, 0.795 mmol) in dichloromethane (5 mL) at 0° C. was added hydrogen chloride (10 mL, 4 M in dioxane) and the mixture was warmed to ambient temperature and stirred for 5 hours. The reaction mixture was concentrated in vacuo and the residue was washed with diethyl ether to provide (R)-3-methoxy-1-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-3-yl)propan-1-one hydrochloride (0.35 g, crude): MS (ES) m / z 303.1 (M+H).
[0637] Step 6: Preparation of (R)-1-(3-((3-(3-methoxypropanoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0638]
[0639] To a solution of (R)-3-methoxy-1-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-3-yl)propane-1-one hydrochloride (0.12 g, 0.32 mmol) in tetrahydrofuran:water (7:3 mL) was added triethylamine (0.13 mL, 0.96 mmol) at 0 ° C., followed by addition of a solution of acryloyl chloride (0.02 mL, 0.24 mmol) in tetrahydrofuran (0.4 mL), and stirred for 15 minutes. The reaction mixture was then quenched with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol / dichloromethane) and further purified by using preparative HPLC to afford (R)-1-(3-((3-(3-methoxypropanoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one as a white solid (0.06 g, 5.5% yield): 1H NMR (400MHz, DMSO-d6, at 80℃) δ12.0(br s,1H),8.73(d,J=7.6Hz,1H),8.18(s,1H),7.87(d,J=5.6Hz,1H),6.55-6.75(m,1 H),6.28(d,J=5.6Hz,1H),5.99(d,J=16.4Hz,1H),5.48-5.62(m,1H),3.95-4.15(m ,1H),3.65-3.80(m,4H),3.50-3.62(m,2H),3.36-3.45(m,2H),3.34(s,3H),2.00 -2.10(m,1H),1.79-1.90(m,1H),1.62-1.73(m,1H),1.50-1.69(m,1H); MS(ES)m / z 357.4(M+H).
[0640] Preparative HPLC method:
[0641] Column: Inertsil ODS 3V (250mm×4.6mm×5mic)
[0642] Mobile phase (A): 0.1% ammonia in water
[0643] Mobile phase (B): methanol
[0644] Flow rate: 1.0 mL / min (45:55)
[0645] Retention time: 3.186 minutes.
[0646] Example 9: Preparation of (R)-1-(3-((3-(cyclopropanecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0647]
[0648] Step 1: Preparation of 4-chloro-3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridine
[0649]
[0650] To a solution of 4-chloro-1H-pyrrolo-[2,3-b]pyridine (400mg, 2.62mmol) in 1.5mL dichloromethane, aluminum chloride (2.43g, 18.3mmol) was added. After stirring at ambient temperature for one hour, cyclopropanecarbonyl chloride (236 μL, 2.62mmol) was added. The reaction was stirred overnight at ambient temperature. The reaction was quenched with a saturated solution of Rochelle salt. The solution was rapidly stirred for 1 hour. The resulting yellow solid was collected by vacuum filtration to provide 4-chloro-3-cyclopropanecarbonyl-1H-pyrrolo-[2,3-b]pyridine (580mg, 2.62mmol): MS (ES) m / z 221 (M+H).
[0651] Step 2: Preparation of tert-butyl (3R)-3-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate
[0652]
[0653] To the solution of 4- chloro- 3- cyclopropanecarbonyl -1H- pyrrolo-es [2,3-b] pyridine (95mg, 0.430mmol) in N- methylpyrrolidine (2mL) from step 1, (3R) -3- aminopiperidine -1- carboxylic acid tert-butyl ester (258mg, 1.29mmol) and triethylamine (59.9 μ L, 0.431mmol) are added. The solution is treated with microwave radiation for a total of 13 hours at 130 ° C. After cooling, the solution is distributed between ethyl acetate and water. The organic layer is concentrated, and normal phase chromatography (ethyl acetate / heptane) is used to purify the residue. The desired material was collected and concentrated to afford tert-butyl (3R)-3-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate (20.0 mg, 0.052 mmol) as a light yellow oil: MS (ES) m / z 385 (M+H).
[0654] Step 3: Preparation of 1-[(3R)-3-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidin-1-yl]prop-2-en-1-one
[0655]
[0656] To the solution of (3R) -3- ({ 3- cyclopropanecarbonyl -1H- pyrrolo- [2,3-b] pyridin-4-yl} amino) piperidine -1- carboxylic acid tert-butyl ester (20mg, 0.0520mmol) in dichloromethane (2mL) from step 2, trifluoroacetic acid (1mL) is added, and the solution is stirred for two hours, and concentrated in a vacuum. Residue is dissolved in tetrahydrofuran (1mL), and triethylamine (18.0 μ L, 0.130mmol) is added. To the solution, N- [3- (dimethylamino) propyl group] propanamide hydrochloride (12.0mg, 0.0624mmol), prop-2-enoic acid (3.55 μ L, 0.0520mmol) and triethylamine (18.0 μ L, 0.130mmol) in tetrahydrofuran (0.5mL) are added. The mixture is stirred at ambient temperature for 4 hours. The solution is distributed between ethyl acetate and water. The organic layer was separated and concentrated. The crude material was purified using normal phase chromatography (dichloromethane / methanol) to provide 1-[(3R)-3-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidin-1-yl]prop-2-en-1-one (4.5 mg, 0.013 mmol): 1 H NMR(400MHz,DMSO-d6)δ12.26(br s,1H),8.85-9.02(m,1H),8.43-8.52(m,1H),7.84-7.93(m,1H),6.48- 6.89(m,1H),5.86-6.16(m,1H),5.40-5.72(m,1H),4.38-4.64(m,1H),4 .08-4.34(m,1H),3.52-3.91(m,2H),3.38-3.51(m,1H),2.96-3.12(m,1 H),1.91-2.10(m,1H),1.36-1.91(m,3H),0.86-1.05(m,4H); MS(ES)m / z 339(M+H).
[0657] Example 10: Preparation of 1-(4-((3-(cyclopropanecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0658]
[0659] Step 1: Preparation of 4-chloro-3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridine
[0660]
[0661] To a solution of 4-chloro-1H-pyrrolo-[2,3-b]pyridine (400mg, 2.62mmol) in 1.5mL dichloromethane, aluminum chloride (2.43g, 18.3mmol) was added. After stirring at ambient temperature for one hour, cyclopropanecarbonyl chloride (236 μL, 2.62mmol) was added. The reaction was stirred overnight at ambient temperature. The reaction was quenched with a saturated solution of Rochelle salt. The solution was rapidly stirred for 1 hour. The resulting yellow solid was collected by vacuum filtration to provide 4-chloro-3-cyclopropanecarbonyl-1H-pyrrolo-[2,3-b]pyridine (580mg, 2.62mmol): MS (ES) m / z 221 (M+H).
[0662] Step 2: Preparation of tert-butyl 4-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate
[0663]
[0664] To the solution of 4- chloro- 3- cyclopropanecarbonyl -1H- pyrrolo-es [2,3-b] pyridine (50mg, 0.2265mmol) in N- methylpyrrolidine (2mL) from step 1, 4- aminopiperidine -1- carboxylic acid tert-butyl ester (136mg, 0.680mmol) and triethylamine (31.5 μ L, 0.227mmol) are added. The solution is treated with microwave radiation at 130 ° C for 19 hours. After cooling, the resulting solution is distributed between ethyl acetate and water. The organic layer is washed with salt water, dried over magnesium sulfate, filtered and concentrated. The crude material is purified using normal phase chromatography (dichloromethane / methanol). The desired material was collected and concentrated to afford tert-butyl 4-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate (36.0 mg, 0.0936 mmol) as a light yellow oil: MS (ES) m / z 385 (M+H).
[0665] Step 3: Preparation of 1-[4-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidin-1-yl]prop-2-en-1-one
[0666]
[0667] To the solution of 4-({3-cyclopropanecarbonyl-1H-pyrrolo-[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylic acid tert-butyl esters (36mg, 0.0936mmol) in dichloromethane (2mL) from step 2, trifluoroacetic acid (1mL) is added, and the solution is stirred for two hours, and concentrated in a vacuum. Residue is dissolved in tetrahydrofuran (1mL), and triethylamine (32.5 μ L, 0.234mmol) is added. To the solution, a solution of N-[3-(dimethylamino) propyl group] propanamidine hydrochloride (21.7mg, 0.112mmol), prop-2-enoic acid (6.41 μ L, 0.0936mmol) and triethylamine (32.5 μ L, 0.234mmol) in tetrahydrofuran (0.5mL) is added. The mixture is stirred at ambient temperature for 4 hours. The solution is distributed between ethyl acetate and water. The organic layer was separated and concentrated. The crude material was purified using normal phase chromatography (dichloromethane / methanol) to provide 1-[4-({3-cyclopropanecarbonyl-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidin-1-yl]prop-2-en-1-one (7.50 mg, 0.0222 mmol): 1 H NMR(400MHz,DMSO-d6)δppm 12.16-12.33(m,1H),8.88-8.99(m,1H),8.48(s,1H),8.24-8.32(m,1H),7.82-7.90( m,1H),6.78-6.89(m,1H),6.04-6.17(m,1H),5.59-5.73(m,1H),4.40-4.64(m,1H),4. 07-4.22(m,1H),3.64-4.01(m,2H),3.35-3.42(m,1H),2.93-3.16(m,1H),2.70-2.88( m,1H),1.91-2.07(m,1H),1.23-1.49(m,2H),0.78-1.05(m,4H); MS(ES)m / z339(M+H).
[0668] Example 11 and Example 12: Preparation of 1-((R)-3-((5-((S)-tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0669] The title compound was prepared by the method described in Scheme 14.
[0670] Scheme 14. Preparation of 1-((R)-3-((5-((S)-tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0671]
[0672] Preparation of N-methoxy-N-methyltetrahydrofuran-3-amide
[0673]
[0674] To a stirred solution of tetrahydrofuran-3-carboxylic acid (1 g, 8.61 mmol) in dichloromethane (10 mL) was added N,O-dimethylhydroxylamine hydrochloride (2 g, 21.52 mmol) and triethylamine (3 mL, 30.14 mmol) at 0°C. The reaction mixture was stirred for 10 minutes, and then propylphosphonic anhydride solution (50% in ethyl acetate) (10 mL, 34.44 mmol) was added and stirred at ambient temperature for 12 hours. The reaction mixture was poured into water and extracted with dichloromethane (2 x 50 mL). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide N-methoxy-N-methyltetrahydrofuran-3-amide (1.2 g, 92% yield) as a brown liquid: MS (ES) m / z 160 (M+H).
[0675] Step 1: Preparation of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(tetrahydrofuran-3-yl)methanone
[0676]
[0677] To a stirred solution of 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (prepared by the method described in Example 7, 1.4 g, 3.86 mmol) in diethyl ether (20 mL) was added n-butyl lithium (3.6 mL, 5.80 mmol, 1.6 M in hexane) at -78 ° C. The mixture was stirred for 0.5 hours, and then a solution of N-methoxy-N-methyl-tetrahydrofuran-3-amide (0.84 mL, 5.80 mmol) in diethyl ether (2 mL) was added. The mixture was stirred at this temperature for 1 hour. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate (2×40 mL). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (40% ethyl acetate / hexanes) to afford (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(tetrahydrofuran-3-yl)methanone (1.0 g, 68% yield) as a brown liquid: MS (ES) m / z 381.0 (M+H).
[0678] Step 2: Preparation of tert-butyl (3R)-3-((5-(tetrahydrofuran-3-carbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate
[0679]
[0680] To a stirred solution of (4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(tetrahydrofuran-3-yl)methanone (0.85 g, 2.23 mmol) in N-methyl-2-pyrrolidone was added (R)-tert-butyl 3-aminopiperidine-1-carboxylate (0.67 g, 3.34 mmol), and the mixture was heated in a sealed tube at 180 ° C for 4 hours. The reaction mixture was poured into water and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (15% ethyl acetate / hexanes) to afford tert-butyl (3R)-3-((5-(tetrahydrofuran-3-carbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.75 g, 62% yield) as a brown liquid: MS (ES) m / z 546 (M+H).
[0681] Step 3: Preparation of tert-butyl (3R)-3-((5-(tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate
[0682]
[0683] To a stirred solution of (3R)-tert-butyl 3-((5-(tetrahydrofuran-3-carbonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.75 g, 1.37 mmol) in tetrahydrofuran (6 mL) was added tetrabutylammonium fluoride (8 mL, 1 M in tetrahydrofuran) and the solution was heated to 80° C. for 16 hours. The reaction was allowed to cool to ambient temperature, poured into ice water, and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified using flash chromatography (4% methanol / dichloromethane) to afford tert-butyl (3R)-3-((5-(tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate (0.6 g, 79% yield) as a yellow liquid: MS (ES) m / z 416 (M+H).
[0684] Step 4: Preparation of (4-(((R)-piperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(tetrahydrofuran-3-yl)methanone hydrochloride
[0685]
[0686] To a stirred solution of (3R)-3-((5-(tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-piperidine-1-carboxylic acid tert-butyl ester (0.60 g, 1.44 mmol) in dichloromethane (2 mL) was added hydrogen chloride (2.5 mL, 6.05 mmol, 4 M in dioxane) at 0°C, and the mixture was stirred at ambient temperature for 16 hours. The reaction was concentrated in vacuo, and the residue was washed with diethyl ether to provide (4-(((R)-piperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(tetrahydrofuran-3-yl)methanone hydrochloride (1.0 g, crude) as an off-white solid: MS (ES) m / z 316 (M+H). The crude product was used in the next step.
[0687] Step 5: Preparation of 1-((3R)-3-((5-(tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0688]
[0689] To a stirred solution of (4-(((R)-piperidin-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)(tetrahydrofuran-3-yl)methanone hydrochloride (0.5 g, 1.58 mmol) in tetrahydrofuran:water (7.0:3.0 mL) at 0 ° C was added triethylamine (0.48 mL, 0.4.75 mmol) followed by a solution of acryloyl chloride (0.25 mL, 2.85 mmol) in tetrahydrofuran (0.5 mL), and the mixture was stirred for 15 minutes. The reaction mixture was quenched with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol / dichloromethane) and further purified by using preparative HPLC to afford 1-((3R)-3-((5-(tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one (0.1 g, 23% yield) as an off-white solid.
[0690] Preparative HPLC method:
[0691] Column: X-Bridge C18 (100mm×4.6mm×3.5mic)
[0692] Mobile phase (A): 0.1% ammonia in water
[0693] Mobile phase (B): methanol
[0694] Flow rate: 1.0 mL / min
[0695] T / %B: 0 / 20, 8 / 50, 12 / 80, 14 / 20, 15 / 20
[0696] Example 11: Preparation of 1-((R)-3-((5-(tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0697]
[0698] The absolute configuration of the tetrahydrofuran stereogenic center is unknown, but is opposite to that of Example 12.
[0699] The title compound was isolated as an off-white solid (0.02 g, 3.4%): 1H NMR(400MHz,DMSO-d6)δ12.6(br s,1H),9.02(d,J=6.8Hz,1H),8.32(s,1H),8.17(s,1H),6.78(m,2H),5.94(t,J=14.8Hz,1H),5.47-5 .60(m,1H),4.09-4.16(m,1H),4.0-4.07(m,2H),3.90-3.98(m,1H),3.64-3.87(m,3H),3.45-3.27(br s,2H),2.14-1.99(m,3H),1.78(m,1H),1.52-1.54(m,1H),1.21(br s,1H); MS(ES)m / z 370.0 (M+H). Retention time: 9.46 minutes.
[0700] Example 12: Preparation of 1-((R)-3-((5-(tetrahydrofuran-3-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0701]
[0702] The absolute configuration of the tetrahydrofuran stereogenic center is unknown, but is opposite to that of Example 11.
[0703] The title compound was isolated as an off-white solid (0.01 g, 2% yield): 1 H NMR (400 MHz, DMSO-d6, at 90°C) δ 8.95 (d, J = 6.8 Hz, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 6.62 (m, 1H), 6.13 (s, 1H), 5.95 (d, J = 16.8 Hz, 1H), 5.51-5.52 (m, 1H), 4.16-4.18 (m, 1H), 3.93-4.04 (m, 3H), 3.63-3.80 (m, 4H), 3.05-3.48 (m, 2H), 2.10-2.14 (m, 2H), 2.02 (m, 1H), 1.56-1.81 (m, 3H); MS (ES) m / z 370.0 (M+H). Retention time: 9.905 minutes.
[0704] Example 13: Preparation of (R)-1-(3-((3-(cyclopentanecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0705]
[0706] The title compound was prepared by the method described in Scheme 15.
[0707] Scheme 15. Preparation of (R)-1-(3-((3-(cyclopentanecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0708]
[0709] Step 1: Preparation of (4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(cyclopentyl)methanone
[0710]
[0711] To a stirred solution of 3-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine (prepared by the method described in Example 7, 4g, 8.28mmol) in diethyl ether (50mL) was added n-butyllithium (8.28mL, 66.5mmol, 1.6M in hexane) at -78°C, followed by addition of a solution of N-methoxy-N-methylcyclopentaneamide (2.59g, 16.56mmol) in diethyl ether (4mL), and stirred at the same temperature for 1 hour. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (15% ethyl acetate / hexanes) to afford (4-chloro-1-((2-(trimethylsilyl)-ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(cyclopentyl)methanone (2.3 g, 55% yield) as a yellow liquid: MS (ES) m / z 379.1 (M+H).
[0712] Step 2: Preparation of (R)-tert-butyl 3-((3-(cyclopentanecarbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
[0713]
[0714] To a solution of (4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(cyclopentyl)methanone (1.5 g, 3.96 mmol) in N-methylpyrrolidone (10 mL) was added (R)-tert-butyl 3-aminopiperidine-1-carboxylate (0.95 g, 4.76 mmol) and the mixture was heated at 150 ° C for 12 hours in a sealed tube. After cooling to ambient temperature, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (10% ethyl acetate / hexanes) to afford (R)-tert-butyl 3-((3-(cyclopentanecarbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.2 g, crude) as a light yellow solid: MS (ES) m / z 543.3 (M+H).
[0715] Step 3: Preparation of (R)-tert-butyl 3-((3-(cyclopentanecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
[0716]
[0717] To a solution of (R)-tert-butyl 3-((3-(cyclopentanecarbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.7 g, 1.29 mmol) in tetrahydrofuran (5 mL) was added tetrabutylammonium fluoride (13 mL, 1 M in tetrahydrofuran) and the solution was heated to 80° C. for 12 hours. After cooling to ambient temperature, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (50% ethyl acetate / hexanes) to afford (R)-tert-butyl 3-((3-(cyclopentanecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.28 g, crude yield) as a brown solid: MS (ES) m / z 413.2 [M+H].
[0718] Step 4: Preparation of (R)-cyclopentyl(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone hydrochloride
[0719]
[0720] To a solution of (R)-tert-butyl 3-((3-(cyclopentanecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.28 g) in dichloromethane (4 mL) was added hydrogen chloride (4 mL, 4 M in dioxane) at 0° C., and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated in vacuo, and the residue was washed with diethyl ether to provide (R)-cyclopentyl(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone hydrochloride (0.26 g, crude) as a light yellow solid: MS (ES) m / z 313.1 [M+H].
[0721] Step 5: Preparation of (R)-(4-((1-(buta-1,3-dienyl)piperidin-3-yl)amino-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopentyl)methanone
[0722]
[0723] To a stirred solution of (R)-(4-((1-(butadienyl)piperidin-3-yl)amino-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopentyl)methanone (0.1 g, 0.28 mmol) in tetrahydrofuran:water (8:2 mL) at 0 ° C was added triethylamine (0.08 mL, 0.57 mmol) followed by a solution of acryloyl chloride (0.01 g, 0.14 mmol) in tetrahydrofuran (0.2 mL) and stirred for 5 minutes. The reaction mixture was quenched with aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol / dichloromethane) to provide (R)-(4-((1-(buta-1,3-dienyl)piperidin-3-yl)amino-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopentyl)methanone as a white solid (0.02 g, 17%): 1H NMR(400MHz,DMSO-d6)δ12.16(s,1H),8.92(d,J=7.6Hz,1H),8.26(s,1H,),7.85(d, J=6.0Hz,1H),6.72-6.82(m,1H),6.48-6.60(m,1H),6.24-6.29(m,1H),5.90-6.09(m ,2H),5.63-5.66(m,1H),5.49-5.50(m,1H),4.21-4.32(m,1H),3.68-3.79(m,2H),3. 46-3.60(m,2H),2.86-2.99(s,1H),1.96-2.09(m,1H),1.59-1.83(m,8H); MS(ES)m / z 367.1(M+H).
[0724] Example 14: Preparation of (R)-1-(3-((3-(1-methylcyclopropane-1-carbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0725]
[0726] The title compound was prepared by the method described in Scheme 16.
[0727] Scheme 16. Preparation of (R)-1-(3-((3-(1-methylcyclopropane-1-carbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one
[0728]
[0729] Preparation of N-methoxy-N,1-dimethylcyclopropane-1-amide
[0730]
[0731] A solution of 1-methylcyclopropane-1-carboxylic acid (2.0 g, 19.99 mmol) and carbonyldiimidazole (3.55 g, 21.92 mmol) in dichloromethane (70 mL) was stirred at ambient temperature for 1 hour, then N, O-dimethylhydroxylamine (2.14 g, 21.99 mmol) was added and stirred at ambient temperature for 16 hours. The reaction mixture was poured into water and extracted with dichloromethane (2 × 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (21% ethyl acetate / hexane) to provide N-methoxy-N, 1-dimethylcyclopropane-1-amide (1.55 g, 52% yield) as a colorless liquid: MS (ES) m / z 144.1 (M+H).
[0732] Step 1: Preparation of (4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(1-methylcyclopropyl)methanone
[0733]
[0734] To a solution of 3-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (prepared by the method described in Example 7, 1.5 g, 4.16 mmol) in diethyl ether (40 mL) was added n-butyl lithium (3.87 mL, 6.24 mmol, 1.6 M in hexane) at -78 ° C and stirred for 0.5 hours. Then, a solution of N-methoxy-N, O-dimethylcyclopropane-1-amide (0.89 g, 6.24 mmol) in diethyl ether (40 mL) was added at -78 ° C and stirred for 1 hour. The reactio...
Claims
1. Use of a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt of the compound in the manufacture of a medicament for treating an ITK-mediated or JAK3-mediated disorder in a subject in need thereof: in: X is N; n is 1 or 2; m is 0, 1, or 2; R1 is selected from COOR6, C1-C5 alkyl-COOR6, bicycloalkyl, C1-C5-alkyl-heterocyclyl, C1-alkyl-C3-C6-cycloalkyl, C3-C6 cycloalkyl, C(O)C1-C5 alkyl, C(O)C3-C6 cycloalkyl, wherein cycloalkyl, bicycloalkyl, heterocyclyl and alkyl are optionally substituted with one or more groups selected from C2-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN and halogen, and wherein when R1 is C3 cycloalkyl, R1 is substituted with one or more groups selected from C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkyl-C1-C5 alkoxy, CN or halogen; R2 is selected from H and C1 alkyl; R3 is H; R4 is selected from H and C1-C6 alkyl; R5 is selected from H and C1-C6 alkyl-N(C1-C6 alkyl)(C1-C6 alkyl); R6 is selected from H, C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5-alkyl-C3-C6-cycloalkyl, C1-C5 alkyl-C1-C5 alkoxy and C1-C5 alkyl-OH.
2. The use according to claim 1, wherein the compound or the pharmaceutically acceptable salt of the compound is selected from:
3. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
4. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
5. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
6. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
7. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
8. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
9. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
10. The use according to claim 2, wherein the compound or the pharmaceutically acceptable salt of the compound is:
11. Use of a therapeutically effective amount of a compound of the following structure or a pharmaceutically acceptable salt of said compound in the manufacture of a medicament for treating an ITK-mediated or JAK3-mediated disorder in a subject in need thereof:
12. The use of claim 1 or 11, wherein the ITK-mediated or JAK3-mediated disorder is selected from arthritis, skin disorders, dermatitis, complications from organ transplantation, inflammatory bowel disease, and combinations thereof.
13. The use according to claim 12, wherein the arthritis is rheumatoid arthritis.
14. The use of claim 12, wherein the skin disorder is selected from psoriasis, alopecia, vitiligo and combinations thereof.
15. The use of claim 14, wherein the skin disorder is psoriasis.
16. The use of claim 14, wherein the skin disorder is alopecia.
17. The use of claim 14, wherein the skin disorder is vitiligo.
18. The use according to claim 12, wherein the dermatitis is atopic dermatitis.
19. The use according to claim 12, wherein the complication from organ transplantation is graft-versus-host disease.
20. The use of claim 1 or 11, wherein the treatment further comprises sequential administration or co-administration of pharmaceutical agents.
21. The use according to claim 20, wherein the pharmaceutical agent is selected from the group consisting of taxanes, inhibitors of bcr-abl, inhibitors of EGFR, DNA damaging agents, antimetabolites, paclitaxel, imatinib, dasatinib, nilotinib, erlotinib, gefitinib, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC, 5-FU, camptothecin, doxorubicin, idarubicin, paclitaxel, docetaxel, vincristine, MEK inhibitors, U0126, KSP inhibitors, vorinostat, pembrolizumab, nivolumab, atezolizumab, avelumab, tesimumab, and durvalumab.
Citation Information
Patent Citations
Fixation staples for use in surgical procedures
US20190046182A1
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5760068A
PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO1999065909A1
Method for inhibiting c-JUN expression using JAK-3 inhibitors
WO2000000202A1
Azaindole compounds as kinase inhibitors
WO2004099205A1
